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Human papillomavirus (HPV) infection, specifically with oncogenic types, has been 
implicated in effectively all cervical cancer cases. Cervical cancer is a global health 
burden, especially in the developing world. Up to 18 types of HPV are considered 
oncogenic, of which HPV -16 and -18 cause 70% of cervical cancer cases worldwide. 
Two vaccines are available on the market: Gardasil®, targeted against HPV -16, -18; -
6 and -11, and Cervarix™, against -16 and -18. Both vaccines are based on the L1 
capsid proteins of the types they are targeted to and are efficient, prophylactic, type-
specific vaccines. However, two problems remain: they do not protect against non-
vaccine types, that may cause a significant proportion of cancers specifically in 
African and HIV -positive populations, and they cannot be used to treat existing 
infections. We therefore designed eight different chimaeric vaccines where regions of 
HPV-16 L1 were replaced with the same number of amino acids (aa) constituting 
different epitopes. Cross-neutralising epitopes derived from HPV -16 L2 protein 
between amino acids (aa) 108-120 (SAF), 56-81 (L2.56), 17-36 (L2.17) and BPV-1 
L2 aa 1-88 (BPV) were inserted after aa 413 in HPV-16 Ll. HPV-16 E7 aa 49-57 
(E7M) and 86-93 (E7H), used in immunotherapy of HPV -related cancer in mice and 
humans respectively, were inserted after aa 417. Additionally, two variations of the 
L1/L2 (108-120) chimaera were created where the E7 epitopes replaced aa 433 to 441 
(E+E7M and E+E7H). All eight constructs were expressed in insect cells and six of 
these (excluding E7H and E+E7H) were tested in animals. Results showed that L2.56, 
L2.17 and SAF elicited anti-L 1 antibodies detected by ELISA, neutralised HPV -16 in 
vitro and expressed well in insect cells. L2.56 and L2.17 also elicited anti-L2 
antibodies. L2.56 showed the most promise as a vaccine candidate, since it elicited the 
highest levels of anti-Ll and anti-L2 antibodies and could assemble into more 
immunogenic higher-order structures. BPV could be eliminated as a vaccine 
candidate based on its immunogenicity and expression levels. Both LlIE7 chimaeras 
elicited anti-L1 antibodies by ELISA, but E+E7M showed more promise as a 
therapeutic vaccine than E7M, because it primed the cellular arm of the immune 
system, whereas E7M primed the humoral arm. Chimaeric L1 vaccines incorporating 
cross-neutralising L2 and immunotherapeutic E7 peptides and replacing up to 27 aa of 
HPV-16 L1 of the helix 4 and the region to its C-terminal are promising second-











1. LITERATURE REVIEW 
1.1 Introduction 
Papillomaviruses (PVs) generally cause benign tumours, including warts. They are 
diverse and occur in many mammalian and bird species (de Villiers et aI. , 2004). 
Because the L1 open reading frame (ORF), which codes for the "late" major capsid 
protein, is the most conserved gene within the genome, it has been used to classify 
new types over the past 15 years. Papilloma viruses constitute the family 
Papillomaviridae, which is divided into 16 genera, of which five, namely the Alpha-, 
Beta-, Gamma-, Mu- and Nu-papillomaviruses, affect humans and collectively they 
constitute the human papillomaviruses (HPVs), which are of interest in this study. The 
HPV genome encodes eight ORFs; namely L1 , L2, E1 , E2, E4, E5, E6 and E7. Figure 
1.1 shows the genome organization of HPV and the genes encoded by its genome as 
well as a structure model for papillomavirus. 
(B) 
Figure 1.1 (AJ HPV genome organisation, indicating the different ORFs. LCR=Long 
control region. This region is a non-coding region involved in regulation of virus gene 
expression. (Modifiedfrom (Human PapillomaviruseslIARC Working Group on the 
Evaluation of Carcinogenic Risks to Humans, 2005) (BJ Structure model of 
papillomavirus. (Taken from (Xu et aI. , 2006) 
HPVs can be divided into mucosotropic types, which affect the epithelial linings of 
the upper respiratory system and anogenital tract; and cutaneous types, which affect 
the skin (Castellsague, 2008; Human Papillomaviruses/IARC Working Group on the 
Evaluation of Carcinogenic Risks to Humans, 2005). Mucosal HPVs occur in benign 
and malignant lesions of the anogenital tract in both sexes. HPVs that only occur in 











cancerous lesions are designated as "high-risk". Mucosotropic HPVs cause genital 
warts and cancers of the cervix, vulva, vagina, penis and anus. They also occur 
occasionally in the oral cavity, oropharynx, larynx and oesophagus. Cutaneous HPV 
cause cutaneous and plantar warts and are associated with Epidermodysplasia 
verruciformis (EV) and some skin cancers. 
Of particular interest in our study are the cervical cancer-causing HPV types, which 
all fall into the alpha-genus of the family Papillomaviridae (de Villiers et aI., 2004). 
Of all the human papillomavirus (HPV) types, about 15 types are considered high-risk 
for cervical cancer (Castellsague, 2008). These high-risk types, according to 
Castellsague (2008), are types 16, 18,45,31,33,52,58,35,39,59,56,51,68, 73 and 
82, but three types are considered as probable high-risk. These are HPV -26, -53 and -
66 (Moodley et al., 2009). HPV-16 is the causative agent in about 53% of cases and is 
thus the major type involved in carcinogenesis (Castellsague, 2008). 
Infection with a high-risk HPV is the single causative factor for cervical cancer, with 
95 to 99% of cases associated with the virus (Castellsague, 2008). In fact, there are 
four necessary steps in the development of cervical cancer, the first of which is 
infection with human papillomavirus (Human Papillomaviruses/IARC Working 
Group on the Evaluation of Carcinogenic Risks to Humans, 2005). Secondly, the 
infection must persist; in fact, in 90% of cases, the infection will be cleared within 2 
years (Cutts et al., 2007). If the infection persists, it must then progress to 
precancerous lesions, at which stage the lesion could also still regress naturally, 
followed by invasion of the tissue by the transformed cells. (Human 
Papillomaviruses/IARC Working Group on the Evaluation of Carcinogenic Risks to 
Humans, 2005). 
Cervical cancer is a global health burden, especially so in the developing world. 
About half a million women worldwide are affected annually and 260 000 die as a 
result (Cutts et al., 2007). Of these women, 80% are in developing countries. In South 
Africa, HPV infection and cervical cancer prevalence is high: 20.4% of women with 
normal cytology are infected (Williamson et aI., 2002). It is the second most prevalent 
cancer in women (Williamson et al., 2002; Mqoqi et al., 2004) in South Africa with 











annually as a result (Sinanovic et at., 2009). In the black population, it is the most 
common cancer amongst women (Mqoqi et at., 2004). 
There is a need for a vaccine, especially in developing countries where the mortality 
and morbidity rate is high (Cutts et at., 2007). Prophylactic vaccination is supposed to 
be the most effective way of eradicating and preventing disease in general (World 
Health Organisation, 2005). In developed countries, screening programmes have 
reduced the incidence of cervical cancer, but this has not been the case in developing 
countries (Lowy et at., 2008) and in South Africa (Sinanovic et at., 2009). Limited 
resources prevent effective implementation of screening policies and so vaccination 
programmes could bridge the gap. 
There are two prophylactic HPV vaccines on the market. Cervarix ™ is manufactured 
by Glaxosmithkline, and is targeted against HPV-16 and -18, while Gardasil® is 
manufactured by Merck and is targeted against types -6 and -11 as well (Schiller et 
at., 2008). Both vaccines are polyvalent vaccines based on Ll ofthe respective HPV 
types against which they are targeted (Schiller et at., 2008). Although native capsids 
ofHPV consist of both Ll and L2 proteins (Human Papillomaviruses/IARC Working 
Group on the Evaluation of Carcinogenic Risks to Humans, 2005), Ll by itself can 
self-assemble into virus-like particles (VLPs), which have been shown to be 
immunogenically similar to the native human papillomavirus, while being non-
infectious (Kirnbauer et at., 1992). Antibodies (Breitburd et at., 1995), specifically 
those targeted against Ll (Kirnbauer et at., 1992), have been shown to be the major 
factor in preventing PV infection in animals. 
One problem is the high cost of current vaccines on the market. At current prices, 
vaccination against HPV is only cost-effective in countries that can afford to 
implement such a programme (Techakehakij & Feldman, 2008). In South Africa, the 
vaccine price needs to be reduced by at least 60% in order to make a vaccination 
strategy on top of a screening programme more cost-effective (Sinanovic et al., 2009). 












This reVIew considers clinical trial data showing the high efficacy of current 
prophylactic HPV vaccines that are on the market. It also considers the two major 
problems that still need to be addressed in order to combat cervical cancer and that 
need to be considered in the development of second-generation HPV vaccines; 
namely, prevention against HPV types not included in current vaccines, and treatment 
of existing infections. It discusses the use of essential epitopes from HPV proteins 
other than L1, specifically L2 and E7, to combat these problems. The use ofLl as a 
carrier molecule for essential epitopes is also discussed. 
1.2 The efficacy of currently licensed HPV vaccines 
Gardasil® and Cervarix™ have been extensively tested and are still being tested in 
clinical trials. Both have shown exceptional efficacy in populations not previously 
exposed to HPV infection. Since the aim is to vaccinate girls before sexual debut, data 
on prevention of infection in such a population would be most important. It is also 
important to consider the different endpoints the vaccine should prevent. The vaccine 
may in some cases not prevent infection with an HPV type, but may help clear the 
infection before it progresses to cancerous lesions. Another consideration is whether 
the endpoint is due to a vaccine-specific type or not. Lastly, levels of antibodies 
secreted will also be important, since that would be an indication of the strength of an 
immune response mounted as well as an indication ofthe memory immune response. 
Gardasil® showed a >90% efficacy rate in populations not previously exposed to 
HPV against all endpoints, such as infection with vaccine-specific types, cervical 
intraepithelial neoplasia (CIN) of all grades of severity, adenocarcinoma in situ (AIS), 
vulvar intraepithelial neoplasia (V IN) , vaginal intraepithelial neoplasia (VaIN) and 
genital warts (Tay et at., 2008; Villa et at., 2006; Garland et aI., 2007; Ault, 2007; 
loura et at., 2007; loura et at., 2008). In most analyses, it was 100%. 
In one study (FUTURE II STUDY GROUP, 2007), Gardasil® given to women who 
were positive for at least one, but fewer than 4 HPV types at the start of the study or 
became so in between vaccinations, showed a 91.1 % efficacy against development of 
CIN and 93.8% efficacy against external vaginal or anogenitallesions. The efficacy 











study. The vaccine was, however, 100% effective at preventing higher-grade lesions 
in this trial. 
For Gardasil®, in the FUTURE I trial (Garland et at., 2007), 99.5% of subjects 
seroconverted one month after the last dose. In combined results from FUTURE I and 
FUTURE II (Joura et at., 2008), 89% or more of subjects had seroconverted to types 
6, 11 and 16 44 months after the first vaccination. Seroconversion to type 18 was 
lower, with only 60% of subjects positive, but protection against lesions caused by 
type 18 remained as high as for the others. Five years after the first vaccination, 
participants in one of the clinical trials (Olsson et at., 2007) had antibody levels at 
least as high as one would have from natural infection with HPV, in most cases 
higher. One study tested the memory immune response of Gardasil®. A challenge 
dose of vaccine was given 5 years after the first dose. Eighty-three percent of 
participants mounted a memory immune response with antibody levels higher than at 
month 60. Of those who had been seronegative at month 60, 75% seroconverted. 
More than 50% of them mounted an immune response higher than they did after the 
third vaccination. Antibody levels also rose more rapidly than for any of the other 
boosts. Gardasil® thus elicited high titres of antibodies. 
For Cervarix™, in the main Phase III trial that was conducted (Paavonen et at., 2009; 
Paavonen et at., 2007), only women aged 15-25 years were included, thus 
representing a population of young women most likely to receive the vaccine. 
Endpoints included HPV infection, precancerous lesions and CIN2 and CIN3. In a 
population that was HPV negative at month 0 and month 6, the vaccine was 
determined to be efficient at preventing 92.9% of CIN2+ due to both vaccine types. 
CervarixTM was also efficient at preventing 80.4 and 75.9% of 6 month and 12 month 
persistence of vaccine-type infection respectively (Paavonen et at., 2007). Where 
existing lesions were assigned to specific types, 98.1 % of CIN2+ due to type 16 or 18 
could be prevented (Paavonen et at., 2009). 
For Cervarix™, it was shown that a very high number, more than 99.5% of women, 
seroconverted. Different age groups did not affect the strength of the immune 
response (Pedersen et at., 2007; Schwarz et at., 2009). No data is available to date on 











The data above would indicate that both Cervarix™ and Gardasil® are highly 
efficient type-specific prophylactic vaccines. They would be highly efficient at 
preventing HPV -16 and -18 related infection and lesions in young girls vaccinated 
before sexual debut as well as at eliciting high levels 0 f anti-HPV -16 and -18 
neutralising antibodies. Ll forms the basis of these highly efficient vaccines, therefore 
the use of this protein as a basis for the design of second-generation vaccines is a 
highly feasible approach. 
1.3 The need for a more broadly neutralising prophylactic vaccine 
1.3.1 Ll elicits type-specific antibodies 
The question is whether current vaccmes on the market would prevent against 
infection with types other than the types they are targeted to. It is known that 
neutralising antibodies elicited by vaccination with Ll VLPs are mostly type-specific. 
Rabbits vaccinated with bovine papillomavirus (BPV) particles, who are then 
challenged with cottontail rabbit papillomavirus (CRPV), are not protected against 
developing papillomas (Breitburd et al., 1995). It is known that conformational 
epitopes are neutralizing sites and from monoclonal antibody (mAb) studies, it is 
known that most mAbs bind conformational epitopes and that they are type-specific. 
Many mAbs bind epitopes found on the surface loops ofLI (Bishop et al., 2007b). 
The reason for eliciting type-specific antibodies is related to the structure of VLPs. 
Even though the amino acid sequences of Ll proteins from different types are highly 
conserved, and their core p-sheet structures superimpose well, amino acid differences 
in their surface loops cause the loops to deviate significantly from one another in 
structure. This deviation was shown in a study by Bishop et al. (Bishop et al., 2007b) 
where the structures of pen tamers, which display surface loops in the same way that 
VLPs would, oftypes 16, 11,35 and 18, were compared to one another. (Seventy-two 
Ll pentamers assemble to form VLPs) The deviation provides a structural reason for 
the type-specificity of anti-Ll antibodies. Figure 1.2 illustrates the distinct structural 











Figure 1.2 The deviation in structure of surface loops on LI pentamers from (A) 
HPVll, (B) HPV35, (C) HPV-16 and (D) HPV-IB. Surface loops are shown in 
colour to distinguish them from the rest of the pentamer. Be loops are shown in 
orange, DE loops in violet, EF loops in yellow, FG loops on green and HI loops in 
blue. Indicated on HPV-ll and HPV-16 are amino acids essential to binding sites 
for neutralising mAbs. Black squares: Hll.FI and Hll.G5 binding sites. Orange 
square: HII .H3. Red square: H16. V5 and HI6.E70. Figure takenfrom Bishop et al. 
{Bishop et aI., 2007b) 
In humans, Ll-based vaccines elicit very low levels of cross-neutralising antibodies. 
As already mentioned above, Cervarix™ and Gardasil® are highly efficient type-
specific vaccines, but are far less efficient against types not included in the vaccines. 
Data from clinical trials involving Gardasil® show a significant reduction in efficacy 
when lesions caused by types other than -16 or -18 are not excluded in intention-to-
treat (ITT) populations (Garland et al., 2007; Joura et al., 2007; Ault, 2007; Barr et 











applied; for example, they may be HPV -positive with abnormal cytology before 
vaccination. In HPV -naIve women, efficacy against types other than those included in 
the vaccine, was much lower than for the vaccine types (Brown et aI., 2009). Efficacy 
against infection with the most closely related types, types -45 and -31, was 40.3%, 
and against all members ofthe same species as types -16 and -18, 25%. Against CIN 
1-3 or AIS, it was 43.6 and 23.4 % respectively and against CIN 2-3 or AIS, it was 
58.7 and 32.5% respectively. The lower percentage for less related types suggests that 
efficacy can be positively correlated with relatedness, further supporting type-specific 
protection by Gardasil®. There was however, one study that showed cross-
neutralisation of HPV-45 pseudovirions by human sera, although the neutralisation 
titres were substantially lower than those against the related type-18 (Smith et al., 
2007). 
In the main clinical trial involving Cervarix™ (Paavonen et al., 2009), the vaccine 
was efficient at preventing 70.2% ofCIN2+ in HPV-nalve women when non-vaccine 
types were not excluded from the analyses. This figure is significantly lower than the 
92.9% when these types are excluded. CIN2+ associated with 12 non-vaccine 
oncogenic types was prevented in 54% of cases. Cross-protection against closely 
related types -31 and -45, as well as -33, which belongs to the same species as type -
16, was detected. In the interim analysis of this trial (Paavonen et aI., 2007), efficacy 
against preventing infection with oncogenic non-vaccine types 12 months after 
vaccination, was only about 27% as opposed to 75.9% mentioned previously. 
1.3.2 Factors influencing HPV type distribution 
An unexplored problem is that currently licensed vaccines that are targeted only 
against carcinogenic types 16 and 18 may not necessarily be as effective in all regions 
of the world, as there are regional differences in the proportions of cervical 
abnormalities due to different types of HPV (Adler et al., 2008; Allan et al., 2008; 
Bosch et al., 2008). A global meta-analysis of all the data collected between 1999 and 
2005 (Bosch et aI., 2008) provides data to this effect. Africa has a higher prevalence 
of any type of HPV at 22.1 % of all women with normal cytology infected, versus 
10.4% of women worldwide. Figure 1.3 shows the percentage each HPV type 











Africa, HPV-16 only contributes towards 12.2 % of infections, whereas worldwide it 
contributes towards 25% of infections. Figure 1.3 also shows that type 35 is ranked 
sixth in Africa, whereas it is ranked ninth worldwide and its proportional prevalence 
is three times lower than in Africa. The data therefore indicates a greater burden of 
HPV types other than 16 and 18 in Africa, as compared to worldwide estimates, as 
well as a type distribution shift with respect to HPV -35. These data agree with another 
pooled analysis (Clifford et aI. , 2005), where type 35 was observed to occur at 
significant levels in Africa. In fact , HPV-35 was shown to be as common as HPV-16 
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Figure 1.3.Proportional prevalence of HPV types in women with normal cytology, 
in Africa and worldwide. Types are indicated next to the key, with the relevant 
percentage below each type. Data takenfrom Bosch et al. (Bosch et al., 2008) 
However, statistics for women with higher-grade lesions such as invasive cervical 
cancer (ICC) are more valuable, since it gives a better picture of the types associated 
with cancer. The percentages of HPV types detected in women with ICC is shown in 
Figure 1.4 for Africa and worldwide. Although types 16 and 18 contribute towards 
70% of ICC both in Africa and worldwide, the third and fourth ranked types in both 
Africa and worldwide, types 33 and 45, show a higher incidence in Africa at 7.6 and 
6.6 % respectively, compared to 4.3 and 3.7 % worldwide. In the case of type 35, it is 
ranked the fifth most common type in ICC in Africa, but only the eighth worldwide. 
A review on the epidemiology of HPV in sub-Saharan Africa (Louie et al. , 2009) 
provides similar statistics. It indicates that types observed in women with ICC and 
ranked third to fifth most prevalent, types 45, 33 and 35, each contribute towards 9.8, 
7.1 and 4.5% ofthe types observed, which is significantly higher than the worldwide 
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Figure 1.4. HPV type prevalence in women with invasive cervical carcinoma, in 
Africa and worldwide. Types are indicated next to the key, with the relevant 
percentage below each typ e. Data takenfrom (Bosch et aI. , 2008) 
Other studies have looked at the type distribution in countries within Africa and have 
shown that HPV -16 does not necessarily predominate as it does worldwide. In 
Mozambique, HPV-35 was reported to be the most common type amongst women 
with no cervical abnormality and cervical dysplasia (a precursor to squamous cervical 
carcinoma), although in women with cervical cancer, types 16 and 18 still caused 
69% of disease, but with co-infections with other types being common (Naucler et al. , 
2004). In Uganda (Banura et al. , 2008), although the data does not give an indication 
of the cytology, of the carcinogenic types, HPV -18 and 52 were the most common, 
followed by type 16, 51 and 33 in order of prevalence. Another small-scale study in 
Uganda, which also didn't take lesion grade into consideration (Blossom et al. , 2007), 
showed that ofthe high-risk types, type 52 was by far the most common, followed by 
type 16, 58, 59 and 51. HPV-18 may also not necessarily be the second-highest 
ranked type in cervical cancer in African countries. In Senegal, one study found that 
HPV -16 and HPV -58 were most strongly associated with cervical cancer (Xi et at. , 











Similarly to the situation in African countries, in a recent study in South Africa (Allan 
et at., 2008), in black and mixed-race women with HSILs, the most prominent types 
emerged as types 16, 35, 31 and 52. Type 18 only emerged as the fourth most likely 
cause of high-grade squamous intraepithelial lesions (HSILs) or CIN2+. It is 
important to consider that many of the infections in this study were multiple, and that 
in many cases, type 35 only occurred as a co-infection with type 16. There were, 
however, some single infections with type 35. HPV-16 and -35 were associated with 
increased disease severity in this study, and more so compared to type 18. Another 
small-scale study involving 159 women from Pretoria in South Africa also showed the 
potential of the non-vaccine type HPV -35 to significantly contribute towards the 
cervical cancer burden, since it emerged as the predominant type in HSIL cases in this 
study (Said et at., 2009). Marais et at. (Marais et at., 2008) conducted a study on 
1003 mixed-race and black women in South Africa and found that types 16, 53 and 52 
were equally prevalent, regardless ofthe grade of the lesion. 
In HIV-infected women there is also a shift towards types other than HPV-16 and 
HPV-18 (Clifford et at., 2006; Allan et at., 2008; Adler et aI., 2008). A 2006 meta-
analysis of all published data on HPV types among HIV-positive women (Clifford et 
at., 2006) revealed that the proportion of HPV infection caused by HPV type 16 is 
lower in HIV -positive women than in HIV -negative women, regardless of cervical 
cytology. As the severity of cervical lesions increased, the number of infections 
attributable to HPV -16 became more dominant, but less so than in the general 
population. HIV -positive women with HSIL were more likely to be infected with 
other high-risk types and also some types regarded as low-risk, but which may be 
responsible for HSIL in immunosuppressed individuals. The low-risk types, are, 
however, in the majority of cases, only a co-infection with a high-risk type, and may 
therefore be benign in itself Once again, there were a few HIV -positive HSIL patients 
with single low-risk type infections. In Sub-Saharan Africa (Louie et aI., 2009) HPV-
52 was shown to be more prevalent than HPV-18 in ICC cases. HPV-16 only 
contributed to 39.2% of ICC cases, compared to the about 50% estimated worldwide 
and other types, like HPV-35 and -58, contributed significantly to the number of ICC 
cases. In their review, co-infections involving HPV-16/18 and another type were often 
seen, which may confound the estimations, but it is not clear to what extent the co-











Many studies in South Africa and other African countries have shown that HPV -16 
does not predominate over other types as much as is seen in HIV -negative women. 
For example, in a South African study (Moodley et at., 2009), among women with 
abnormal cervical smears, HPV-16, -58 and -51 were equally prevalent and in Zambia 
(Sahasrabuddhe et at., 2007), the most prevalent types occurring in women with HSIL 
and see were HPV -52, -53 and -58, which were more prevalent than types 16 and 
18. Other studies in African countries also indicate the lack of predomination by 
HPV-16 (Blossom et at., 2007; Singh et at., 2009; Banura et at., 2008) 
From the data above, it is therefore possible that Sub-Saharan Africa may have a 
bigger requirement for prophylactic vaccines targeted at non-vaccine types than other 
regions of the world. This requirement is due to a significantly higher burden of 
cervical cancer attributed to non-vaccine types compared to other regions of the 
world. Secondly, the higher number of people infected with HIV in the Sub-Saharan 
region means that HPV -16 predominates to a lesser extent in cervical cancer in this 
region. There is therefore an urgent need for vaccines effective against multiple types 
and against types other than HPV-16 and HPV-18. 
1.4 The role of L2 in creating a more broadly neutralising HPV 
vaccine 
The full-length minor capsid protein, L2, has been shown to elicit antibodies reactive 
against native HPV virions of types other than the type to which its sequence 
corresponds. When sheep were immunized with bacterially expressed HPV -6, -16 or-
18 full-length L2, the obtained sera neutralised both homologous and heterologous 
types of pseudovirions, whereas immunisation with L1/L2 capsids did not have this 
effect (Roden et at., 2000). 
1.4.1 Cross-neutralising epitopes of L2 
Much research has been done on mapping cross-neutralising epitopes of the ~500 
amino acid L2. The N-terminal ofL2 or the first 200 amino acids have been the focus 











2007a; Kondo et al. , 2007). However, the cross-neutralising region can be further 
narrowed down to the first 120 amino acids. Firstly, the first 120 amino acids ofHPV-
16 L2 are highly conserved across papillomavirus types (shown in Figure 1.5) and 
more so compared to the C-terrninal of the protein (Lowe et al. , 2008; Yang et ai., 
2003). Furthermore, in a study where HPV 16 L2 peptides were displayed on bacterial 
thioredoxin, amino acids 1-120 were used as a positive control, indicating that this 
region should contain all the possible epitopes of L2 to elicit neutralising and cross-
neutralising antibodies to L1 (Rubio et ai., 2009). 
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Figure 1.5. Alignment of the first 120 amino acids ofL2from 7 divergent PV 
types, showing the high level of conservation. Red indicates a high level of 
conservation, whereas blue indicates regions that are semi-conserved. Sequences 
were aligned using MultAlin. (Carpet, 1988) 
In other studies, neutralising epitopes were consistently mapped to within the frrst 120 
amino acids. In this region, there are three main regions of focus, of which the 
boundaries have not been clearly defmed in all cases. The frrst such region stretches 
from amino acid 17 to 36. This peptide is highly conserved across HPV types, as can 
be seen in Figure 1.5, and it has so far been very promising as a region eliciting cross-
neutralising antibodies. Linked to various haptens and immunostimulatory molecules, 
it can elicit antibodies which cross-neutralise up to 10 types of HPV tested so far, as 
well as the divergent BPV-1 (Gambhira et al., 2007b; Alphs et al., 2008). A 
monoclonal antibody, RG-1 , was generated against this peptide, and neutralised both 
type 16 and 18 pseudo virions, as well as protecting mice against challenge with HPV -
16 pseudo virions containing a luciferase gene (Gambhira et ai., 2007b). Depletion 
studies were also carried out. In these studies, polyclonal sera are depleted of 
antibodies targeted against a particular epitope, by removal of these antibodies with a 
column. Removal of antibodies targeted against amino acids 17-36, drastically 
reduced the ability of anti-L2 sera to cross-neutralise HPV-16 and -18, and in most 
cases, eliminated it (Gambhira et al. , 2007b). These data could indicate that 17-36 is 











Other researchers have used similar regions to the RG-l epitope in their studies. 
Schellenbacher et al (Schellenbacher et at., 2009) inserted amino acids 18-31 into 
BPV Ll, creating a chimaeric protein. Only when this protein was denatured, did it 
induce low titres of cross-neutralising antibodies. This result would indicate that 
residues 17 and 32 to 36 are probably essential to the epitope. The peptide 18-38, 
linked to keyhole limpet haemocyanin (KLH), did not induce significant cross-
neutralising titres, supporting the neccessity of incuding amino acid 17 in this epitope, 
but when the same group inserted this peptide into HPV -16 L 1, creating a chimaeric 
protein, cross-neutralisation was broader (Kondo et at., 2007; Kondo et at., 2008). 
Therefore the effect could have been due to poor immunogenicity of the peptide 
coupled to KLH. Another group used the peptide spanning from 20-38, displayed on 
bacterial thioredoxin (Rubio et at., 2009) and obtained excellent neutralisation titres, 
while performing far better than other peptides used in this study. Therefore the 
necessity of residues 17-19 is still open to debate and may depend on the differences 
between studies, like linker haptens and display proteins. 
Another region of significance lies between amino acids 56 and 81 of HPV -16 L2, 
overlapping with a highly conserved region ofL2, as illustrated by Figure 1.5. Amino 
acids 69 to 81 were first tested by Kawana et at. (Kawana et at., 1998) Monoclonal 
antibodies were raised against type 16 L 1 IL2 capsids. Of these, 11 bound linear 
epitopes of L2, and seven of those bound the peptide composed of amino acids 69 to 
81. Sera against VLPs of types 16, 18, 58 and 6b bound to this peptide. Taken 
together, this would suggest that this peptide is a common immunodeterminant. The 
same peptide was also linked to KLH and inserted into BPV L 1, used to raise antisera, 
and neutralisation of native type 11 virions as well as type 16 pseudovirions was 
tested (Slupetzky et at., 2007). Antiserum to the peptide alone only neutralised type 
16 pseudovirions, but antibodies to the displayed peptide also cross-neutralised native 
type 11 virions. Kondo et at. (Kondo et at., 2007) tested the same peptide, and 
antisera to it cross-neutralised two of the three heterologous pseudovirions tested. A 
very similar region from amino acid 64 to 81 inserted into thioredoxin was also tested, 
(Rubio et at., 2009) and antisera to it showed broad cross-neutralisation, although not 











Kondo et at. (Kondo et al., 2007) did a mapping study around this epitope, testing for 
neutralisation of type 18, 31 and 58 pseudovirions. Amino acids 64 to 81, 61 to 75 
and 56 to 75 were tested. Only sera to the latter peptide cross-neutralised type 31, 
suggesting that amino acids 56 to 64 are essential to type 31 neutralisation and that 
amino acids 75 to 81 are not essential. This observation is supported by data where a 
peptide of amino acids 75 to 112 displayed on BPV L1 (Schellenbacher et al., 2009), 
does not neutralise homologous or heterologous pesudovirions, indicating that the 
amino acids between 75 and 81 do not constitute an epitope by themselves. The 
peptide 56 to 75 was also displayed on HPV -16 L 1 proteins, and neutralised all five 
pseudovirion types tested (Kondo et at., 2008). However, according to Kawana et al. 
(Kawana et al., 1998), the first group to test this epitope, amino acids 75 to 81 contain 
essential epitopes, because only one of the monoclonal antibodies raised against 69-
81, also reacts with amino acids 63 to 75. Amino acids 56 to 68 may therefore also 
contain a cross-neutralisation epitope. In summary, not only does the region 
consisting of amino acids 56-81 contain multiple epitopes, but also incorporating all 
of these amino acids in a peptide used for immunisation should safely encompass all 
ofthem. 
The third region of interest lies between amino acids 96 and 122. An epitope 
consisting of amino acids 108-120 was first discovered by Kawana et al. (Kawana et 
al., 1999) These 13 amino acids also constitute a highly conserved region within L2, 
as seen in Figure 1.5. A panel of monoclonal antibodies raised against L1/L2 capsids, 
yielded 2 mAbs that bound to amino acids 108-120 and which also cross-neutralised 
type 6 pseudovirions. The same group has already vaccinated human volunteers with 
this peptide and obtained antibodies neutralising type 16 and 52 pseudo virions 
(Kawana et al., 2003). This peptide, coupled to KLH, and injected into animals, raised 
sera which cross-neutralised native type 11 virions (Slupetzky et al., 2007). However, 
these did not show cross-reaction with ROPV or CRPV (Embers et al., 2002). Other 
peptides from the region of interest have also been tested. Pseudo virion neutralisation 
abilities of sera to peptides comprised of amino acids 90 to 111, 96 to 115 and 107 to 
122 were compared (Kondo et al., 2007). Of these three, sera to amino acids 96 to 115 
were the only ones with broad-spectrum activity, taking into consideration that type 6 
or type 52 pseudovirions were not tested for. These data suggest that amino acids 96 











This peptide displayed on type 16 L1, with residues 101 and 112 mutated, also 
showed broad-spectrum activity (Kondo et at., 2008). The apparent redundancy of 
amino acids 108-120 is supported by Jagu et at. where amino acids 21 to 107 showed 
broad cross-reactivity, but 89 to 200 did not. The necessity of amino acids 111 to 115 
is supported by Schellenbacher et at. (Schellenbacher et at., 2009), where peptides 
omitting amino acids 113 to 115, did not elicit any neutralising activity, and by 
Kawana et at. (Kawana et at., 1999), where no mAbs raised against LlIL2 capsids 
reacted with the peptide 95 to 107. Taken together, it seems as if there is a broader 
cross-reactive epitope to be found between amino acids 96 to 115, but there could be 
an epitope from amino acids 108-120 that induces cross-reactive antibodies against 
types other than those for amino acids 96 to 115. In summary, it may be safe to 
designate the complete region between amino acids 96 to 120 as a general cross-
reactive epitope. 
Regions of L2 from papillomavirus types other than type 16 have also been tested. 
The region between amino acids 1-88 of BPV L2 has been identified as a widely 
cross-reactive area (Gambhira et at., 2007a; Pastrana et aI., 2005). Interestingly, the 
corresponding region from CRPV did not show the same cross-reactivity. The above-
mentioned BPV L2 region showed better cross-neutralisation patterns than the 
corresponding region in HPV -16 L2, and sera raised against this peptide reacted to 
peptides found between amino acids 25 and 68 ofHPV-16 L2. 
1.4.2 Functions of cross-neutralising epitopes ofL2 
The localisation of neutralising and cross-neutralising epitopes of L2 can be attributed 
to these regions having a particular function, as conserved domains usually have an 
important function and are more likely to induce cross-neutralising antibodies. 
Recently published papers suggest a model for HPV infection (shown in Figure 1.6) 
that involves exposure of the N-terminal of L2 on the surface of the capsid and 
cleavage of the first 12 amino acids prior to cellular infection, thus exposing cross-
neutralisation epitopes (Day et at., 2008; Buck et at., 2008; Kines et at., 2009). This 
exposure ofL2 is for a sufficient period oftime to elicit antibodies (Day et at., 2008; 
Kines et at., 2009). It is not clear whether L2 is exposed on the surface of the viral 











it is also known that LI/L2 capsids do not elicit more cross-neutralising antibodies 




Figure 1. 6. A model for in vivo HPV infection. Mature virus capsids, on which 
anti-L2 antibody binding sites are hidden, bind to heparan sulphate proteoglycans 
on the cervicovaginal basement membrane. This interaction leads to a 
conformational change that exposes the N-terminal of L2 on the surface of the 
capsid, enabling cleavage of L2 amino acids 1-12 by furin or a proprotein 
convertase (PC). The capsid can then be transferred to a second receptor on the 
epithelial cells, which leads to endocytosis and infection. This process may be 
inhibited by anti-L1 antibodies, which inhibit the conformational change and 
exposure of L2, thus inhibiting infection. The process is also inhibited by anti-L2 
antibodies, which bind to the exposed N-terminal of L2, thus preventing infection. 
Picture was taken from Kines et al. and modified. (Kines et ai. , 2009) 
The mAb, RG-1 , and polyclonal sera against the L2 peptide 17-36, binds the exposed 
terminal epitope of L2 according to the proposed model (Day et al., 2008; Kines et 
ai. , 2009). RG-1 does not bind mature pseudo virions in solution prior to infection 
(Day et ai., 2008): therefore this region probably only becomes exposed after cell 
binding and furin cleavage. The RG-1 binding site is directly downstream from the 
furin cleavage site (Kines et al., 2009). The position of the binding site makes this 
region the most likely part of L2 to be exposed on the surface of the capsid, but it is 
possible that a greater portion of the N-terminal ofL2 is exposed on the surface, since 
vaccination with HPV-16 LI /L2 capsids have previously yielded monoclonal 
antibodies against amino acids 64-81 and 108-120 of HPV -16 L2 (Kawana et ai. , 











L2 has been shown to bind to the cell surface via a receptor different from Ll, as well 
as greatly enhancing viral infectivity (Kawana et al., 2001; Buck et al., 2008; Day et 
al., 2008; Kines et al., 2009; Yang et al., 2003). It contains several motifs that 
mediate these interactions. One such motif comprises residues 13 to 31, a region 
similar to the RG-l epitope. When residues 18, 19, 21 and 22 were mutated, this 
interaction was abolished. The motif was also important for the infectivity of 
pseudo virions. Another motif is that found between amino acids 108 to 126, as tested 
by Kawana et al. (Kawana et al., 2001). This motif was found to bind to COS-l and 
HeLa cells, and to be essential in pseudovirion infection of these cells, particularly 
when residues 108 to 111 were substituted for. The data is supported by similar 
results from BPV L2 residues 91 to 129, confirming that this region is a conserved 
functional domain (Yang et al., 2003). As mentioned before, amino acids 108-120 
have been identified as a cross-neutralising epitope. 
Another region ofthe L2 protein has been shown to be involved in HPV infection. L2 
was shown to interact with ~-actin, directing intracellular transport of 
papillomaviruses to the nucleus, where the virus replicates (Yang et al., 2003). This 
interaction was common to both HPV -16 and BPV -1, which are distantly related PV s. 
The functional domain involved in this process comprised amino acids 25-45, but 
amino acids 13-31 did not show the same interaction. Amino acids 13-31 comprise a 
region that overlaps with the known cross-neutralising epitope of aa 17 to 36, which 
once again suggests the importance of residues 32 to 36. Antibodies against this ~­
actin-binding region of L2 may not prevent HPV infection, but could prevent 
subsequent intracellular transport and therefore neutralise viral infection. 
In summary, from the above data, major conserved cross-neutralising regions of L2 
emerge within the first N-terminal 120 amino acids. Those regions that have shown 
potential to cross-neutralise HPV, of types other than the type L2 is derived from, 
include HPV-16 L2 amino acids 17-38, 56-81 and 96-120; and BPV-I L2 amino acids 
1-88. These cross-neutralising regions of L2 should be considered in the design of 











1.4.3 Chimaeric L11L2 vaccines 
One approach to the problem of creating a pan-papillomavirus vaccine, which avoids 
lack of surface exposure ofL2 sequences, is to fuse L2, or cross-reactive L2 peptides, 
to Ll. Because papillomavirus VLPs are made up of360 molecules ofLl, arranged as 
72 pentamers, linking L2 to Ll results in a tandem array of L2 in close proximity to 
one another. This tandem array may increase its immunogenicity (Kirnbauer et ai., 
1992; Bachmann & Zinkernagel, 1997). In native virions, the ratio of Ll to L2 can 
range from 5:1 to 30:1 (Buck et ai., 2008), making L2 the subdominant protein within 
the virion and Ll immunodominant. Ll immunodominance could be due to it being 
more closely spaced than L2. Another incentive for linking L2 peptides to Ll is that 
peptides by themselves are not very immunogenic and they need to be linked to 
haptens in order to increase their immunogenicity. Even when L2 peptides are linked 
to molecules such as KLH, they display low immunogenicity. Ll may be an ideal 
carrier molecule, since it can act as an adjuvant for various reasons, as discussed 
further below (Lenz et ai., 2001; Lenz et ai., 2003; Rudolf et ai., 2001a). 
1.5 L1 as a carrier molecule 
1.5.1 Advantages 
The excellent immunogenicity of Ll, as well as its capacity to accommodate 
modifications to its structure, are two reasons for using it as a vehicle to display 
heterologous epitopes. Ll is in itself an excellent adjuvant, as evinced by the fact that 
VLPs can in some cases be injected into animals without an adjuvant and still elicit an 
immune response (OhlschUiger et ai., 2003; Wakabayashi et ai., 2002; Reddy et aI., 
2004; Greenstone et ai., 1998). Ll VLPs and LlIL2 VLPs also bind to multiple cells 
of the immune system, which accounts for their effectiveness in priming both the 
cellular and the humoral arms of the immune system (Lenz et aI., 2003; Da Silva et 
ai., 2001). Not only do they bind to dendritic cells, they also induce acute activation 
of dendritic cells and the repeptitive array of virion surface proteins were implied in 
this interaction (Lenz et ai., 2001; Rudolf et ai., 2001a). Dendritic cells are the most 
important antigen-presenting cells (APes), and play a central role in adaptive 











antigen-specific T - and B-Iymphocytes and towards secretion of cytokines, which in 
tum leads to effective cell- and antibody-mediated responses (Janeway et ai., 1997a). 
It is interesting that assembly-deficient L1 protein was inferior in the induction of 
maturation of dendritic cells (Lenz et ai., 2001). 
The close-packed, ordered structure of VLPs is a key factor in their immunogenicity 
and their induction of both T-cell and B-cell mediated responses (Kirnbauer et ai., 
1992; Bachmann & Zinkernagel, 1997; Lenz et ai., 2001). In fact, this class of antigen 
is rarely encountered in an accessible form in vertebrate hosts and thus assists in 
identifying the antigen as foreign (Bachmann & Zinkernagel, 1997). Also, highly 
repetitive structures assist in cross-linking B-cell receptors, which is a necessary 
signal for T-cell independent B-cell activation and eventual secretion of antibody 
(Janeway et ai., 1997b). Only highly repetitive structures found on many viral capsids 
and bacteria, are able to bypass help from antigen-specific T -cells (Bachmann & 
Zinkernagel, 1997; Janeway et ai., 1997b). 
1.5.2 Immunodominance 
Caution may have to be exercised when L1 is employed as a carrier molecule for 
epitope vaccines, due to the phenomenon known as immunodominance (Sette & 
Fikes, 2003). Immunodominance occurs when the immune response to an antigen is 
focused on only a few or even only one epitope, to the exclusion of other subdominant 
epitopes. Immunodominance has been observed with polytope peptide vaccines (Ie 
Thuy et ai., 2001; Ju et ai., 1993). In fact, even when peptides from diverse organisms 
normally immunodominant within the context of their own antigenic system are 
combined, "superdominant" hierarchies emerge (Sandberg et ai., 1998). Therefore 
immunodominance may not necessarily be intrinsic to an epitope and may be 
dependent on the context in which it is presented (Sandberg et ai., 1998; Kim et ai., 
2007a). The intrinsic high immunogenicity ofL1 (Lenz et ai., 2003; Da Silva et ai., 
2001) may indicate the presence of multiple immunodominant epitopes, which may 
dominate the immune response to the detriment of the inserted peptides. Stable 
tertiary or quarternary structures have been implicated in immunodominance (Ito et 
ai., 2003), which correlates with the situation in L1, where its higher-order structures, 











antibodies (Carter et al., 2006; Sadeyen et al., 2003; Christensen et al., 2001). 
Immunodominant epitopes may even downregulate the immunogenicity of 
subdominant epitopes (Wieland et al., 2010) and the deletion of immunodominant 
epitopes from antigens have been shown the enhance the immune response to other 
subdominant epitopes found within this antigen (Wieland et al., 2010; Cleveland et 
al., 2000b; Dai et al., 2002). Although immunodominance has not specifically been 
studied in the context of L1, there may be indications of this phenomenon in some 
cases. For example, in one study (Bian et al., 2008), when mice were immunised with 
chimaeric L1E7 capsomers, the dominant cellular immune response was directed 
towards L1 and not the inserted E7 peptide. The same effect was seen for antibody 
responses to E7 in the context of LlIE7 chimaeric proteins (Liu et al., 2000) 
However, where chimaeric L1 proteins have been tested in mice for an immune 
response against the inserted peptide, in the vast majority of cases - provided the 
peptide was inserted into an optimum position - an immune response against the 
peptide could be detected. Evidence for this is presented in the discussion of optimum 
insertion sites within L1 below. There were also cases where the immunogenicity of 
an inserted epitope was improved in the context ofLl (Qian et al., 2006; Slupetzky et 
al., 2007). 
1.5.3 Modifications of Ll 
The HPV capsid is made up of 72 pentameric capsomers, with complex loops 
protruding from the surface. L1, which self-assembles into VLPs nearly identical to 
the capsid, can be modified as a carrier for foreign epitopes, even to the extent of 
disrupting interpentameric bonds. When interpentameric bonds are disrupted, for 
instance by the insertion of epitopes into the L1 protein or other modifications, L1 
will still form cap somers. Capsomers have also been shown to be highly 
immunogenic and to elicit neutralizing antibodies (Schadlich et al., 2009; Thanes et 
al., 2008; Varsani et al., 2003; Murata et al., 2009; Slupetzky et al., 2007; Slupetzky 
et al., 2001). It must be said, however, that they are less immunogenic than VLPs and 
therefore a higher dose may be required to elicit the same level of neutralisation 
(Thanes et al., 2008). The immunogenicity of capsomers makes it possible to 











Modifications of Ll utilize its inherent immunogenicity and close-packed structure 
which primes the immune system against displayed epitopes. B-cells require binding 
of intact antigen to its receptors for the initiation of humoral immune responses 
(Janeway et ai., 1997b). Therefore, to generate an antibody response against an 
epitope, it needs to be displayed on the surface of a molecule. It follows, therefore, 
that insertion of pep tides into the surface loops ofLI will ensure their display on the 
surface of the Ll molecule. Ideally, if anti-Ll antibody responses are desired, as in 
the case of prophylactic HPV vaccines, the insertion should not abolish an anti-Ll 
neutralising response, yet should generate a robust response against the inserted 
peptide. The formation ofVLPs is also ideal, since VLPs are more immunogenic and 
would display more epitopes in closer arrays than other less ordered structures would. 
T-cell epitopes for presentation by MHC Class I molecules involved in cellular 
immunity can also be inserted into Ll. Such a modification may seem counter-
intuitive, since the classical pathway for MH C Class I presentation is via the 
endogenous pathway (Rudolf et ai., 2001a; Peng et ai., 1998; Liu et ai., 2000). This 
pathway requires that viral proteins be degraded in the cytosol into peptides that can 
be presented by MHC molecules. Exogenous antigens, like VLPs, have in many cases 
failed to elicit CTL responses (Peng et ai., 1998). However, papillomavirus VLPs do 
access the cellular immune system by interaction with immune cells (Lenz et ai., 
2003; Da Silva et ai., 2001) and uptake by dendritic cells (Da Silva et ai., 2007). 
Since display of T-cell epitopes for the induction of cellular immunity requires 
degradation of proteins in the cytosol, it may seem unnecessary to optimize the 
insertion sites ofT -cell epitopes into Ll. However, surface display or presentation of 
CTL epitopes as multiple copies in repetitive arrays, enhances induction of CTL 
responses (Kruger et ai., 1999). The importance of surface display was reiterated by 
Street et ai. (Street et ai., 1999), who found that the insertion of a hydrophobic CTL 
epitope into a hydrophilic, surface-displayed region of the hepatitis B core antigen, 
caused the CTL epitopes to be invaginated. The invagination led to the abolishing of 
CTL responses and the reason given for this was that the CTL epitopes were not 











against the inserted L2 epitopes were therefore low (Varsani et at., 2003; Kondo et 
at., 2008). 
Ll chimaeric proteins have also been created by fusing proteins or peptides to the C-
terminal ofLl. This has especially been done for LlfE7 constructs (Paz De la Rosa et 
at., 2009; Ashrafi et at., 2008; Kuck et at., 2006; Peng et at., 1998; Liu et at., 2000; 
Wakabayashi et at., 2002; lochmus et at., 1999), and in some cases LlIGFP 
(Windram et at., 2008) and LlIHIV constructs (Liu et aI., 2000; Peng et at., 1998; Liu 
et at., 2002). In all cases, except when expressed in human cell lines, Ll retains its 
ability to form VLPs and to elicit antibodies, despite the deletion of up to 34 amino 
acids from the C-terminal ofHPV-16 Ll or 25 amino acids from BPV Ll. Antibody 
responses against epitopes fused to the C-terminal, which could indicate surface 
display of these epitopes, have not been clearly shown in the literature. Where they 
were tested, antibody responses were low, but the low response could be due to E7 
epitopes being subdominant to Ll epitopes (Liu et at., 2000). However, CTL 
responses against fused epitopes were better when VLPs were in their native form 
than when denatured (Liu et at., 2002). It is likely, according to structural analysis of 
Ll, that epitopes fused to the C-terminal are packed within the interior of the VLP 
shell (Chen et aI., 2000). 
Full-length proteins have also been fused to L2, which were then co-expressed with 
Ll (Qian et at., 2006; Rudolf et at., 2001a; Xu et aI., 2007; Wakabayashi et at., 2002; 
Greenstone et at., 1998; Windram et at., 2008). In all cases they form VLPs and retain 
their ability to elicit antibodies against Ll, but the foreign proteins are unlikely to be 
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Figure 1. 7. A. LI monomer. Surface loops are in pink and helices and the j3-J sheet are in yellow. Picture taken from Chen et at. 
(2000) (Chen et at. , 2000) and modified B. Sequence alignment ofLI from HPV-I6, -35, -11 and -18, showing the position of 
structural features within LI. Conserved residues are shaded in grey, arrows indicate j3-sheets, thick lines indicate helices and the 











1.6 The need for treatment of existing HPV -related cancers 
Another problem not addressed by current HPV vaccines on the market is that of 
treating existing HPV infections and related precancerous and cancerous lesions. A 
clinical trial conducted in Costa Rica with women positive for HPV DNA at the start 
of the study and vaccinated with Cervarix™, showed no evidence of viral clearance 
even after 12 months (Hildesheim et at., 2007). When subjects were stratified 
according to factors indicating disease extent, like viral load or cytological findings at 
entry, there was no correlation between disease severity and vaccine efficacy for viral 
clearance. HPV types other than 16 or 18 were also not cleared by the vaccine. 
Currently, HPV -induced lesions are treated by removal of the abnormal tissues. 
Procedures include surgical removal of tissues, cryotherapy, laser evaporation 
therapy, loop electro surgical excision procedure or cold-knife conization. These 
treatments are not only invasive, but also inefficient, since recurrence is a common 
outcome (Govan, 2005). Immunotherapy, where the immune system is primed to 
specifically target HPV -infected tumour cells, would be more specific and potentially 
more efficient at treatment. In addition, it would be far less invasive. 
Therapeutic vaccination requires that a cell-mediated immune response be elicited. 
This is because tumour cells are targeted and killed by CTL (Human 
Papillomaviruses/IARC Working Group on the Evaluation of Carcinogenic Risks to 
Humans, 2005). Since Ll and L2 are only expressed in terminally differentiated 
epithelial cells, and not in precancerous or cancerous tissue, they are not ideal targets 
for therapeutic vaccines (Govan, 2005). The "early" HPV proteins, especially E6 and 
E7 (Human Papillomaviruses/IARC Working Group on the Evaluation of 
Carcinogenic Risks to Humans, 2005), but also other early proteins such as El, E2 
and E5 (Govan & Williamson, 2007; Brandsma et at., 2007; Liu et at., 2007) are 
expressed in cancerous and precancerous lesions and are therefore better protein 
targets for immunotherapy. Therefore CTL epitopes derived from these proteins, 
should be presented in complex with MHC class I molecules on the surface of 











1.6.1 HPV-16 E7 T-cell epitopes 
Preclinical studies have shown E7 to be an ideal target for therapeutic vaccines 
(Govan, 2005). Various E7-based vaccines are also being or have been tested in Phase 
IIII clinical trials (Roman et ai., 2007; Santin et ai., 2003; Fiander et ai., 2006; 
Einstein et ai., 2007). Like L2, E7 contains essential T-cell epitopes that can be used 
to prime cellular immune responses. Vaccinating with these epitopes instead of whole 
protein may be advantageous for many reasons, including that it circumvents the 
oncogenicity of whole protein, (Liu et ai., 2007; OhlschHiger et ai., 2006) increases 
memory immune responses, (Liu et al., 2007) avoids viral regions with high inter-
strain variability or regions to which tolerance might exist, (Kast et ai., 1994) and 
enhances immunity to subdominant epitopes displayed by MHC molecules on cell 
surfaces (Kast et ai., 1994). 
Human T-cell epitopes derived from HPV -16 E7 have been mapped. Four CTL 
epitopes emerge as significant: these are amino acids 11-20, 12-20, 82-90 and 86-93. 
The binding ofthese peptides to the HLA-A2 allele was first demonstrated by Kast et 
ai. (Kast et ai., 1994), and lysis of a human cervical cancer cell line by CTL 
stimulated by three of these peptides (excluding 12-20), was shown by Ressing et al. 
(Ressing et ai., 1995). Another research group (Jochmus et ai., 1997) stimulated 
peripheral blood lymphocytes from a healthy volunteer and cervical cancer patient 
with different peptides to obtain CTL lines. Only a small number oflow-affinity CTL 
lines against the peptide 86-93 could be obtained and not against any of the other 
peptides used in stimulation, like 11-20, 7-15 and 82-90. Since then, 3 CTL epitopes 
have been tested in Phase IIII clinical trials. Amino acids 86-93 (TLGIVCPI) were 
linked to a universal T -helper epitope (PADRE) (Steller et ai., 1998) and elicited 
immune responses in all patients, but showed no clear clinical effect. In another trial, 
peptide aa 11-20 was mixed with aa 86-93 and a pan-DR T-helper epitope (van Driel 
et ai., 1999). There was no clear clinical response either. Lastly, patients were 
immunized with peptide consisting of amino acids 12-20, and some were immunized 
with the latter peptide as well as amino acids 86-93 fused to PADRE (Muderspach et 
ai., 2000). Once again, there was no clear clinical response, but only the peptide 12-20 
had responders with respect to cytokine release from the patients. Another study 











(11-20) and found that these were upregulated in patients with HPV-16 positive 
carcinomas of the head and neck (Albers et ai., 2005). 
The most significant E7 CTL epitope (amino acids 49-57, RAHYNIVTF) specific to 
mice carrying H2-Db alleles, such as C57/BL6 mice, has also been identified and is 
used regularly in tumour regression and CTL response studies in mice (Bian et ai., 
2008; Kuck et ai., 2006; Liu et ai., 2000; Peng et ai., 1998). This epitope was first 
identified by Feltkamp et ai. (Feltkamp et ai., 1993) to bind strongly to H2-Db MHC 
class I molecules and to protect mice against challenge with HPV -16 transformed 
tumour cells. In a recent article, this epitope was confirmed to be the only CTL 
epitope in mice (Khammanivong et ai., 2003). Immunotherapy with this peptide is 
highly successful in mice with the H2-2Db allele (Torrens et ai., 2005; Daftarian et 
ai., 2006; Paz De la Rosa et ai., 2009). 
1.6.2 Problems related to vaccination with E7 T-cell epitopes 
Several problems still need to be overcome before immunization with T-cell epitopes 
will be effective. The first problem is that immunisation with CTL epitopes has so far 
not been successful in cervical cancer patients, as can be seen from the clinical trials. 
In order to efficiently activate the MHC Class I pathway, appropriate adjuvants need 
to be co-administered (Peng et ai., 1998). The biggest reason why immunisation with 
CTL epitopes has not been successful, however, is immune evasion by HPV. When 
HPV infects epithelial cells, immunosuppressive cytokine expression is upregulated. 
Low viral protein expression, the lack of a danger signal and lack of cross-
presentation are all factors that serve to aid HPV in evading the immune system 
(Daftarian et ai., 2006). It is also known that MHC Class I molecules may be 
downregulated in cervical cancer cells, therefore targeting CTL epitopes may not be 
such an efficient approach (Hohn et ai., 1999). Indeed, there are studies that suggest 
that CD4 T-cell epitopes play a significant role in mediating tumour regression: 
regression and loss of HPV infection was associated with cell-mediated immune 
responses to a CD4+ T-cell epitope (Kadish et ai., 2002; Peng et ai., 2007), CD4+ 
tumour-infiltrating lymphocytes have been suggested to directly mediate tumour 
regression by recognition of MHC Class II-presented antigens in the absence of 











responses have been far more frequent than CD8+ in cervical cancer patients (Piersma 
et ai., 2008). It is also becoming widely accepted that the inclusion of a T-helper or 
CD4+ epitope in a peptide-based vaccine, is important in stimulation of the immune 
system to eradicate tumours (Muderspach et ai., 2000; Steller et ai., 1998; van Driel et 
ai., 1999; Daftarian et ai., 2006; Doan et ai., 2005; Vambutas et ai., 2005; Tindle et 
ai., 1991; Xu et ai., 2009; Qin et ai., 2005). 
The second problem still to be overcome is that of targeting HLA alleles other than 
HLA-A2 (HLA*A*0201), on which most, if not all, of the focus has been. The 
HLA * A *0201 allele is the most common allele in the Caucasian population 
(Madeleine et ai., 2008), but women of other races do not necessarily carry the same 
alleles to the same frequency. Furthermore, more analysis is needed to look at 
populations of tumour-infiltrating lymphocytes and their HLA specificity. The HLA-
A2 allele has actually been shown not to confer as high a risk for cervical cancer as 
have others (Madeleine et ai., 2008). No region of E7 was shown to be preferred in 
anti-tumour responses, showing the variety of epitopes and their binding alleles 
potentially involved in cervical cancer. For MHC class II alleles, HLA-DQ and HLA-
DP were shown to be preferred restriction elements, even though they are less 
abundantly expressed (Piersma et ai., 2008). There are a few studies that have focused 
on mapping E7 T-cell epitopes presented by a specific MHC molecule, like HLA-B8 
(Oerke et ai., 2005) and HLA-B7 (Ellis et ai., 1995), which are more associated with 
cervical cancer, HLA-A24 (Morishima et ai., 2007), which is more abundantly 
expressed in Asian women, and HLA-B18 (Bourgault, I et ai., 2000). Some studies 
have focused on mapping epitopes within E6 and E7 binding to a variety of alleles 
simultaneously (Piersma et ai., 2008; Rudolf et ai., 2001b). 
The third problem to be overcome is that of immunotherapy for patients infected with 
types other than type 16. Not many studies have focused on identifying CTL epitopes 
relevant to other types. Most studies on types other than type 16 have identified T-cell 
epitopes specific to HPV-18 (Smith et ai., 2005; Kather et ai., 2003; Castellanos et 
ai., 2001; Rudolf et ai., 2001b). CD4+ T-cell epitopes were identified for types 59, 68 
and 33 (Sette et ai., 1993; Hammer et ai., 1993; Hohn et ai., 2000) and CTL epitopes 
have been mapped for HPV-ll (Xu et ai., 2008). However, the question remains to 











types. An HPV-16E7 (11-20)-specific CTL line was tested for its ability to kill cells 
transfected with full-length type -16, -52, -45 and -31 (Y oude et at., 2005). Only cells 
transfected with type 52 could be killed. Tumour infiltrating lymphocytes were found 
to be specific to either HPV -16 or -18 respectively, and no cross-reaction was seen 
between the two types (Piersma et at., 2008). A CD4+ T-cell epitope correlated with 
regression ofCIN (Kadish et at., 2002) showed non-type-specific effects, however, it 
couldn't be ruled out that patients could previously have been infected with type 16 
and therefore these responses present memory responses. A cervical cancer cell line 
derived from an HPV-59 positive patient, TIL-CCAl, responded to B cells transfected 
with the E7 gene from HPV-59 and -68, but not -16 or -35 (Hohn et at., 1999). 
Lastly, an HPV18f45 cross-reactive T-cell, HLA-A2-binding epitope has been 
identified, demonstrating that cross-reactive T cell responses against closely related 
HPV types can be induced in vivo (McCarthy et at., 2006). All this evidence seems to 
suggest that cell mediated immunity may be as type-specific as humoral immunity for 
HPV. 
1.6.3 Chimaeric LlIE7 vaccines 
The leading candidate vaccines for the treatment or prevention of cervical cancer in 
humans are LlfE7 chimaeric virus-like particles (Rudolf et at., 2001a). This approach 
is feasible for two reasons: These are creating vaccines that are simultaneously 
prophylactic and therapeutic, as well as seeking to enhance the immunity of E7 by 
utilizing the inherent immunogenicity of VLPs. So far, design of chimaeric VLPs 
containing targets for immunotherapy has exclusively focused on C-terminal fusion. 
Full-length E7 or the N-terminal part ofE7 has been fused either to the C-terminal of 
Ll (Bian et aI., 2008; Kuck et at., 2006; Ashrafi et at., 2008; Kaufmann et at., 2001; 
Kaufmann et aI., 2007; lochmus et at., 1999) or to the C-terminal ofL2 (Qian et at., 
2006; Rudolf et aI., 2001a; Xu et at., 2007; Greenstone et at., 1998) creating LlfE7 or 
LlIL2fE7 cVLPs respectively. The efficiency of eliciting a cellular immune response 
in mice was compared between LlfL2 and Ll cVLPs and it was found that LlIE7 
cVLPs were more efficient at doing so (Wakabayashi et at., 2002). Only in two cases 
have CTL epitopes been used in chimaeric VLPs. One study inserted the mouse H2-
Db-restricted epitope into the C-terminal ofBPV-LI and was able to show efficacy in 











HPV-16 E7 epitopes, including the mouse-restricted epitope 49-57, the human-
restricted epitope 86-93, and the human-restricted T-helper epitope 37-54, and one E6 
epitope to the C-terminal ofHPV-16 Ll, of which the last 34 amino acids have been 
deleted (Paz De la Rosa et ai., 2009). 
Phase I clinical trials in humans have been carried out only for LlIE7 chimaeric 
vaccines (Kaufmann et ai., 2007) and a non-significant trend was seen in efficacy. In 
vitro studies of cellular immune responses in human donors by LlIL2fE7 and LlfE7 
vaccines have shown promise (Warrino et ai., 2005; Kaufmann et ai., 2001; Rudolf et 
ai., 2001a) and therefore LlIE7 chimaeric vaccines is a line of research worth 
pursumg. 
1.7 Conclusion 
Ll VLPs have proven to be highly immunogenic as prophylactic vaccines in humans. 
Their ability to prime and bind to cells of the immune system, as well as their 
repetitive nature, is the reason for their high immunogenicity. Therefore Ll is an 
adjuvant in itself. Ll can also easily be modified to carry foreign proteins and 
epitopes, while still forming immunogenic, higher-order structures. 
Currently licensed vaccines are highly effective type-specific prophylactic vaccines, 
which also elicit high titres of neutralising antibodies. Even though the vaccines are 
directed against the most prevalent types worldwide implicated in cervical cancer, 
they may not be as effective in all populations, since type distribution is affected 
geographically as well as by concurrent HIV infection. A vaccine that will neutralise 
multiple types is therefore needed. A protein that elicits cross-neutralising antibodies 
is L2, the minor capsid protein. It contains multiple cross-neutralising epitopes that 
could be incorporated into Ll to produce a highly effective broad-spectrum vaccine. 
Current vaccmes also cannot be used to treat existing infections and physical 
treatment methods are not effective. Vaccination with proteins that are expressed in 
carcinogenic, HPV -infected cells, could boost cellular immunity that would eliminate 











to reduce tumours in animals. Immunotherapy with CTL epitopes still has several 
problems to overcome. The first one is low immunogenicity in humans. Using CD4-
T-cell epitopes in vaccination may be a key to overcoming this problem. Secondly, 
CTL epitopes are HLA-specific, and humans are highly polymorphic in this respect. 
Thirdly, CTL epitopes may be type-specific and little work has been done in mapping 
CTL epitopes against types other than -16 or -18. 
Chimaeric LlfE7 vaccines are the leading candidate vaccines. Such vaccines can be 
both prophylactic and therapeutic and the adjuvanticity of Ll can be utilised. 
Although clinical trials have not shown high efficacy with respect to immunotherapy, 
chimaeric vaccines remain a good approach towards solving the problem of treating 
cervical cancer. 
1.8 Objectives of this study 
The aim of this project was first to address the need for a broad-spectrum prophylactic 
vaccine by incorporating the sequences of four different cross-neutralising L2 
epitopes into the sequence ofHPV-16 Ll. The four epitopes that have been shown to 
elicit cross-neutralising antibodies neutralising divergent human papillomavirus types, 
HPV-16 L2 amino acids 17-36 (Gambhira et ai., 2007b), 56-81 (Kawana et ai., 1998) 
and 108-120 (Kawana et ai., 1999); and BPV -1 L2 amino acids 1-88 (Pastrana et ai., 
2005), were employed in the design of these vaccines. The peptides were inserted into 
the helix 4 position, since such an insertion has been shown to be optimum both for 
anti-Ll and anti-L2 immunogenicity (Varsani et ai., 2003). 
The second aim was to address the need for immunotherapeutic vaccines by 
incorporating the sequence of an HPV-16 E7 CTL epitope into the sequence of Ll. 
HPV-16 E7 amino acids 49-57, a CTL epitope specific to the mouse H2-Db allele and 
useful for testing in mice (Feltkamp et ai., 1993), as well as HPV-16 E7 amino acids 
86-93, a human CTL epitope binding to HLA-A2 alleles (Kast et ai., 1994), were 
inserted into the helix 4 ofHPV-16 Ll, creating two different chimaeras respectively. 
Two chimaeras were also created where the cross-neutralising L2 epitope, consisting 











epitopes mentioned above into the region between the helix 4 and the ~-J sheet, also 
shown to be a region useful for insertion 0 f foreign epitopes into HPV -16 L 1 (Varsani 
et at., 2003). 
In this project, we aimed to express these eight chimaeric proteins in a baculovirus 
expression system and to test their ability to elicit neutralising and cross-neutralising 
antibodies (the latter only in the case of L1/L2 chimaeras) as well as the ability of 












2. EXPRESSION OF Ll CHIMAERIC PROTEINS IN 
INSECT CELLS 
2.1 Introduction 
Human papillomaviruses (HPVs) infect epithelial tissue and cause warts and other 
lesions, which are largely benign; however, high-risk genital lesions may become 
malignant (de Villiers et al., 2004; Human Papillomaviruses/IARC Working Group 
on the Evaluation of Carcinogenic Risks to Humans, 2005). There are at least 120 
HPV types (Bernard et al., 2010) that are the cause of a large variety of symptoms or 
disease. The most significant disease, for which HPV is the causal agent, is cervical 
cancer. This disease is a significant global health burden, with 260000 deaths 
occurring annually as a result, 80% of which occur in developing countries (Cutts et 
al., 2007). Globally, HPV-16 and -18 are the types most frequently implicated in 
cervical cancer, with a 70% incidence rate (Bosch et al., 2008). The other 30% is 
contributed by at least a further 13 types (Castellsague, 2008). 
Vaccination has historically been the most effective way to eradicate infectious 
• 
diseases, therefore vaccination against HPV is supposed to be the most effective way 
of combating cervical cancer (World Health Organisation, 2005). Vaccines against 
types 16, 18,6 and 11 (the latter two types are most frequently associated with genital 
warts (de Villiers et al., 2004)) are available. These are based on Ll-only virus-like 
particles (VLPs), which differ from native HPVs where the capsid consists ofLI and 
L2 proteins, but are immunogenically similar. Merck manufactures Gardasil®, a 
vaccine consisting of a mixture ofVLPs ofthe four types listed above. Each VLP type 
was independently expressed in Saccharomyces cerevisiae, followed by a two-step 
purification involving micro filtration and cation exchange chromatography. The final 
concentration of each VLP type range between 40 to 80 Ilg/ml (Shi et al., 2007). The 
other presently available vaccine is manufactured by GlaxoSmithKline and consists of 
a mixture of HPV -16 and -18 VLPs at a concentration of 20 Ilg/ml each. These were 
expressed in insect cells or Hi-5 Rix4446 cells derived from Trichoplusia ni 
(Electronic Medicines Compendium, 2009). Both vaccines have shown high efficacy 
in preventing infection and disease by vaccine-specific types (Schiller et al., 2008). 











must still be continued, smce current vaccmes have limited efficacy against 
carcinogenic, non-vaccine types. It will also still be years until HPV is eradicated by 
vaccination, because of the high prevalence of infected women and the inability of 
current vaccines to clear existing infections. The pricing also makes them inaccessible 
to the developing world where they are needed most (Bosch, 2009). 
Current research therefore focuses on finding broad-spectrum second-generation 
prophylactic vaccines (Huh & Roden, 2008) .. Some of this research is focused on L2 
(Huh & Roden, 2008), the minor capsid protein, which can elicit cross-typic 
neutralising antibodies (Roden et at., 2000). One approach is to vaccinate with cross-
neutralising L2 peptides, (Jagu et aI., 2009; Kawana et at., 2003; Rubio et at., 2009; 
Alphs et at., 2008) but much research has been done on replacing surface sections of 
L1 with L2 peptides or inserting L2 peptides into these sections without deleting any 
amino acids from Ll. Possible modifications ofL1 have been thoroughly researched 
(Varsani et aI., 2003; Murata et aI., 2009; Slupetzky et at., 2001; Chackerian et at., 
1999). This strategy of creating a broad-spectrum vaccine is attractive, since, if L1 
specific to a carcinogenic type is used, high titres of neutralising antibodies can be 
achieved, while also obtaining cross-typic antibodies. On top of that, VLPs - due to 
their ability to potently activate the immune system - serve as an adjuvant to the 
coupled peptides and could therefore be ideal carrier molecules (Lenz et at., 2001; 
Rudolf et at., 2001a). 
The possibility of the L1 epitopes being immunodominant over the conjugated 
peptides must be considered (Sette & Fikes, 2003). It could be surmised that the 
immune response to L 1 may downregulate the immune response to the peptides or 
even completely abolish it, especially since L1 is known to be an immunodominant 
protein capable of eliciting strong immune responses. However, there is no evidence 
for a humoral or cellular immune response to an inserted peptide being completely 
negated by the immune response to Ll. There are examples, where E7 peptides have 
been inserted, showing that the dominant immune response might be targeted towards 
L1 and not E7 (Bian et at., 2008; Liu et at., 2000). There is, however, a study which 
showed the enhancement of humoral immunity to L2 peptides by incorporating them 
into L1, rather than injecting them in a form where they were conjugated to keyhole 











vaccines remain a research direction to pursue in the search for a second-generation 
vaccine with the capability to elicit broad cross-protection. 
Immunotherapy is another research focus, since mechanical ways of treating cervical 
cancer do not have a high success rate, and are invasive (Govan, 2005). Here the 
focus is on creating cellular antitumour immune responses by administration ofE6- or 
E7-based vaccines (Govan, 2005). There are still many problems to be overcome in 
this area of research. One research focus is on improving the low immunogenicity by 
better adjuvanting of proteins or peptides (Daftarian et ai., 2006; Daftarian et ai., 
2007; Steller et ai., 1998; Xu et ai., 2009; Govan et ai., 2008; Brandsma et ai., 2007; 
Yan et ai., 2009). 
Low-cost vaccines for the developing world are under investigation. Vaccine cost can 
be reduced by tiered pricing or financing strategies for developing countries. It would 
be more effective if developing countries owned the technology for production of 
vaccines and if vaccines could be produced at a lower cost (Bosch, 2009). One way of 
producing vaccines at a lower cost would be to utilise expression systems that can be 
cultivated more cheaply on a large scale and can express high levels of protein. 
Recombinant proteins have been expressed in cell cultures of bacteria, yeasts, fungi, 
mammals, plants, insects or via transgenic plants and animals (Demain & Vaishnav, 
2009). HPV L1 has been expressed for the purpose of vaccine production in a variety 
of systems, including transgenic plants (Kohl et ai., 2007; Warzecha et ai., 2003; 
Regnard et ai., 2010), bacteria (Yuan et ai., 2001; Ohlschlager et ai., 2003a; Li et ai., 
1997), yeasts (Sasagawa et ai., 1995; Carter et ai., 1991), the mold Pichia Pastoris 
(Bazan et ai., 2009) and insect cells (Park et ai., 1993). Bacterial systems are 
beneficial in that they express high levels of protein rapidly and inexpensively, 
however, E. coli mostly produces capsomers and not more immunogenic VLPs 
(Yuan et ai., 2001; Li et ai., 1997). Another disadvantage with bacteria is the high 
level of endotoxins. Transgenic plants, yeasts and molds can produce correctly folded 
VLPs that are immunogenic. The advantages of these expression systems is that they 
express at much higher levels than even E. coli, making them highly cost-effective. 
They can all be cultivated cheaply, are more robust and can easily be scaled up 











Insect cells are known for their superior ability to fold soluble mammalian proteins 
correctly. Other advantages include eukaryotic posttranslational modifications, proper 
disulphide bond formation (which is specifically important for VLP formation), safety 
due to the host specificity of baculovirus, expression of large proteins and efficient 
cleaving of signal peptides. Insect cells are also easy to scale up and express at 
relatively high levels, but they are inferior to some expression systems with respect to 
expression levels (Demain & Vaishnav, 2009). They are also more expensive to 
cultivate than yeast or bacteria and may be easily contaminated with other 
microorgamsms. 
L1 expressed from insect cells and administered to animals is accepted as the standard 
against which L1 produced in other systems are compared (Maclean et at., 2007; Kohl 
et at., 2007). For the latter reason, and because of their superior ability to produce 
correctly folded proteins that would be immunogenically active implies that in order 
to draw comparisons pertaining to immunogenicity between different VLP and/or 
capsomer-based vaccine candidates, it would be better to express them in insect cells 
before expressing them in other systems that may not produce correctly folded 
proteins. 
Our study formed part of a project aimed at developing a local technology for 
affordable, broad-spectrum second-generation vaccines. In previous work done in our 
laboratory (Varsani et at., 2003) regions ofHPV-16 L1 were replaced with the cross-
neutralising peptide, L2 amino acids 108-120 (Kawana et at., 1999). From this work, 
the helix 4 and the region between the helix 4 and the ~-J sheet in the C-terminal were 
identified as the best regions to display the L2 epitope, while at the same time 
retaining high anti-L1 immunogenicity. In our study, chimaeric L1 genes were 
designed to incorporate two other cross-neutralising regions of HPV -16 L2, amino 
acids 56-81 and 17-36 respectively (Kawana et at., 1998; Gambhira et at., 2007b), 
and amino acids 1-88 from bovine papillomavirus type 1 (BPV-1) (Pastrana et at., 
2005). They were inserted into the helix 4, replacing the same number of amino acids 
in HPV-16 L1, resulting in four different L1/L2 chimaeric genes. In the same way, 
MHC class I-restricted HPV-16 E7 epitopes, one with potential for immunotherapy in 
humans (Steller et at., 1998) and another one designed specifically for pre-clinical 











HPV-16 Ll. These epitopes encompassed amino acids 86-93 and 49-57 respectively. 
The rationale ofthe latter approach was to create vaccines combining the prophylactic 
abilities of L1 with the therapeutic abilities of the E7 epitope, thus creating a dual 
vaccine. Further building on the sequence of the dual vaccine as a backbone, in order 
to create a dual vaccine also displaying cross-neutralising ability, two further 
chimaeras were designed. In this design, the sequence of Chif..F-L2 previously 
constructed in our laboratory (Varsani et at. , 2003) was human codon-optimised and 
named SAF. SAF was used as the basis for chimaera construction, and the 
abovementioned E7 epitopes inserted into the region between the ~-J sheet and the 
helix 4, replacing the same number of amino acids in SAF. 
In work reported in this chapter, the eight constructed chimaeric genes (including 
SAF) were cloned into appropriate vectors and expressed in the standard insect cell 
expression system. Six of the chimaeras (excluding the two where the human MHC 
class I-restricted E7 epitope occurs) were then expressed at levels sufficient for the 
vaccination of mice. Expression levels were quantitated. Two possible methods for 
purification of chimaeric proteins were also tested. 
2.2 Materials and methods 
2.2.1 Synthesis of chimaeric Ll genes 
The HPV-16 L1 sequence was derived from a South African patient (GenBank 
accession no. AY177679). This sequence is identical to the L1 domain encoded by the 
updated canonical HPV-16 L1 sequence (Swiss-Prot: P03101.2). It was then modified 
as follows: Amino acids 414-426 were replaced with amino acids 108-120 derived 
from HPV -16 L2. The nucleotide sequence was optimised for human codon usage, 
synthesised and cloned into PCR4Blunt-TOPO by GENEART AG, Germany. The 
resulting gene was named SAFMOD by GENEART, but hereafter will be referred to 
as SAF. 
SAF was the basic genetic structure used for all further modifications, and since all 











modifications were achieved by synthesising only the C-terminal amino acids 406-
505, to replace a fragment of identical length in SAF. 
The name ofthe chimaera, the amino acid sequences inserted into HPV-16 Ll (South 
African strain), their sites of insertion and the origin of the inserted amino acids are 
listed in Table 2.1. 
Table 2.1. Modification of HPV-16 Ll (South African strain) gene to create 
chimaeric L 1 genes. 
Chimaera Amino acids inserted Source of Amino 
inserted acids 
amino replaced in 
acids Ll 
L2.56 GGLGIGTGSGTGGRTGYIPLGTRPPT HPV-16 L2 414-439 
aa 56-81 
L2.17 QLYKTCKQAGTCPPDIIPKV HPV-16 L2 414-433 
aa 17-36 
BPV MSARKRVKRASAYDLYRTCKQAGTCPPDVI BPV-l L2 414-505 
PKVEGDTIADKILKFGGLAIYLGGLGIGTW aa 1-88 
STGRV AAGGSPRYTPLRT AGSTSSLASI 
E7M RAHYNIVTF HPV-16 E7 417-425 
aa 49-57 
E7H TLGIVCPI HPV-16 E7 417-424 
aa 86-93 
E+E7M LVEETSFI DAGAP HPV-16 L2 414-426 
aa 108-120 
HPV-16 E7 433-441 
RAHYNIVTF 
aa 49-57 
E+E7H LVEETSFIDAGAP HPV-16 L2 414-426 
aa 108-120 
TLGIVCPI 












Amino acids 406-505 derived from HPV-16 Ll (South African strain) containing the 
different modifications were synthesised by GENEART AG and cloned into 
PCR4Blunt-TOPO, except in the case of L2.17, where the fragment was cloned into 
pGA18. 
2.2.2 Cloning 
SAF was cloned from PCR4Blunt-TOPO into the vector pGA4, as shown in Figure 
2.1(A). This vector contained another irrelevant gene, which had been cloned 
previously by another member of our research group. This irrelevant gene was 
replaced with SAF and clone into the HindIII and XhoI restriction enzyme sites. (The 
vector pGA4 can be obtained from GENEART AG). The cloning into pGA4 was 
done to avoid unwanted enzyme restriction sites in the PCR4Blunt-TOPO backbone. 
All other chimaeric genes were created by cloning the synthesised modified fragments 
into pGA4 containing SAF, into the PstI and XhoI sites (Figure 2.1(B)). This destroys 
one of the EeoR! restriction enzyme sites. 
All chimaeric Ll genes, excluding SAF, were then further subcloned into 
pFastBacDual (Invitrogen) under the polyhedron promoter (Figure 2.2). Chimaeric 
constructs were digested with EeoR! and XhoI and cloned into the vector's EeoR! and 
Sal! sites. SAF was subcloned non-directionally using EeoR!, and the direction ofthe 
cloned gene was confirmed by Pst! digestion. 
Restriction enzyme digestion products were separated by gel electrophoresis using 
0.8% agarose in Tris-borate buffer with ethidium bromide. The desired bands were 
excised under long wavelength UV light and DNA was eluted using the QIAquick® 
Gel Extraction Kit supplied by QIAGen. Vectors digested with restriction enzymes 
were dephosphorylated using shrimp alkaline phosphatase (Roche) and ligation 
reactions were performed using T4 DNA ligase (Fermentas). 
Plasmid DNA was prepared and purified using the QIAPrep® Spin Miniprep Kit 


























































Figure 2.1. (A) Cloning of SAF from PCR4Blunt-TOPO into the HindIII and XhoI restriction enzyme sites of pGA 4 containing an 
irrelevant gene. (B) Creating chimaeric genes by replacing a fragment of SAF with the relevant modification for creating the new 
chimaeric gene. Shown as an example is the modification to create L2.56. The L2.56 insert was cloned into the PstI andXhoI 













5o U(6185) Ps tl (623 1) 
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Figure 2.2. Subcloning of chimaeric LI genes into pFastBacDual. SAF was 
cloned non-directionally from pGA4 into the EcoRl sites of pFastBacDual. The 
direction of the cloned gene was confirmed by Pst! digestion. The other 
chimaeric pGA4-constructs, of which pGA4-L2.56 is shown as an example, 
were digested with EcoRl and Xhol and the genes cloned directionally from 
pGA4 into the EcoRl and Sail restriction enzyme sites of pFastBacDual. 
2.2.3 peR and primer design 
Colony PCR was used to confirm the presence of a cloned insert after each cloning step. 
Det~ils regarding the primers designed in our study are shown in Figure 2.3 , while the details 
of the PCR reactions are shown in Table 2.2. The general PCR protocol, where only the 
annealing temperature would vary for each unique set of primers, is shown below. The final 
concentration ofMgCh in each reaction for all primers was 3mM. Reactions 1-5, 7, 9 and 11 
were specifically used in colony PCR. The PCR products were visualised on a 0.8% agarose 











95 DC for 5min 
95 DC for 30sec 
Annealing temperature for 20 sec 
72 DC for 30 sec 
72 DC for 3 minutes 
2.2.4 Sequencing 
X25 
All constructs were sequenced to confirm sequence identity. Sequencing was carried out by 
the DNA Sequencing Service, Department of Molecular and Cell Biology, University of 
CapeTown. 
2.2.5. Preparation of bacmid DNA 
Purified pFastBacDual constructs were transformed into DHlOBac™ E. coli (Invitrogen), to 
create recombinant baculovirus DNA, according to the Bac-to-Bac® Baculovirus Expression 
System Manual. Colonies were selected using colony PCR as described above. Bacmid DNA 
was extracted from E.coli by the following method: 5 m1 Luria broth was inoculated 
overnight and centrifuged for 3 minutes at 13000 rpm in a benchtop centrifuge. 100 I.d of 
solution I (0.25 M Tris-CI pHS, 0.5 M Glucose, O.IM EDTA in water) was added and the 
resuspended pellet kept at room temperature for 5 minutes, then on ice. Then freshly made 
200 J..lI Solution II (0.2M NaOH, 1% SDS in water) was added and the tube was kept on ice 
for 5 minutes. Cold Solution III (3M potassium acetate, made to pH 4.S with acetic acid), 150 
J..lI, was added, followed by 5 minutes on ice. The resultant mix was then pelleted at 14000 
rpm in a benchtop centrifuge to obtain the supernatant. Nine hundred microliters of 96% 
ethanol was added and the DNA pelleted at 13000 rpm in a benchtop centrifuge. The air-
dried pellet was resuspended in 300 III Tris EDTA pH S (10 mM Tris, 1M EDTA), to which 
15 J..lI 3M sodium acetate and 630 III 96% ethanol was added. This was followed by a 20 
minute centrifugation step at 13000 rpm at 4DC in a benchtop centrifuge. The DNA pelleting 
step was then repeated with 70% ethanol, the pellet air-dried and resuspended in 50 III Tris-
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Forward 
primers 
Name Sequence Key 
FwdModNew 5'-CGACGACCTGTACATCAAGG-3' ---+ 
TLGIFwd 5'-CTGGGCATCGTGTGCCCT ATC-3' ---+ 





TLGIRev 5'-T AGGGCACACGATGCCCAGG-3' +-
L2Rev 5'-GGATGTAGCCGGTCCTGC-3' +-
QLYKRev 5'-ACCTIGGGGATGATGTCAGG-3' 
SALIBPVRev 5'-TATCT AGGGCTICCTCCAGC-3' +-
EndModRev 5'-CATCACAGCTICCGTTICTTCC-3' +-
Figure 2.3. Primers designed for use in diagnostic and colony peR reactions and 
their complementarity to Ll chimaeras. Each chimaeric Ll gene is indicated as a 
solid, black line, with its unique inserted sequence indicated as a coloured block. 
Primers are indicated as coloured arrows and are placed above their binding sites 
within the chimaeric genes. The key to the primers is shown in the table below the 












Table 2.2. Annealing temperatures and the expected SIZe of the PCR product of PCR 
reactions used to confirm the presence of an insert. 
Reaction Chimaera Annealing Primer Size of band 
number temperature combination yielded (bp) 
(OC) 
1 SAF 58 FwdModNew 410 
and VEETRev 
2 L2.56 58 FwdModNew 442 
and L2Rev 
3 L2.17 60 FwdModNew 444 
andQLYKRev 
4 BPV 60 FwdModNew 559 
and 
SAL1BPVRev 
5 E7M 55 FwdModNew 419 
andRAHYRev 
6 64 RAHYFwd 224 
and 
EndModRev 
7 E+E7M 55 ModFwdNew 467 
andRAHYRev 
8 64 RAHYFwd 227 
and 
EndModRev 
9 E7H 55 FwdModNew 416 
and TLGIRev 
10 61 EndModRev 227 
and TLGIFwd 
11 E+E7H 55 FwdModNew 467 
and TLGIRev 
12 61 EndModRev 176 
and TLGIFWD 
13 All Chimaeras 60 FwdModNew 700 
except BPV and 
EndModRev 
2.2.6 Preparing viral infectant from Spodoptera/rugiperda Sf-21 cells 
Purified bacmid DNA was then transfected into Sf-21 insect cells. A 35 mm tissue culture 
dish was seeded overnight with 1x106 cells per well in complete TC-100 (TC-100 supplied by 
Sigma, 10% fetal calf serum, 100 units/ml penicillin, 100 Ilg/ml streptomycin). A volume of 
5 III ofbacmid DNA was used regardless of concentration and the medium used was TC-100. 
Otherwise the protocol in the Bac-to-Bac® Baculovirus Expression System Manual was 











Cellfectin® (Invitrogen) was mixed with 100 III TC-100. The two solutions were mixed and 
left at room temperature for 15-45 minutes, after which it was made up to a total volume of 1 
ml. The cell monolayer was washed twice with TC-100 to remove all traces ofBSA and the 
DNA mixture added to the cells. The cells were then incubated for 5 hours at 27°C, after 
which another 1 ml of complete TC-100 was added. The primary supernatant was removed 
from the cells 48-72 hours post-transfection and clarified by centrifugation. Fresh medium 
was added to the cells and incubated for a further 48 -72 hours and the secondary supernatant 
removed as for the primary. 
Cells were then harvested in order to check protein expression by washing them off the 
bottom of the well with cold Dulbecco's PBS (DPBS), the cells were washed by 
centrifugation at 6000 rpm and the cell pellet resuspended in 100 III DPBS. The cells were 
then subjected to three freeze-thaw cycles and protein expression verified by western blotting 
using J4 monoclonal antibody (a gift from Dr. Neil Christensen, Penn State Pathology and 
Laboratory Medicine). 
If protein expression could be verified, the secondary supernatant was plaque-purified using 
Sf-21 cells. This was done to purify a single viral clone, which would enhance protein 
expression levels. The Bac-to-Bac® Baculovirus Expression System Manual was followed 
here. Briefly, 1.5x106 Sf-21 cells in 2 ml of complete TC-lOO were seeded in a 35 mm tissue 
culture dish and allowed to attach for 30-60 minutes. A tenfold dilution of the secondary 
supernatant was prepared in complete TC-100. Dilutions from 10-4 to 10-9 were used in this 
assay. The medium was removed from the cells and replaced with 1ml of the viral dilution. 
The virus was allowed to infect for 2 hours, after which the viral infectant was removed from 
the cells and the cells overlaid with 3ml per well of 1 % SeaPlaque Agarose (Adcock Ingram 
Scientific) in Grace's Insect Plaquing Medium. The cells were then incubated for about 96 
hours in an airtight container. The agarose-overlaid cells were then stained with 1ml of 100 
Ilg/ml of neutral red in complete TC-100 for 3-5 hours, the dye removed and the cells 
incubated overnight at 27°C. Agarose from areas that stained white against the red 
background or one single plaque were then removed with a sterile pipette tip and resuspended 
in 1 ml complete TC-1 00. 
The medium containing the single plaque was then amplified twice serially. First, 500 III 











hour, after which the infectant was removed and 2ml complete TC-I00 added. The 
supernatant was removed after 96 hours and clarified by centrifugation, yielding Passage 1 
infectant. One milliliter of Passage 1 infectant was then added to 5xl06 cells for 1 hour, after 
which it was removed and 10 ml complete TC-l 00 added. The supernatant was removed after 
96 hours and clarified by centrifugation, yielding Passage 2 infectant. The Passage viral stock 
is then titreed in order to determine the plaque forming units per ml (pfulml) using a plaque 
assay according to the The Bac-to-Bac® Baculovirus Expression System Manual and as 
described above for single plaque purification, except that titration was generally done in 
duplicate at dilutions ranging from 10-6 to 10-9• 
2.2.7 Screening for purity of viral infectants 
DNA extracted from plaque-purified, amplified viral supernatant was used to verify the 
identity of the construct and to eliminate the possibility of cross-contamination with other 
constructs. DNA was extracted using the RTP® DNA/RNA Virus Mini Kit (Invitek). The 
DNA was then used in a series ofPCR reactions. This is described in Table 2.3. In each case 
positive controls, constructs that would yield a band with a specific primer combination, were 
included. BPV was the exception in that a set of primers (Reaction 13) binds to all the other 
chimaeras except BPV. Thus a negative result was used to confirm its identity. This was done 
because the reverse primer used in reaction 3 is semi-complementary to BPY. All other 
chimaeras were included as controls with the primers used in reaction 13. 
2.2.8 Preparation of protein for vaccination purposes from Spodoptera Jrugiperda Sf-9 
cells 
Expression in Sf-9 cells is not expected to differ in any way to expression in Sf-21 cells. 
Therefore Sf-9 cells were infected at a multiplicity of infection (MOl) of 1 and a cell density 
of lxl06 cells/ml for 96 hours. Cells were counted, pelleted by centrifugation at 1000xg, 
washed with DPBS and pelleted again. Pellets were stored at -70°C and then resuspended in 
20 times less volume of DPBS than the volume the cells were in. The cells were then lysed 
by three freeze-thaw cycles (-70°C, 37°C), the debris pelleted twice and the supernatant 
stored at -70°C, taking aliquots for analysis to avoid multiple freeze-thaw cycles of protein 











Table 2.3. Reactions used in a diagnostic PCR to confirm absence of cross-contamination 
Reaction number from Table 2 
Chimaera 1 2 3 4 6 8 10 12 13 
SAF + - - - - - - - NP 
L2.56 - + - - - - - - NP 
L2.17 - - + - - - - - NP 
E7M - - - - + - - - NP 
E7H - - - - - - + - NP 
E+E7M NP - - - - + - - NP 
E+E7H NP - - - - - - + NP 
BPV NP NP NP + NP NP NP NP -
. . 
NP=not perfonned. + and - denote posItIve and negatIve reactIons respectively . 
2.2.9 Quantification of protein 
The quantity of L1 chimaeric protein was estimated by western blotting. Before 
electrophoresis, protein samples were diluted to the desired concentration in 5xloading buffer 
(2% SDS, 100mM Tris-HCI pH 7.5, 2mM EDTA, 91% glycerol, 7.6% beta-mercaptoethanol) 
and boiled at about 90°C for 5 minutes. Samples were then loaded onto a 12% acrylamide gel 
and electrophoresed for 2 hours at 20 mAo The gel was then blotted onto a nitrocellulose 
membrane for 1h30min at 15V. The membrane was blocked with blocking buffer (0.1 % 
Tween-20 and 5% skim milk in 1 xPBS pH 7.6), then incubated for at least 1 hour with a 1: 10 
000 dilution of primary antibody (Camvir-l, Abcam® ) in blocking buffer. This antibody 
binds to the linear epitope, aa 230-236 (McLean et at., 1990), which is not destroyed by any 
of the insertions. Secondary antibody was anti-mouse IgG (Sigma) used at 1: 1 0 000 in 
blocking buffer for at least 1 hour. After each antibody step, the membrane was washed thrice 
for 15 minutes in wash buffer (0.1 % Tween-20 in 1 xPBS pH 7.6). Bands were visualised 
with nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indoyl-phosphate (NBTIBCIP) 
substrate (Roche). 
SAF previously quantified against wild-type Ll was used to construct a standard curve by 
loading a doubling dilution. Similarly, a dilution series of the sample to be quantified was 











Syngene, Synoptics Ltd). A log curve was fitted to the readings of the standards using 
Microsoft Excel and the equation used to estimate the quantity of protein in each sample. 
2.2.10 Purification of chima eric Ll protein by ultracentrifugation 
Ultracentrifugation usmg the density gradient medium iodixano 1 (the tradename is 
Optiprep TM) was tested as a potential method to purify chimaeric L 1 protein. Optiprep ™ 
(Sigma), 60% w/v iodixanol in water, was diluted to 24% in DPBS. Cells were resuspended 
and lysed by freeze-thaw cycles in DPBS as described above. One millilitre of supernatant 
was then mixed with a OptiprepTM-in-DPBS solution to a final concentration of 24% 
OptiprepTM. The sample was centrifuged in a SWSSTi rotor at 3S000 rpm for about 16 hours. 
The tube was then punctured with a needle at the bottom, either to collect ten SOO III 
fractions, or on the side to extract the bands. Fractions were analysed by dot blot. Briefly, 2 
III of sample was dotted onto a nitrocellulose membrane. The membrane was then treated as 
for a western blot, using J4 as the primary antibody. 
2.2.11 Protein purification by cation exchange chromatography 
The method used was based on a method published by Cook et al. (Cook et aI., 1999). 
Diafiltration buffer (0.2 M (Na+)MOPS, pH 7.0 lOAM NaCl), column Buffer A (O.OS M 
(Na+)MOPS, pH 7.0 + O.SM NaCl) and Column Buffer B (O.OS M (Na+)MOPS, pH 7.0 + 
l.SM NaCl) were made up according to this paper. Sf-9 cells were harvested by 
centrifugation at 1000xg. The pellet was washed with lxDPBS and pelleted again. The pellet 
was resuspended at 12.6xl06 cells/ml (the count after infection) in diafiltration buffer 
containing protease inhibitor. Cells were sonicated, the cell debris pelleted and the 
supernatant filtered through a OAS urn filter. Chromatography was first carried out using 
three cation exchange columns and the Akta Explorer 10 Chromatography System: 
Sulfopropyl (SP) Sepharose™ Fast Flow, carboxymethyl (CM) Sepharose™ Fast Flow and 
sulfopropyl (SP) Sepharose™ XL (supplied by GE Healthcare Life Sciences). The column 
was pre-equilibrated with S column volumes of diafiltration buffer. One millilitre of sample 
was loaded onto the column. The column was then washed with 10 volumes Column Buffer 
A. Protein was eluted using a 100% Column Buffer A-I00% Column Buffer B linear 
gradient. The column was washed with 2 column volumes buffer B and the waste collected. 











In another instance, the HS50 POROS® column (Applied Biosystems) was used. A flow rate 
of 15-75 ml/min is suggested for this column, however, the Akta Explorer 10 
Chromatography System cannot perform at such a high rate, thus a flow rate of 10 mVmin 
was used. The sample prepared above was further diluted to 1x106 cells/ml. Four milliliter of 
sample was injected. The protocol in Cook et al. (Cook et al., 1999) was followed, except 
that the protein was eluted in 5 column volumes. Samples were analysed by indirect ELISA. 
2.2.12 Indirect ELISA 
A 96-well plate (Maxisorp, Nunc), was coated with 100 III per well of 1 :2000 Camvir-1 
overnight at 4°C, followed by 2 hours blocking with 0.5% (w/v) polyvinyl alcohol (PV A) in 
PBS. The wells were then coated with 100 III test samples of protein for 2 hours. The 
standard curve was wild type L1 with six doubling dilutions ranging from 9ng/ml to 300 
ng/ml. Polyclonal rabbit anti-L1, 100 III per well, diluted to 1:1000 in 0.5% PYA, was then 
added and incubated overnight at 4°C. Polyclonal swine anti-rabbit antibody, conjugated to 
horseradish peroxidise, was diluted to 1 :2000 in 0.5% PV A, 0.8% polyvinylpyrrolidine in 
PBS and 100 III added to each well for 30 minutes. The substrate, o-phenylenediamine 
dihydrochloride (OPD) tablets (supplied by Dako) was diluted as per instructions and 100 III 
added per well. Development time was thirty minutes, the reaction was stopped with 0.5M 
H2S04 and read at 490nm. All solutions were made up in PBS (pH 7.6) and between each 
step the wells were washed four times with 300 III PBS per well. 
2.3 Results 
2.3.1 Verification of protein expression in Sf-21 cells 
All eight chimaeric L1 genes, those listed in Table 2.1 as well as SAP, could be expressed as 
the full-length protein in Sf-21 insect cells after transfection with recombinant bacmid DNA 
and harvesting of the cells. Protein was harvested from the cells, because it is known from 
previous work that HPV L1 is expressed within the cell (Park et al., 1993). The expression of 
the full-length constructs was confirmed using western blotting and probing with J4, a 
monoclonal antibody that detects a linear epitope (aa 261-280) (Christensen et al., 1996) in 
HPV-16 Ll. This epitope is not destroyed by any of the insertions. The western blots are 
shown in Figure 2.4. Figure 2.4E shows cell lysate from Sf-9 cells infected with non-











expression in Sf-21 cells. Camvir-1 reacted non-specifically with a protein about 40 kDa in 
size, but no 55 kDa band could be seen for protein samples derived from cells infected with 
non-recombinant baculovirus. 
E7H and E+E7H would not be used in mouse experiments, because the inserted CTL 
epitopes are specific to human alleles . . Therefore these two chimaeric proteins were not 
included in further analyses. 
M P N L2.56 SAF E+E7H M P N E+E7M L2.17 
A' L::~~ _ _ 1r! ~_LJ B. 
E. 
M N P E7H E7M M BPV 
MNBNBP MNBNBP 
Figure 2.4. Verification of expression of Ll chimaeric genes in Sf-21 insect 
cells after transfection with recombinant bacmid. A. L2.56, SAF and E+E7H 
B. E+E7M and L2.17. C E7H and E7M D. BPV. E. Insect cell lysate after 
infection with non-recombinant baculovirus. The blot on the left was probed 
with Camvir-l, and on the right with J4 mAb. P=previously tested positive 
sample, N=mock-infected Sf-21 cells, NB=non-recombinant baculovirus, 
M=protein marker, showing the 55 and 70 kDa bands respectively and the 
40 kDa band in the case of E. All the blots were probed with J4, an HPV-16-
specific mAb, except as statedfor E. All chimaeras were -55kDa in size. 
2.3.2 Verifying chimaera identity by peR 
Since antibodies specific to the inserted epitopes were not available, the only way to 
distinguish between the different L1 chimaeric proteins and to ensure purity of the viral 
infectant, was to perform PCR on DNA extracted from viral infectant. This was done using 
primer sets that bind to the inserted epitopes as described in Section 2.2.7. Figure 2.5 shows 
examples of such PCR amplifications, as performed for SAF and BPV. The purity of all 
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Figure 2.5. Diagnostic PCR. (A) DNA extracted from injectant containing 
plaque-purified SAF-recombinant baculovirus (denoted as pi in the figure) was 
tested for purity with different primer sets in PCR. Pos=Positive control, either 
bacmid DNA or DNA extracted from viral infectant and previously tested from a 
construct that would yield a band with the relevant primer set. The primer set 
used in each reaction is denoted on top of the brackets. (B) DNA extracted from 
infectant containing plaque-purified BPV-recombinant baculovirus (denoted as 
BPV in the figure) was tested for purity, using a primer pair that would not yield 
a band with BPV, but would yield a band if used with all the other constructs. 
The primer set used in each reaction is denoted on top of the brackets. Bacmid 
DNA or DNA extracted from viral infectant confirmed to be positive for the 
relevant construct from all the other chimaeric constructs was tested as positive 
controls. N=no DNA control. 
2.3.3 Expression levels of chimaeric Ll proteins 
When the chimaeric Ll proteins were expressed in insect cells under identical conditions, the 
expression levels were found to differ greatly when assayed by an indirect quantitative 
ELISA. The difference in expression levels indicates that expression levels of a protein could 
be influenced by the nature of the amino acids inserted, the length of the insertion or the exact 
position of insertion. This effect can be seen in Figure 2.6A, where the six chimaeric Ll 











flask of cells, and extracted under identical conditions. This trend roughly corresponds to the 
trend seen in a previous experiment where proteins were purified by Optiprep 
ultracentrifugation and visualised by western blotting (Figure 2.6B). It is possible that not all 
the proteins migrate to a similar position within the Optiprep gradient, however, a difference 
in migration among the different constructs was not observed to be the case (data not shown). 
The range of concentrations obtained for the different L1 chimaeric proteins from various 
experiments are shown in Table 2.4. The highest levels seen were for L2.17 at 562 ~g/ml per 
106 cells, followed by L2.56 with 149 ~g/ml per 106 cells, E7M with 53 ~g/ml per 106 cells, 
SAF with 42 ~g/ml per 106 cells, BPV with 10 ~g/ml per 106 cells and E+E7M with 6 ~g/ml 
per 106 cells. Expression levels were highly variable between experiments performed for the 
same construct; therefore the levels cannot be deemed significantly different between SAF, 
L2.56, L2.17 and E7M. However BPV and E+E7M consistently expressed lower levels of 
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Figure 2.6. Ll chimaeric genes yield different levels of protein when 
expressed in and extracted from insect cells under similar conditions. 
A. Indirect LI-ELISA was used to quantify protein levels. Sf-9 insect 
cells were infected at MOI=l with cell density at lxl06/ml and 
harvested after 96 hours. Cell pellets were resuspended in equal 
volumes of DPBS containing protease inhibitor and sonicated. The 
supernatant containing total cellular protein was tested in the ELISA. 
The error bars indicate standard deviation between replicates. B. 
Western blot detection, using J4 antibody, of proteins expressed and 
extracted as above, and subjected to a 5%-25% step Optiprep 
ultracentrifugation. Equal volumes of protein (20ul each) were 











Table 2.4. Concentration of protein obtained and the number of cells/ml post-infection for 
different batches of chimaeric L1 
Chimaera Concentration Cell count post-infection Protein 
(Ilg/ml) (million cells/ml) concentration per 
106 cells (Ilg) 
SAF 29.2 0.98 29.80 
18.5 1.6 11.56 
2.3 1.46 1.58 
43.7 1.05 41.62 
L2.56 3.2 0.14 22.86 
68.5 0.46 148.91 
L2.17 6.4 0.51 12.55 
22 1.07 20.56 
376.6 0.67 562.09 
BPV 0.3 0.03 10 
3 0.82 3.66 
E7M 4.8 0.09 53.33 
13.9 NA NA 
53.3 NA NA 
E+E7M 0.9 0.24 3.75 
3 0.58 5.17 
7.6 1.85 4.11 
9.6 1.6 6 
NA=information not available 
2.3.4 Purification by ultracentrifugation 
OptiprepTM is the tradename for 60% iodixanol (weight/volume in water) and is a desirable 
medium for ultracentrifugation for various reasons. It is a ready-made, sterile and endotoxin-
free solution that is safe to be injected into animals. These properties make it desirable for 
purification of vaccines for mouse studies, because no dialysis is required, as long as high-
salt buffer is not employed. Optiprep ™ is also iso-osmotic and isotonic, which reduces 
destabilisation of proteins. 
For these reasons, OptiprepTM was the first ultracentrifugation medium of choice for 
purification of L1 chimaeric proteins. A self-generated, continuous gradient consisting of 











at 35000 rpm overnight. After centrifugation, the tubes yielded a constant banding pattern. A 
band could be seen within the bottom 1 m1 of liquid, and another one towards the top. The 
bottom band was shown to contain Ll protein as determined by a dot blot, probing with J4 or 
Camvir-l. However, when cells infected with non-recombinant baculovirus were subjected to 
the same process, the same banding pattern was seen. Subsequently, after fractionation, it was 
observed that the bottom 1 m1 of liquid contains all of the Ll chimaeric protein. When these 
fractions were subjected to electrophoresis on an SDS-PAGE gel, stained with Coomassie 
Brilliant Blue R, and compared to cell lysate, no difference was seen between non-purified 
and purified protein. The L 1 chimaeric protein was not concentrated by this method, either. 
Therefore it was concluded that this particular gradient does not separate out insect cell 
produced proteins, but rather sediments all the proteins at the bottom of the tube. This is 
shown in Figure 2.7. 
Fr2 Frl Band Lys M Lys Band Frl Fr2 
SAF 
Figure 2.7. A continuous gradient generated using 24% 
Optiprep does not concentrate or purify chimaeric L1 proteins. 
The figure shows a stained SDS-PAGE gel aligned with the 
other half of the gel as a mirror image used in a Western. Equal 
volumes of sample were loaded. Fr= 5 00 ul fraction as counted 
from the bottom of the tube. Band=bottom band extracted from 
the ultracentrifuge tube, Lys=unpurified cell lysate. 
2.3.5 Cation exchange chromatography 
Purification trials were performed with four different cation exchange columns. Cation 
exchange columns were used because the calculated pI for SAF indicated an overall positive 
charge, and previous work in our laboratory as well as literature (Cook et al., 1999) indicates 
that a cation exchange column should be used. Previous work in our laboratory was based on 











because these columns are better suited to the chromatography system and are routinely used 
in our laboratory. Two columns were strong cation exchangers with sulfopropyl functional 
groups. One column was a weak cation exchanger with carboxymethyl functional groups. 
SAF was tested as a proof of concept for the other chimaeras. Figure 2.8A indicates that the 
fIrst three columns tested were not feasible for use. SAF eluted mostly in the pre-elution 
wash, except in the case of column 2, where SAF also eluted in fractions 1-3 and in the post-
elution wash. The elution of SAF both in the pre-elution and post-elution wash is an aberrant 
result that could not be explained. It remains, however, that neither of the three columns 
tested fIrst are feasible for purification of SAF. Figure 2.8B shows results for the HS50 
POROS@ column. SAF elutes from fraction 11 to 15. These fractions were also tested on a 
western blot, and the correct size of protein could be detected (data not shown). 
2.3.6 Western blot quantification 
The concentration of protein in the vaccine preparations was estimated by western blot. It is 
known from literature that the relationship between absorbance and protein mass on a 
western blot is not linear (Heidebrecht et ai., 2009). Saturation occurs, causing the curve to 
plateau. For this reason, a log curve was fItted to the points of the standard curve and the 
equation of this curve was used to calculate values for test samples. An example of how this 
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Figure 2.8. A. Testing purification of SAF by cation exchange. Three 
different columns with either su/fopropyl (strong cation exchange) or 
carboxymethyl (weak cation exchange) functional groups were tested. 
Fractions were eluted over an increasing O.5M to 1.5M NaCl gradient, 
dotted onto a membrane and probed with J4 antibody to detect the 
presence of SAF. The columns to which the fractions correspond are 
indicated to the right of the dot blot. Fraction descriptions are in the 
righ-hand bottom corner of each block containing a dotted fraction. 
Fr=fraction, Pre=Pre-elution wash, Post=Post-elution wash. B. Testing 
purification of SAF by cation exchange employing the HS50 POROS 
column, containing su/fopropyl functional groups. (strong cation 
exchange) Fractions were eluted over an increasing O.5M to 1.5M NaCI 
gradient and tested for the presence of SAF by indirect ELISA. 
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Figure 2.9. Estimating the concentration of protein by western blotting quantification. 
A. Western blot of E+E7M, probed with Camvir-l .The standard curve samples were 
loaded into lanes 3-6, with the total mass loaded per well indicated on top. Lanes 7-
10 contain the test samples and the total volume of sample loaded is indicated above. 
B. The absorbance values of each band were plotted on a graph and a log curve was 
fitted to the data points. The R2 value is displayed as well as the equation used in 
calculations. Below it is a table showing how the concentration of protein in the test 
sample was estimated. The equation indicated in B was used, where y=absorbance 













2.4.1 Expression of chima eric Ll constructs 
All the chimaeric constructs could be expressed in insect cells as shown by western blot in 
Figure 2.4. The absence of a 55kDa band in any of the mock-infected or non-recombinant 
baculovirus samples confirmed that the bands seen for the recombinant constructs were 
indeed specific. However, it became clear that not all the chimaeric proteins expressed at 
similar levels in insect cells, as can be seen in Table 2.4 and Figure 2.6. The order of 
maximum expression from highest to lowest levels was L2.17, L2.56, E7M, SAF, BPV and 
E+E7M. 
Expression levels were highly variable between experiments performed for the same 
construct and therefore expression levels between SAF, L2.56, L2.17 and E7M were not 
deemed to be significantly different. However, E+E7M and BPV were consistently expressed 
at lower levels than the other chimaeric proteins. These two chimaeras differ from the others 
in that they have amino acid replacements to the C-terminal end of aa 439. They also differ in 
that a longer region of Ll is modified; for E+E7M a region of effectively 27 aa is modified, 
whereas BPV has the whole C-terminal replaced from aa 414 to 505. In contrast, L2.56 also 
has a region of25 amino acids modified, almost as long as for E+E7M, and it is expressed to 
high levels. For this reason, the lower expression levels obtained for E+E7M and BPV may 
be due to the Ll protein having amino acids replacements to the C-terminal end of aa 439, 
but whether it is due to the length of region modified, is not clear. 
The inferior quantity of BPV may perhaps be ascribed to the deletion of nuclear localisation 
sequences. This effect was observed in other studies. Maclean et al. (Maclean et a!., 2007) 
showed that expression in plants of a chloroplast-targeted construct where 22 amino acids 
were deleted from the C-terminal, thus truncating the nuclear localisation signal (NLS), was 
much lower than for the other constructs, where the NLS was not deleted. Senger et al. 
(Senger et al., 2009) also reported inefficient production ofHPV-16 LIL1E7(l-6o), which has 
the 34 aa deleted from the C-terminal ofHPV-16 Ll, in insect cells. In contrast to these two 
studies, Kohl et a!. (Kohl et al., 2007) found that HPV-ll Ll could only be expressed in 
plants if the NLS was removed; other chimaeric Ll vaccines have also been expressed in 











could be obtained (Wakabayashi et al., 2002; Liu et al., 2002; Kuck et al., 2006). It is 
therefore not entirely clear whether the deletion of nuclear localisation signals affect 
expression ofHPV L1 protein. 
The stability of BPV may be another reason for its low accumulation in insect cells. On a 
western blot, many degradation products were observed, but the number of degradation 
products was not markedly different from those obtained from any of the other constructs 
(data not shown). 
The modification of a sequence by only a few amino acids can affect its expression and this 
may explain the differences in expression levels observed for different constructs in our 
study. Other studies in the literature have shown that different gene variants can often express 
at different levels. This difference in expression was seen when the expression of the South 
African HPV-16 L1 isolate was compared to its human codon-optimised and plant codon-
optimised versions' in plants, (Maclean et aI., 2007) yielding vastly different expression 
levels between the different genetic variants. The human codon-optimised variant expressed 
at the highest levels, whereas the plant codon-optimised variant did not express at all. The 
authors suggested that the disruption 0 f inhibitory sequences in the N -terminal 0 f the human 
codon-optimised L1 gene could be one of many factors responsible for the higher expression 
of this variant. In our study, all nucleotide changes to HPV-16 L1 were in the C-terminal, but 
it is still possible that some of the sequences inserted contained inhibitory sequences, whereas 
others did not. It should be mentioned here that the entire sequence, both that of L1 and the 
inserted L2 sequences, of each construct in our study were human codon-optimised to 
optimise expression. 
Another study (Touze et al., 1998) also looked at expression levels for different L1 gene 
isolates. It was observed in one case that even one amino acid difference could majorly 
influence the expression levels ofL1, and it was speculated that the difference in expression 
levels could be the result oftruncated L1 RNA transcripts (Neeper et al., 1996). However, all 
the mutations in Touze et al. 's study occurred in the region between residues 83 to 97 ofL1, 
which does not correspond to the modifications made to L1 in our study. It is still 
conceivable, though, that the replacement of amino acids within L1 could affect the protein's 
expression levels, either at the transcriptional level or the translational level. Senger et al. 











expression levels and concluded that translation rate and protein stability have a stronger 
impact on yield. It is likely that the different amino acids inserted may prevent the protein 
from folding properly, leaving the protein more prone to degradation. 
The exact insertion site could be another factor influencing expression levels. In our study, all 
the chimaeric constructs, except those bearing E7 epitopes, had epitopes inserted after aa 413. 
However, due to the differences in length of the peptides replacing amino acids in Ll, the 
exact insertion region differs between the constructs. According to Murata et al. (Murata et 
al., 2009), when the proline residues flanking the helix 4 are not deleted, either when the 
helix 4 is deleted or replaced with a similarly-sized peptide, this impairs quantity and quality 
of capsomers produced. Whether monomers are still produced in their case, is not clear. The 
authors suggest that the proline residues impose structural constraints on the structure of the 
protein and that it affects quantity and quantity of capsomers produced. In our study, the 
proline residues are removed up to the C-terminal end of helix 4 in the case ofL2.17, L2.56 
and E+E7M, but not to the N-terminal end. In the case of SAP and E7M, proline residues 
flank the insertion on both sides, but in contrast to Murata et al.'s results, these two 
constructs were not inferior to the other constructs in our study with respect to expression 
levels. Because total protein content, regardless of whether higher-order structures assembled 
or not, were assessed in our study, and not capsomer quantity, as in the case of Murata et al., 
their results may not be directly comparable with ours. However, as stated before, the 
inability to form higher-order structures may affect the stability of the protein. Their data 
does support that the notion that precise amino acid position where an epitope is inserted into 
Ll may affect quantity and quality of chimaeric protein produced due to the loss or retaining 
of key residues that have an impact on the structure ofthe protein. 
Infectious constructs in this study were infected at the same MOl, with cells at the same 
density and harvested after the same period of time. The optimal conditions had been 
previously determined for SAP by our research group. However, optimal conditions may 
need to be separately determined for each construct. Cell density and infection time are the 
factors most likely to affect expression levels (Pillay et al., 2009). Protein production can also 
be optimised by expression in a different cell line. It was determined for chimaeric HIV-l 
VLPs that Trichoplusia ni Pro™ expressed protein at slightly higher levels than Sf-9 cells 
(Pillay et al., 2009). Protein production levels can also be enhanced by the use of the 











improvements over the conventional system. It was shown that by usmg this system, 
constructs that could not be produced efficiently by the conventional system, could now be 
expressed at much higher levels. Ways of improving the yield oflow expressers like BPV or 
E+E7M therefore include using a different MOl, cell density, infection time, cell line or the 
MultiBac baculovirus expression system. 
The stability of the baculoviruses after several passages may also differ from construct to 
construct. After plaque purification, passaging of the viral infectant was kept to a minimum 
for all the constructs in this study and each infectant was titreed with respect to plaque 
forming units per millilitre. However, the stability of each construct is not known. 
2.4.2 Verifying the identity of the chimaeric protein 
It was essential to develop a method that would distinguish between any two of the 
chimaeras, which would ensure that only one species of chimaeric Ll protein was present in a 
sample and that no cross-contamination had taken place. In order to make meaningful 
comparisons between the different chimaeric Ll proteins with respect to their 
immunogenicity, which was the ultimate aim ofthis project, each sample had to contain only 
one species of chimaeric Ll protein. Even if only low levels of contaminating protein is 
present, it may still have an effect, since Ll is highly immunogenic. 
The different constructs could not be distinguished from one another by immunological 
techniques, unless mAbs binding to the specific L2 epitopes are used Such antibodies were 
not available in our laboratory and may not generally be available for all the epitopes that we 
had inserted into HPV-16 Ll. Therefore recombinant baculovirus DNA was extracted from 
the viral infectant to be used in protein production, using the RTP® DNA/RNA Virus Mini 
Kit. A diagnostic PCR was then performed with this DNA. The PCR used unique 
combinations ofprimers that would either yield or not yield a PCR product with the construct 
to be tested, or would yield products of different sizes. The PCR method is set out in Tables 
2.2 and 2.3 and in Figure 2.3. 
As can be seen in Figure 2.5, the purity of each protein sample could be confirmed. No doubt 
can therefore exist that cross-contamination with other chimaeric Ll proteins could have 











The RTP® DNA/RNA Virus Mini Kit proved a very successful tool in isolating viral DNA 
from viral infectant, but also from crude insect cell lysate supernatant. Low levels of 
baculoviruses are likely to be present in the cells, despite the majority ofthem being secreted 
into the extracellular medium. We were therefore also able to distinguish between the 
different constructs, not only prior to infection, but also after extraction of total protein, 
before any purification steps have been attempted.(data not shown) 
2.4.3 Purification of chimaeric Ll protein 
It is desirable to purify and concentrate a protein to a high degree of purity before 
vaccination. This is to avoid immune responses against proteins that are not of interest. Such 
immune responses may interfere with the immune response against the protein of interest by 
downregulating it. Also, high levels of antibodies against many different proteins increase the 
chances of obtaining cross-reactive antibodies. Cross-reactive antibodies may cause high 
levels of background in an ELISA or western blot, which may mask the true immune 
response to the protein of interest. We therefore attempted purification of the six different 
chimaeric Ll proteins by two methods, ultracentrifugation and cation exchange. 
2.4.3.1 Ultracentrifugation 
We attempted to purify the different chimaeric Ll proteins by ultracentrifugation, usmg 
OptiprepTM and a self-generated gradient. This has not been attempted to our knowledge for 
empty L 1 VLPs or capsomers. 
Ll VLPs, especially chimaeric VLPs, when prepared for animal vaccination studies, are most 
commonly purified by a two-step purification involving sucrose and caesium chloride as 
gradient media (Varsani et al., 2003; Kondo et aI., 2008; Kuck et al., 2006; Schellenbacher et 
al., 2009). The disadvantages to these media are that dialysis is required, a step that would 
involve loss of protein. Both media can also destabilise proteins due to being hyperosmotic, 
whereas OptiprepTM is an isoosmotic gradient medium (Axis-Shield, 2007). OptiprepTM does 
not need to be removed from protein samples prior to animal vaccination. The disadvantage 
is its expense, but optimisation of a method to purify chimaeric VLPs by ultracentrifugation 











convenient in that the results are highly reproducible and multiple samples can be processed 
rapidly. 
As can be seen in Figure 2.7, SAP did not separate out sufficiently according to buoyant 
density, which indicates that the gradient was not steep enough. For a steeper gradient a 
higher percentage Optiprep should be used and centrifugation should be at a higher speed. 
Because swinging bucket rotors are not suitable for self-generating gradients, vertical or near-
vertical rotors should be used (Axis-Shield, 2009). 
Alternatively, a pre-formed continuous gradient could be employed. Buck et al. (Buck et al., 
2004) optimised a method for harvesting of HPV pseudovirions by using three steps of 
Optiprep at 27,33 and 39% respectively. This method may have to be optimised to be applied 
to our work, since the chimaeric Ll particles in our studies are most likely to be capsomers 
not containing DNA and have a different buoyant density range, high-salt PBS unsuitable to 
vaccination studies is employed in their method, which is likely to change the density 
gradient, and the pseudovirions are purified from mammalian cells, not insect cells. However, 
purification of protein by Optiprep for animal vaccination studies should be investigated 
further, as it could be a simple, rapid method for preparing protein on a small scale without 
losses incurred by dialysis. We did not investigate this method further, due to time constraints. 
2.4.3.2 Cation exchange chromatography 
Another method employed in the purification of Ll protein is by cation exchange (Cook et 
al., 1999). In fact, it is by this method that the VLPs contained in the Gardasil® vaccine have 
been purified (Shi et al., 2007). For this reason, cation exchange was attempted in the 
purification of SAF as a prototype for all the other chimaeric Ll proteins. This was done 
using Sepharose columns routinely used in our laboratory that are well adapted to the Akta 
Explorer 10 Chromatography System. Unfortunately these columns could not be used in the 
purification ofSAF. Figure 2.8A indicates that most of the protein is eluted in the pre-elution 
wash when the sepharose columns were tested. The elution of protein in the pre-elution wash 











Because the sepharose columns did not bind SAF, we tested another cation exchange column, 
the HS50 POROS column, previously tested in our laboratory and shown to purify SAF. 
From Figure 2.8B, it was clear that the HS50 POROS column does bind and elute SAF. 
The most likely reason why the Sepharose columns did not bind SAF, whereas the HS50 
POROS column did may be the difference in the make-up of the matrix. The sepharose 
columns consist ofa 6% highly cross-linked beaded agarose matrix, and in the case ofthe SP 
XL column, it has long dextran chains coupled to the matrix to increase surface exposure of 
the functional groups. The POROS column has a matrix consisting of cross-linked 
polystyrene divinylbenzene. This matrix may be more permissible to binding of large 
particles like capsomers than the agarose matrix. It is likely that the functional groups are not 
responsible for the differences in binding of SAF, since the POROS column has the same 
sulfopropyl functional group as the SP Sepharose columns. Because the same buffers were 
used in both cases, it could also not be due to the ionic strength or pH of the buffer. 
The HS50 POROS column is therefore a feasible method to be used in purification of SAF, 
and it also shows potential for the other chimaeric proteins, since all of them had an overall 
positive charge as indicated by their calculated pI, which were all very similar (data not 
shown). This method as applied to the other chimaeric proteins still needs to be tested, 
because the calculated pI is for the linear protein and does not take into account the surface 
charge of the protein. Isoelectric focusing could be employed in the future to determine the 
overall charge of the protein and whether this method may be used for all the chima eric 
proteins. 
2.4.4 Quantification of protein by western blot 
In this study, the concentration of protein in samples to be used in vaccination studies was 
estimated by immunoblotting, as shown in Figure 9. There were several reasons for choosing 
this method over the conventionally used ELISA. Firstly, both Camvir-l and J4, the antibody 
bound to the wells of the ELISA plates, showed cross-reaction with other proteins. Therefore 
this would give artificially high readings. On a western blot, because the proteins are 
separated according to size, the protein corresponding to the size of Ll can be quantitated, 
excluding cross-reactive proteins. Another reason for quantifying protein in a denatured state, 











is that it is not known how the binding of antibodies are affected by the epitope inserted into 
the protein. The protein could fold in such a way that the linear epitopes to which J4 and 
Camvir-l antibodies bind are hidden. 
This method was also chosen over using bovine serum albumin to construct a standard curve 
on a stained SDS-PAGE gel. Using SDS-PAGE was not a feasible method, because of the 
impurity of the protein extracts and the possible co-migration of other proteins of similar size 
to Ll. 
This method is a semi-quantitative method. A more accurate indication of the concentration 
may have been obtained if replicates of experiments were performed and if the standard and 
samples were loaded in replicate. However, different dilutions of samples were loaded, which 
allowed for replicate samples by which the average concentration of protein could be better 
determined. 
Even though the standard and the sample were subjected to the same conditions within the 
experiment, there may still be differences within the blot. Not all bands necessarily transfer 
similarly from the protein gel to the nitrocellulose membrane, due to non-constant 
distribution of electrical resistance, which depends on protein amount and other factors, such 
as blot or gel irregularities (Heidebrecht et al., 2009). 
The relationship between the absorbance measured for each protein band on the western blot 
and the protein content is actually more complex than the one assumed in our study. 
Heidebrecht et al. (Heidebrecht et at., 2009) showed that the relationship is more complex 
and is based on a hyperbolic function derived from the Michaelis-Menten equation. Applying 
their method of regression could have resulted in more accurate results. However, even 
though the absolute amount of protein in each sample may be inaccurate, the amounts of 
protein relative to one another could still be obtained in this manner, since all protein 
amounts were estimated against the same standard and in the same manner. It is also not 
uncommon for protein quantities to be estimated, rather than precisely determined, and used 
in vaccination studies. Estimation was previously done for insect cell lysate orally 
administered to mice where different formulations containing the same amount of protein 












In conclusion, eight HPV-16 Ll chimaeric proteins were constructed with cross-neutralising 
and immunotherapeutic epitopes from L2 and E7 respectively. All could be expressed in 
insect cells. Crude extracts of six of the eight chimaeras were prepared from insect cells and 
quantified for purposes of animal studies. Of these, BPV and E+E7M expressed at lower 
levels than the others. Ultracentrifugation, using iodixanol as a centrifugation separation 
medium, may be a rapid, effective way of preparing protein on a small scale, however, a 
steeper gradient needs to be generated to obtain separation of proteins by this method. For 
large-scale preparation of proteins, column purification may be used in combination with 
other methods. The HS50 paRaS cation exchange column bound and eluted SAF and this 











3. IMMUNOGENICITY OF CHIMAERIC Ll VACCINES 
3.1 Introduction 
The selection of vaccine candidates is based mainly on its immunogenicity. Vaccines are first 
tested in animal models in order to obtain insight into their immunogenicity. Often a 
challenge model exists. These animals can be infected with the same infectious agent and the 
prophylactic or therapeutic ability of the vaccine can be tested directly. There are 
papillomaviruses that infect animals and cause similar disease to that caused by HPV, for 
example cottontail rabbit papillomavirus (CRPV). Vaccination strategies can be tested in 
these animal models utilising the species-specific virus, but the conclusions drawn from these 
studies may not necessarily be directly applied to HPV. Mice are a preferred animal model, 
because they are genetically well-characterised, easy to breed, easy to house and care for and 
biological reagents are readily available. Mouse cells can also be transformed with high-risk 
oncoproteins and implanted into laboratory mice to model tumours caused by HPV (Fausch 
et ai., 2003). Indicators of immune responses, such as antibody levels, cytokine release or T-
cell counts, can also easily be assessed in mice. 
There are two branches of the immune system, the humoral and the cell-mediated. The 
humoral immune system involves the binding of antibodies to extracellular pathogens and 
toxins for uptake and destruction by cells of the immune system. The cell-mediated immune 
system combats pathogens that replicate intracellularly and involves the killing of infected 
cells, thus preventing replication and release of new viruses (Janeway et ai., 1997a). Of the 
two branches of immunity, humoral immunity, or levels of neutralising antibodies, have been 
found to be the most important factor in preventing infection with papillomavirus (Breitburd 
et ai., 1995). In fact, the majority of antibodies are targeted against Ll, the major capsid 
protein, and not L2, the minor capsid protein (Roden et ai., 2000). However, antibodies 
against L2 have been shown to elicit antibodies that neutralise pseudo virions in vitro (Roden 
et ai., 2000; Kawana et ai., 2003). Therefore mice or rabbits can be vaccinated with an HPV 
vaccine and levels of antibodies against both Ll and L2 in the blood can be assayed for as an 
indicator of how immunogenic the vaccine is. 
A challenge model does not exist for HPV, however, antibody-mediated neutralisation of 











encapsidating a reporter plasmid, can be produced in mammalian cells and employed in a 
pseudovirion neutralisation assay (Pastrana et al., 2004). Human embryonic kidney cells 
over-expressing the SV40 large T-antigen (HEK293TT) are transfected with plasmids that 
contain an SV40 replication origin. These plasmids express the capsid proteins Ll and L2 of 
a particular HPV type as well as a reporter gene. The plasmid expressing the reporter gene is 
encapsidated by the assembled pseudovirions and is therefore of optimal size for 
encapsidation (Buck et al., 2004). The pseudovirions are then harvested and used in a 
neutralisation assay. The pseudovirions infect HEK293TT cells in a way similar to that of 
native virus infection, resulting in the expression of the reporter plasmid. The reporter gene, 
as in this case, expresses alkaline phosphatase (AP) and the enzyme is secreted into the 
extracellular medium. Levels of this enzyme can then be assayed for in the extracellular 
supernatant by adding a substrate. When sera containing antibodies against HPV are added to 
the pseudovirion - infected cells neutralization of the pseudovirions occurs, and is quantified 
as a reduction in the level of AP in the extracellular supernatant. The percentage reduction in 
AP activity is therefore an indication of the levels of neutralising antibodies in the sera 
(Pastrana et al., 2004). 
The cell-mediated immune response has been found to be important in the clearance and 
regression of existing tumours caused by HPV (Human Papillomaviruses/IARC Working 
Group on the Evaluation of Carcinogenic Risks to Humans, 2005). For therapeutic HPV 
vaccines, therefore, indicators of cell-mediated immunity must be used. The spleens of 
vaccinated mice can be removed and the splenocytes, amongst which are vaccine-specific T-
cells, can be co-cultured with cells presenting the specific vaccine antigen in order to asses 
the function of vaccine specific T cells. Cytokines secreted by vaccine specific T cells in 
response to this stimulation indicates responses to the test vaccine. These cytokines can be 
assayed by a flow cytometric bead array (CBA) assay, a modification of ELISA (Janeway et 
al., 1997d), and it has been one of the assays employed in this study to evaluate vaccine 
efficacy. The type of cytokine secreted also indicates whether the response is skewed towards 
a Thl (cell-mediated) or Th2 (antibody) response (Janeway et al., 1997c). The frequency of 
vaccine specific cells secreting a specific cytokine can be determined using an ELIspot assay. 
In this study the IFN-y.ELIspot assay was used to determine the frequency of vaccine specific 
T cells secreting IFN-y. Specific cytotoxic T-cell activity can also be assessed by 51Cr-release 
or 3H-thymidine release/retention assays (Janeway et aI., 1997d) but such assays have not 











Therapeutic HPV vaccines can also be tested directly for regression of tumours in mice by 
implanting tumour cells subcutaneously. Two cell lines are available for these purposes, C3 
and TC-1. C3 cells are mouse cells that have been transformed with the complete HPV 
genome and the ras oncogene (Feltkamp et ai., 1993), while TC-1 cells have been 
transformed with the transforming proteins, E6 and E7, as well as ras (Torrens et ai., 2005). 
The tumour regression capacity of a vaccine can be assessed as the ability to cause regression 
of tumour size induced by either of these 2 cell lines. Vaccines can also be assessed for their 
ability to prevent tumour formation in a tumour challenge experiment (Torrens et ai., 2005). 
For this, animals are first vaccinated with the vaccine, then challenged with tumour cells and 
subsequently the tumour size is compared to that in the absence of vaccination. Tumour 
regression experiments are accepted as superior to tumour challenge experiments for 
evaluating vaccines because C3 or TC-1 cells do not have a 100% rate in forming tumours 
(Personal communication, Peter OhlschHiger). It is important to note here that when C3 cells 
are employed in tumour formation, vaccination with L1, which otherwise cannot be used to 
treat infections in humans (Hildesheim et ai., 2007), does mediate protection against tumours 
in mice (De Bruijn et ai., 1998; Ohlschlager et ai., 2003b). 
If a peptide-based vaccine is tested for its therapeutic ability in mice, the peptide should be 
one restricted by the immune system of mice, unless transgenic mice expressing human MHC 
molecules are employed (Schreurs et ai., 2005). If mice that are not transgenic are employed, 
the results are not necessarily a true reflection of reality. In cases where the E7 peptide 
restricted by H2-Db MHC class I molecules in mice was administered to mice, very good 
tumour regression was achieved (Torrens et ai., 2005; Paz De la Rosa et ai., 2009; Feltkamp 
et ai., 1993) However, when a similar approach is followed in humans, using a peptide 
restricted by human MHC class I molecules, no significant trend in the regression of tumours 
were seen in human volunteers (Muderspach et ai., 2000; Steller et ai., 1998; van Driel et ai., 
1999). Tumour regression experiments in mice have therefore not been a good indicator of 
peptide-based vaccines' therapeutic efficacy in humans, but they remain the best way to 
ascertain therapeutic efficacy ofHPV vaccines in preclinical studies. 
In order to elicit a measurable immune response, whether humoral or cellular, in mice, an 
adequate dose needs to be administered. Previously, in other studies, a wide range of doses 
have been administered subcutaneously. Thanes et ai. (Thanes et ai., 2008) observed 











three doses at 3ng each of VLPs injected subcutaneously without adjuvant. Biemelt et al. 
administered three injections of 40ng of plant- and insect cell-produced VLPs subcutaneously 
and detected an antibody response, however, the vaccine was mixed with adjuvant. On the 
other hand, Maclean et al. (Maclean et al., 2007) detected a poor neutralising antibody 
response after vaccination of mice with one dose of 1 J!g of insect-cell derived VLPs 
containing no adjuvant. The poor response may be attributed to the lack of booster 
vaccinations given. The number of boosts given is important as boosts are important for 
magnifying the immune response (Janeway et al., 1997a). 
For tumour challenge experiments, it seems at least 30 J!g ofLI1E7 chimaeric VLPs (cVLPs) 
were necessary to achieve an 80% survival rate amongst mice (Wakabayashi et al., 2002) 
This necessity for a high dose may also be a result of applying only a single dose and no 
boosters. However, immunisation with a single dose of 10 J!g of L lIL2/E7 without adjuvant 
afforded complete protection against tumour challenge in another study. (Greenstone et al., 
1998). 
From the literature there emerges no clear optimum dose ofVLPs to be administered to mice. 
Extracting data from a variety of sources, however, without distinguishing between humoral 
and cellular immune responses, indicates that any dose of Ll, LI/E7, LlIL2 or LlIL2 E7 
VLPs ranging from 5 to 100 J!g, with or without adjuvant, with any number of injections 
ranging from 1 to 4, administered subcutaneously, may elicit an immune response 
(Greenstone et al., 1998; Kawana et al., 1998; Slupetzky et al., 2007; Varsani et al., 2003; 
Sadeyen et aI., 2003; Maclean et aI., 2007; Wakabayashi et aI., 2002; Greenstone et al., 
1998; Paz De la Rosa et aI., 2009; Qian et al., 2006; Reddy et al., 2004; Kim et al., 2007b; 
Christensen et al., 1996; Fleury et al., 2006; Ryding et al., 2007). 
However, when Ll is in pentamer, as opposed to VLP formation, a higher dose is necessary 
to elicit the same immune response. According to Thanes et aI, 2008, three injections of 48 
ng of Ll pentamers each, elicited a detectable immune response that is very low, yielding 
only 34% neutralisation in an HPV -16 pseudovirion neutralisation assay. Adjuvants may 
rescue the immunogenicity, but this may depend on the adjuvant applied, because in their 
study, two injections of 10 J!g each mixed with one adjuvant but not another, elicited an 
immune response. E. coli-produced pentamers (OhlschHiger et aI., 2003) in another study 











humoral immune response. In another study, 5 Ilg of pentamers without adjuvant were 
injected twice and a humoral immune response obtained (Schiidlich et al., 2009). 
The immunogenicity ofL1 depends in part on its assembly into higher structures (Lenz et al., 
2001; Thones et al., 2008; Kuck et al., 2006; Schiidlich et al., 2009). In fact, it seems to 
depend strongly on its ability to form at least capsomers (Kuck et al., 2006) and it is also 
known that denatured L1 does not elicit the desired immune response (Schellenbacher et al., 
2009). The ability to assemble into "small VLPs" or T=l particles of about 30-40 nm in size 
also enhances humoral immunity and the levels elicited may be comparable to those elicited 
by VLPs or T=7 particles (Schiidlich et al., 2009). Assembly into T=l particles did not show 
to be of benefit to the cellular immune response and therefore the formation ofT=7 particles 
remains preferable in such a case. Despite the lower immunogenicity of capsomers, they may 
still be employed in vaccine formulations, since adjuvants can compensate for their lowered 
immunogenicity. 
The assembly of L1 into VLPs or capsomers may be influenced by modifications of L1. In 
our study, most modifications, except for BPV, disrupted the helix 4. This modification has 
repeatedly been observed to abolish formation of any higher-order structure other than 
capsomers (Schiidlich et al., 2009; Murata et aI., 2009; Bishop et al., 2007a; Varsani et al., 
2003). All the chimaeras created and used in our study have the helix 4 deleted and are 
therefore expected to assemble into capsomers. 
In our study, we immunised mice with insect cell lysates containing six different chimaeric 
vaccines as constructed in Chapter 2. Vaccination with crude preparations is not uncommon 
in the literature and may be a rapid way of assessing immunogenicity of a particular construct 
without having to purify it (Maeda et al., 1996; Fan et al., 2007; Cusi et al., 1995; Sullender 
& Britt, 1996; Thanes & Muller, 2007). Vaccination with crude preparations can be 
employed as long as the negative control is also cell lysate negative for the protein of interest 
and the assays used to evaluate immunogenicity specifically selects for the response to the 
protein of interest. 
In this chapter, the 6 chimaeras constructed, expressed in and extracted from insect cells and 
quantified as described by Chapter 2, are compared with respect to immunogenicity for 











respect to their ability to elicit protective homologous and heterologous antibodies, whereas 
the LlIE7 chimaeras were assessed for their ability to elicit cell-mediated immune responses 
essential for treatment of existing HPV -induced lesions and to effect tumour regression in 
mice. All the chimaeras were also analysed with respect to their ability to assemble into 
higher-order structures by electron microscopy. 
3.2 Materials and Methods 
3.2.1 Mice and cellUnes 
Female C57/BL6 mice were purchased from the South African Vaccine Producers Animal 
Unit (Johannesburg, South Africa) and maintained under BSL2 conditions according to 
European Guidelines in force in the Animal Unit of the Health Science Faculty, University of 
Cape Town. All mice were 7 weeks of age at the time of vaccination and prebleeds were 
taken 5-7 days before vaccination. Permission for this work was obtained from the Research 
Ethics Committee, University of Cape Town (REC REF 008/037). 
C3 cells and EL-4 cells were kindly provided by Peter OhlschHiger. C3 cells were cultured in 
RPMI with glutamax, supplemented with 10% FCS, 0.1 mg/ml kanamycin, 0.8 mg/mlof 
G418 and 1 % penicillin-streptomycin. The G418 was only added to the medium 3 days after 
cell culture was started. EL-4 cells were cultured under the same conditions, but without 
G418 or kanamycin. 
3.2.2 Immunisation 
For assessment of humoral immune responses, mIce were vaccinated with SAF, L2.56, 
L2.17, BPV and a negative control. The details ofthis experiment are listed in Table 3.1. The 
negative control was cell lysate previously infected with wild-type baculovirus and prepared 
as for the other vaccines, as described in Chapter 2. All celllysates were adjusted such as to 
contain the dose listed in Table 3.1 in the total volume of DPBS listed in Table 3.1. The 
vaccine was then homogenised by the syringe-extrusion technique (Koh et al., 2006) in 
Incomplete Freund's Adjuvant (Sigma) at a 1:1 ratio of vaccine to adjuvant. The volume of 











T bl 3 1 D t'l f . fc h a e . e aI s 0 llnmumsahon or t e assessment 0 fh umora Immune responses 
Vaccine Number of mice Dose Volume Injection site Vaccination Final 
(groupsxnumber of DPBS schedule bleed 
in group) 
SAF 3x3 5 Ilg 200 III Subcutaneous Day 0, 14, Day 
42, 70 77-80 
L2.17 2x3 and 1x4 5 Ilg 200 III Subcutaneous Day 0, 14, Day 
42, 70 77-80 
L2.56 3x3 5 Ilg 200 III Subcutaneous Day 0, 14, Day 
42, 70 77-80 
BPV 3x3 1.8 Ilg 600 III Subcutaneous Day 0, 14, Day 
42, 70 77-80 
Negative 2x3 and 1x4 N/A 200 III Subcutaneous Day 0, 14, Day 
control 42, 70 77-80 
NI A=not applicable 
For assessment of cell-mediated immune responses, mice were vaccinated with SAF as the 
negative control, E7M, E+E7M and a DNA vaccine (HPV-16E7SH), expressing a shuffled 
E7 gene and thus having no transforming potential (OhlschHiger et aI., 2006), as a positive 
control. The details of this experiment is shown in Table 3.2. The DNA vaccine was kindly 
provided by Peter OhlschHiger and was prepared by using the EndoFree® Plasmid Giga Kit 
from Qiagen. SAF, E+E7M and E7M were adjusted to their final concentration, homogenised 
with adjuvant and administered as described above. The DNA vaccine was not mixed with 
adjuvant. 
Table 3.2 Details of immunisation for assessment of cell-mediated immune responses 
Vaccine Number of mice Dose Volume Injection site Vaccination Final 
(groupsxnumber of DPBS schedule bleed 
in group) and 
spleen 
removal 
SAF 2x3 and 1x4 5 Ilg 200 III Subcutaneous Day o and Day21 
14 
E7M 2x3 and 1x4 5 Ilg 200 III Subcutaneous Day 0 and Day21 
14 
E+E7M 2x3 and 1x4 3 Ilg 600 III Subcutaneous Day o and Day21 
14 












For tumour regression experiments, mice were subcutaneously injected with 0.5x106 C3 cells 
resuspended in 200 III Dulbecco's Phosphate Buffered Saline (DPBS) on the right flank:. 
When the tumours reached a size of 2-3mm in diameter, mice were vaccinated with SAF, 
E7M, E+E7M, HPV-16E7SH as a positive control and cell lysate previously infected with 
wild-type baculovirus as a negative control. SAF, E+E7M, E7M and the negative control 
were adjusted to their final concentration, homogenised with adjuvant and administered as 
described previously. The DNA vaccine was not mixed with adjuvant. Tumour size was then 
measured every 2-3days. Mice were killed and bled by cardiac puncture as soon as the 
tumour volume reached 2500 mm3 or at the end of the experiment. 
Table 3.3 Details of immunisation in tumour regression experiments 
Vaccine N umber of mice Dose Volume Injection site Vaccination End of 
(groupsxnumber of schedule experiment 
in ~roup) DPBS 
SAF 2x3 and 1x4 5 Ilg 200 III Subcutaneous Day 0 and Day 78 
Day 14 
E7M 2x3 and 1x4 5 Ilg 200 III Subcutaneous Day 0, 14, Day 60 
39 
E+E7M 2x3 and 1x4 3 Ilg 600 III Subcutaneous Day 0, 14, Day 60 
39 
HPV- 2x3 and 1x4 100 50 III Intramuscular Day 0 and Day 78 
16E7SH Ilg Day 14 
Negative 2x3 and 1x4 N/A 200 III Subcutaneous Day 0, 14, Day 60 
control 39 
NI A=not applicable 
3.2.3 ELISA for detection of anti-L1 antibodies 
3.2.3.1 Extraction of plant-produced SAF for use as antigen in ELISA 
Because SAF had been previously tested in our laboratory, it served as a positive control for 
our experiments. Therefore SAF was used in an ELISA to detect antibodies in mouse sera. 
The protein was expressed in and purified from plants, because SAF produced in insect cells, 











mice were immunized with insect cell lysate. Agrobacterium tumefaciens were transformed 
with pTRAkc-rbcs1-cTP, into which the SAF gene had been cloned by Cathy Pineo, as well 
as pBIN-NSs, according to the method outlined by Maclean et at. (Maclean et at., 2007) 
Nicotiana tabacum plants were infiltrated by injection as outlined by the same publication, 
but as many leaves as possible were infiltrated per plant. Five days post-infection, the leaves 
were harvested and the big stems excised. Leaves were ground up in liquid nitrogen, using a 
mortar and pestle. The leaf material was then suspended at 19 of leaf material per 12.5 mlof 
high-salt phosphate-buffered saline (HSPBS) with 0.5 M NaCI and EDT A-free protease 
inhibitor (Roche). The material was allowed to defrost and ground again, after which it was 
homogenised for about 10 minutes. The material was then sonicated for 9x30 sec with 20 sec 
rests after which it was filtered through Miracloth (supplied by CALBIOCHEM), a filtration 
material for gelatinous grindates, to get rid of the particulate matter. It was then centrifuged 
for 5 minutes at 25 OOOxg, the supernatant retained and centrifuged again under the same 
conditions. The final supernatant was stored at -80DC. 
3.2.3.2 Purification of SAF from plant extracts 
SAF was purified from crude plant extract by CsCI centrifugation. Crude supernatant was 
made up to 40% CsCI in HSPBS containing protease inhibitor. Samples were then subjected 
to centrifugation for about 23 hours at 36000 rpm in a SW55Ti rotor. Fractions (~500 JlI 
each) were taken after centrifugation and 2 JlI per fraction was spotted onto a nitrocellulose 
membrane. The membrane was blocked with blocking buffer (0.1 % Tween-20 and 5% skim 
milk in 1xPBS pH 7.6), then incubated for at least 1 hour with a 1 :10000 dilution of primary 
antibody (Camvir-1, Abcam® ) in blocking buffer. This antibody binds to the linear epitope, 
aa 230-236 (McLean et at., 1990), which is not destroyed by any of the insertions. Secondary 
antibody was anti-mouse IgG conjugated to alkaline phosphatise (Sigma) and used at 1:10 
000 in blocking buffer for at least 1 hour. After each antibody step, the membrane was 
washed thrice for 15 minutes in wash buffer (0.1 % Tween-20 in 1 xPBS pH 7.6). Spots were 
visualised with nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indoyl-phosphate 
(NBT/BCIP) substrate (Roche). 
Densitometry (GeneTools, Syngene, Synoptics Ltd) was used to measure the intensity of 
absorbance in each spot by placing a circle of the same size on each spot. A similar spot was 











pixels per spot were then divided by those of the background. Only fractions with values at 
least twice as much as that of the background were pooled and served as the purified sample 
to be used in ELISA. 
3.2.3.3 Quantification of SAF 
SAF was then quantified by Western blotting as follows: Before electrophoresis, protein 
samples were diluted to the desired concentration in 5xloading buffer (2% SDS, 100mM Tris-
HCl pH 7.5, 2mM EDTA, 91% glycerol, 7.6% beta-mercaptoethanol) and boiled at about 
90°C for 5 minutes. Samples were then loaded onto a 12% acrylamide gel and 
electrophoresed for 2 hours at 20 rnA. The gel was then blotted onto a nitrocellulose 
membrane for Ih30min at 15V. The membrane was blocked with blocking buffer (0.1% 
Tween-20 and 5% skim milk in 1 xPBS pH 7.6), then incubated for at least 1 hour with a 1: 1 0 
000 dilution of primary antibody (Camvir-l, Abcam® ) in blocking buffer. This antibody 
binds to the linear epitope, aa 230-236 (McLean et ai., 1990), which is not destroyed by any 
of the insertions. Secondary antibody was anti-mouse IgG (Sigma) used at 1:10 000 in 
blocking buffer for at least 1 hour. After each antibody step, the membrane was washed thrice 
for 15 minutes in wash buffer (0.1% Tween-20 in lxPBS pH 7.6). Bands were visualised 
with nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indoyl-phosphate (NBT/BCIP) 
substrate (Roche). 
SAFMOD previously quantified against wild-type Ll was used to construct a standard curve 
by loading a doubling dilution. Similarly, a dilution series of the sample to be quantified was 
also loaded. The intensities of the bands were measured by densitometry (GeneTools, 
Syngene, Synoptics Ltd). A log curve was fitted to the readings of the standards using 
Microsoft Excel and the equation used to estimate the quantity of protein in each sample. 
3.2.3.4 ELISA 
ELISA was performed as follows: 96-well plates (Maxisorp, Nunc) were coated with 30 ng 
of purified SAF per well diluted in lxPBS pH 7.6 overnight at 4°C. Plates were then blocked 
with blocking buffer, (1% low-fat milk in lxPBS) 300 III per well, for 2 hours at room 
temperature. Sera from mice vaccinated for assessment of antibody production, as well as 











pooled for each group, resulting in three groups per vaccine. Sera were diluted in a fourfold 
series, in triplicate, ranging from 1 :50 to 1 :51200, in blocking buffer and 1 00 ~l was added to 
each well. Positive control wells, containing V5 monoclonal antibody binding to 
conformational epitopes at 1 :2000 (a gift from Dr Neil Christensen) and blank wells 
containing no antibody were included. Sera were incubated in the wells for 2 hours at room 
temperature. Anti-mouse antibody conjugated to horseradish peroxidise at a 1 :2000 dilution 
in blocking buffer was added at 1 00 ~l per well and incubated for 1 hour at 37°C. Here, and 
in between each previous step, plates were washed 4 times with 300 ~l per well of 1xPBS. 0-
phenylenediamine dihydrochloride (OPD) tablets (supplied by Dako) were then diluted as per 
instructions and 1 00 ~l added per well. Plates were developed in the dark for 30 minutes at 
room temperature. The reaction was stopped with 0.5M H2S04 and the absorbance read at 
490nm. 
A two-tailed, non-paired t-test was used to calculate statistical significance as for the tumour 
volumes. 
3.2.4 Western blot detection of anti-L2 antibodies 
3.2.4.1 Preparation ofL2 protein for use as antigen in Western blotting 
His-tagged L2 produced in E. coli was used in a Western blot to detect anti-L2 antibodies in 
the sera of mice vaccinated with L1/L2 chimaeras. L2 was produced and purified by 
extracting inclusion bodies as follows: L2 in the pProEX htb vector. 100ml E.coli was grown 
to an optical density of 0.6 and induced by addition ofiso-propyl-B-D-thiogalactoside (IPTG) 
to 0.6 mM. The culture was grown for another 3 hours under shaking. The cells were then 
harvested by centrifuging at 3800xg for 15 minutes at 4°C. The pellet was retained and 
weighed. Cells were resuspended in 4 volumes lysis buffer (50mM Tris pH 8.5, 5 mM B-
mercaptoethanol) and phenylmethanesulfonyl fluoride (PMSF) added to OAmM, as well as 
lysozyme (Roche) to 0.08 ~g/~l. The cells were then left on ice for 20 minutes. Triton-X was 
then added to 1 % final concentration and the cells left for a further 20 minutes at 37°C until 
the solution was viscous. DNAse and RNAse were then added to 4 ~g/ml and 40 ~g/ml fmal 
concentration respectively. Cells were then left at 30 minutes at room temperature until it 
wasn't viscous any more and centrifuged at 13000 rpm in a benchtop centrifuge for 15 











(2.5 mM Tris pH 8.0, 3.125 mM p-mercaptoethanol, O.2mM EDTA, 0.0025% Triton-X 
diluted in water) and left to lyse for ten minutes at room temperature. Another 13000 rpm 
centrifugation step was carried out for 15 minutes at 4DC, followed by four washes of the 
pellets with lxPBS. The fmal pellet was resuspended in 1 volume of the weight ofthe pellet 
of1xPBS. 
3.2.4.2 ~estel11 blot 
His-tagged L2 protein was then subjected to electrophoresis on a 10% acrylamide gel. 
However, instead of using a gel with 10 wells, a comb was used which has one well on the 
left to load the marker and the other nine wells fused together, to form a large well on the 
right, into which a total of 1.8 ~g of purified His-tagged L2 protein was loaded and equally 
spread across the width. The rest ofthe protocol was identical to the one described above for 
Western blotting quantification. However, after blotting of the gel onto a membrane, only the 
area on the blot containing proteins between 55 and 100 kDa (since L2 is -70 kDa in size) 
was excised. This strip was then divided into enough equally-sized strips to probe with 
different mouse sera. The resulting blocks were transferred to 25-well tissue culture plates 
and blocked with blocking buffer (0.1% Tween-20 and 5% skim milk in lxPBS pH 7.6) Sera 
from all nine or ten mice vaccinated per construct in the antibody assessment experiments as 
well as mice vaccinated with E+E7M in the cellular immune response experiments were 
pooled, diluted in blocking buffer and added to different wells containing a section of 
membrane. One section was probed with mouse anti-His antibody (Serotec), at a 1 :2000 
dilution for a positive control. The same was done for the prebleeds on a different gel and 
blot. Sera were incubated with the membrane sections for 1 hour. The rest of the protocol as 
described for western blotting quantification was then followed. 
3.2.4.3 Cross-absorption of non-specific antibodies 
Because of high levels of non-specific interactions with the L2 protein by prebleed and 
negative control sera, cross-absorption of the sera with E.coli, insect cell and baculovirus 
proteins was also attempted. One set of strips of nitrocellulose membrane, 20x7.5 mm each, 
was coated overnight at 4 DC with E. coli lysate, prepared as described above, but containing 
no L2 protein. In some cases, E.coli, expressing another unrelated his-tagged protein and 











coated, also overnight at 4°C, with Sf-9 insect cell lysate infected with wild-type baculovirus 
or, in some cases, with baculovirus containing an unrelated gene. The insect cells were at 
lxl06 cells per ml, resuspended in lxDPBS. The strips were washed thrice with blocking 
buffer. Two strips were then placed together into a well in a 25-well tissue culture plate. Sera 
pooled as described above were diluted in blocking buffer and added to different wells. 
Cross-absorption was for 2 hours at room temperature by shaking. The diluted sera were than 
removed from the cross-absorption membranes and transferred to the membrane sections 
onto which L2 protein had been transferred. 
3.2.5 Pseudovirion neutralisation assays 
3.2.5.1 Pseudovirion production 
Protocols for this procedure can be obtained from 
http://home.ccr.cancer.gov/lco/protocols.asp. All work with pseudovirions performed in our 
study was based on these protocols, but there were modifications. HEK293TT cells were 
maintained in complete Dulbecco's Modified Eagle Medium (cDMEM) which contains 
GlutaMAXTM and high glucose content (supplied by Gibco), containing 10% fetal bovine 
serum, 100 units/ml penicillin, 100 Ilg/ml streptomycin, 10 Ilg/ml Fungin TM. 
For pseudovirion production, cells were preplated in complete DMEM in a 175 cm2 flask so 
they would reach 70-80% confluence the next day. The medium was replaced with fresh 
medium the next day. FuGene6 (Roche), 175 Ill, was added to 5.7 ml of DMEM with 
glutamax and incubate for 5 minutes at room temperature. A total of 80 Ilg of DNA was 
added and the mixture incubated for a further 30 minutes. The mixture was then added 
dropwise to the cells. After 4-6 hours, the medium was replaced with fresh complete DMEM. 
The flask was incubated for 40-48 hours in a 37°C, 5% C02 humidified incubator. 
Pseudo virions were harvested as follows. Cells were trypsinised and the reaction inactivated 
with complete DMEM. The cells were then transferred to a conical polystyrene tube, -which 
is very important, since pseudo virions adhere to polypropylene tubes- centrifuged and the 
pellet washed with DPBS. The pellet was then resuspended in the same volume of DPBS 
supplemented with extra 9.5 mM MgCh as the volume of the pellet itself. Brij-58 was added 











dependent DNase were added to 0.2% (vfv) each. The mixture was incubated at 37°C for 45 
minutes to effect lysis and then transferred to the preferred temperature for maturation of 
pseudovirions overnight. (25° for HPV-16 and 37° C for the others) After maturation, the cell 
lysate was clarified by adjusting the NaCI concentration to 850 mM and incubation at 4°C for 
10 minutes. The lysate was then centrifuged for 10 minutes at 10 OOOxg and 4°C. The 
supernatants were aliquoted into polystyrene conical tubes and stored at -80°C until further 
use. 
3.2.5.2 Neutralisation assays 
Pseudo virion neutralisation assays were performed as described in the protocols on the 
website listed. Doubling dilutions ranging from 1 :200 to 1 :25600 were used to titrate type 16. 
Because the titre was expected to be lower for types other than type 16, dilutions from 1: 1 00 
to 1:12800 were used to titrate types 45 and 52. The dilution of pseudo virions to be used in 
the neutralisation assay was chosen as one being within the linear range of the resulting curve 
of luminescence versus concentration of pseudovirions. 
Sera from mIce vaccinated with SAF, L2.56 and L2.17 in the antibody assessment 
experiment, as well as from mice vaccinated with the LlfE7 chimaeras for ELI spot were 
tested for neutralisation of HPV-16. Only sera from SAF, L2.56 and L2.17 were further 
tested with types 45 and 52. Final bleed sera were pooled per group and each group was 
diluted fourfold in triplicate with dilutions ranging from 1 :40 to 1: 1 0240. Prebleeds were also 
pooled as for the final bleeds and tested at 1 :40 in triplicate and in some cases 1: 160. Sera 
from all ten mice vaccinated with negative control cell lysate were pooled and the group was 
tested at 1 :40 in triplicate. 
Each 96-well plate included controls: four wells with pseudovirions, and two wells with no 
pseudovirions or antibodies for a background reading of cell culture supernatant. Positive 
control antibodies were also titrated against the pseudovirions. Monoclonal antibodies were 
kindly donated by Dr Neil Christensen and these included H16.V5 and H45.N5 ascites as 
well as H52.Dll and H52.Cl supernatants. H16.V5 neutralises HPV-16 and was used at a 
tenfold dilution ranging from 10-4 to 10-7• H45.N5 neutralises HPV-45 pseudovirions and was 
used at a four-fold dilution range from 1 :400 to 1 :25600; and on another occasion at a tenfold 











1:40 000 and H52.C1 at a tenfold dilution from 1:100 to 1:100000. H52.Dll and H52.C1 
neutralise HPV -52. 
SEAP activity was assayed for by using the Great EscAPe ™ SEAP Chemiluminescence Kit 
2.0 (Clontech Laboratories, Inc.) according to the instructions in the manual. However, due to 
the expense of the substrate, the volumes used per well were adjusted to be 0.6 of that given 
in the protocol. 
The neutralisation titres ofthe test sera were calculated as the highest dilution of serum which 
reduced the maximum SEAP activity, as measured in the wells where only pseudo virions 
were added to the cells. 
3.2.6 Assays to determine cell mediated immune responses to vaccination 
3.2.6.1 Preparation of splenocytes 
Splenocytes were used in all cell mediated immune response assays. The spleens of each 
group of mice within the given experiments were pooled. Splenocytes were separated by 
meshing the pooled spleens of each group through a metal sieve (pore size 70/lm) in RPMI 
medium (Gibco). Suspensions were transferred to 50 ml Sterilin™ tubes and centrifuged at 
400 g for 5 min. The resulting cell pellet was resuspended in 50 ml of RPMI and the 
centrifugation step repeated. Resulting pellets underwent two further washes. Fibrin clots 
were removed using a Pasteur pipette before the final centrifugation step. Red blood cells 
(RBCs) were lysed in aliquots ofthe splenocytes by suspending 50x106 cells in 1ml ofRBC 
lysis buffer (5 mM Tris-HCI, 140 mM NH4CI, pH 7.3, Sigma) for 2 minutes. The cells were 
then pelleted by centrifugation at 400 g for 7 minutes. The supernatant containing the lysed 
red cells was discarded and splenocytes were suspended at a final concentration of 5 x 106 
cells/ml in RIO medium (RPMI supplemented with 1 % penicillin G/streptomycin, 10% FCS 
and 0.1 % 2-mercaptoethanol). 
3.2.6.2 IFN-y ELlspot assay 
The IFN-y ELIspot assay was one of the assays used to measure the cell-mediated immune 











frequency of ex vivo vaccine-specific effector CD8 T cells in the spleen that release IFN-y 
when splenocytes are stimulated with the E7 peptide. An IFN-y ELI spot assay kit supplied by 
BD Biosciences was used. 
The membranes of the ELIspot plates were pre-wet in 35% ethanol (15 Ill/well) for 60 
seconds and then washed three times with 200 III PBS (supplied by Gibco, pH 7.2). Plates 
were then coated with 100 III purified anti-mouse IFN-y antibody, diluted to 5llg/ml in PBS 
and stored overnight at 4°C. The next day, the antibody was discarded, the wells washed once 
with RIO and then blocked with 200 III RIO/well for two hours at room temperature. 
Blocking buffer was discarded and the wells and the membranes were washed once with RIO. 
The stimulants, in 100 III RIO, were then added. These were either medium only (to 
determine background responses); lL-2 (to determine background responses to lL-2); E7 
peptide; E7 peptide and lL-2; or Concanavalin A (assay control). Recombinant mouse lL-2 
expressed in E. coli was supplied by R&D and used at a concentration of 10ng/ml, of which 
1.6 III was added to every 100 III splenocytes. The peptide was the H2-Db restricted HPV-16 
E7 peptide, amino acids 49-57 (RAHYNIVTF) and used at 1 Ilmol per well. It was obtained 
from Dr Ohlschlager. Concanavalin A (final concentration 0.5 Ilg/ml) was supplied by 
Sigma. Each pooled group of splenocytes was assayed in triplicate. 
Plates were incubated for 24 hours at 37°C in a 5% C02-humidified incubator. After the 
incubation, the cell suspensions were discarded from the plates and the membranes were 
washed three times with deionised water. The water was removed from the wells, and the 
membranes were washed three times with PBS+ 0.05% Tween 20 (Sigma-Aldrich, USA). 
The PBS + 0.05% Tween 20 was then discarded and a volume of 100 III ofbiotinylated anti-
mouse IFN-y detection antibody (2Ilg/ml in PBS with 10% FCS) was added to each well. The 
plates were incubated at room temperature in the dark for two hours after which the 
antibodies were discarded and the membranes washed three times with PBS+ 0.05% Tween 
20. A volume of IOOIlI of avidin-horseradish peroxidase (Avidin-HRP) (5 Ilg/ml in PBS with 
10% FCS) was added to each well and the plates were incubated at room temperature in the 
dark for one hour. The membranes were washed three times with PBS+ 0.05% Tween 20 
then three times again with PBS (Sigma-Aldrich, USA). The substrate solution Nova Red 
(Vector) was prepared in distilled water and a volume of 100 III was added to each well. The 











The reaction was stopped by washing five times with distilled water. The plates were dried in 
the dark before analysis. 
The ELIspot plates were scanned using an ImmunoSpot CTL Reader and the spots in each 
well were counted using ImmunoSpot Software version 3.2. For each reaction, the mean 
number of spots from triplicate wells and the standard deviation (SD) of this mean were 
calculated and adjusted to 1 x 106 splenocytes and expressed as spots forming units per 1 x 
106 splenocytes (SFU/l06 splenocytes). Positive responses of the splenocytes to the stimuli 
for each group were considered to be those greater than twice the background response. For 
all positive responses, the background responses of the group were subtracted from the E7-
specific responses and the response then expressed as net SFU/l 06 splenocytes. 
3.2.6.3 Flow cytometric bead array assay 
Splenocytes were also used in a flow cytometric bead array (CBA) assay. This assay detects 
the range of cytokines secreted into the supernatant by effector CD8 T cells in the spleen in 
response to stimulation with the E7 peptide. This assay was done to determine the Th1 or Th2 
type of immune response induced by the vaccine. It was also done because IFN-y may not 
necessarily be the only cytokine secreted, as measured by the IFN-y ELI spot assay. Other 
cytokines may also be secreted. 
3.2.6.3.1 Stimulation of splenocytes for 48 hours 
To a 96-well plate, 100 ~l of each stimulant, as listed in Section 3.2.6.2, was added, as well 
as 100 ~l of splenocytes at a cell density of 15x106/rnl. The splenocytes were cultured for 48 
hours, the predetermined time required for maximum secretion of cytokines . After this 150 
~l of supernatant was removed and stored at -20°C until analysis by the BDTM flow 
cytometric bead array (CBA) assay, using the mouse inflammation kit from BD Biosciences, 
according to the instructions ofthe manufacturer. 
3.2.6.3.2 Stimulation of splenocytes for 6 days 
In vitro stimulation of splenocytes for 6 days with the E7 peptide was performed to expand 











CD8 T cells expand through proliferation to effector cells. Prolonged peptide stimulation 
allows detection of vaccine induced memory cells which would not be detected in the IFN-y 
ELIspot assay and the 48 hour stimulation protocol (Ohlschlager et al., 2003; Ohlschlager et 
al.,2006). 
For this, pooled splenocytes were cultured for 6 days at a starting cell density of 1 Oxl 06 
cells/ml in RlO, together with 4 Ilg/ml of the E7 peptide. After 6 days, live lymphocytes 
were harvested from the cultures as follows: Cells were pelleted, resuspended in RPMI and 
counted. Cell concentration was adjusted to l5-30xl06 cells/ml (including dead cells) and 5 
ml of cells transferred to polystyrene conical-bottomed tubes. The cells were then underlaid 
with 5ml of lympholyte M (Cedarlane, Canada) and the tubes centrifuged at 930 g for 20 
minutes at room temperature, with no brake applied. After centrifugation, the supernatant was 
discarded and the interface containing live lymphocytes carefully removed. The lymphocytes 
were pelleted, washed three times with RPMI and then resuspended in complete RPM!. The 
lymphoyctes were further cultured as follows: 3xl06 EL-4 cells (antigen presenting cells) 
+3xl06 Iymphocytes+4 Ilg/ml E7 peptide in a final volume of600 III RIO. The cultures were 
stopped at 4 hours, 8 hours and 24 hours respectively and harvested supernatant used in the 
BDTM flow cytometric bead array (CBA) assay, using the mouse inflammation kit from BD 
Biosciences, according to the instructions of the manufacturer. This assay was done to 
determine the array of cytokines release by E7 specific CD8 T cells in the lymphocyte 
population. 
3.2.7 Calculation of tumour volume 
Tumour volume was calculated as 0.5xwidth2xlength. The tumours were measured with 
calipers every 3-4 days. When tumours reached a size of 2500 mm3, the mice were killed. 
GraphPad Prism® 5.01 was used for statistical calculations and construction of a survival 
curve. A two-tailed, non-paired t-test was used to calculate whether the mean tumour 
volumes were significantly different. The Kaplan-Meier method was used to construct a 
survival curve, detailing the time points where tumours reached a cut-off size of 250 mm3. A 
log-rank (Mantel-Cox) Test and a Gehan-Breslow-Wilcoxon Test were used to determine 












3.2.8 Electron microscopy analysis 
Protein samples were treated as they would before vaccination. Protein samples were 
defrosted overnight at 4°C, resuspended in DPBS to the concentration at which they would 
be injected and incubated at 37°C for 30 minutes. The aliquots were then diluted a further 20 
times in DPBS. Human codon-optimised Ll was expressed in insect cells (see Chapter 2) in 
the same way as for the other constructs. Neat cell lysate containing Ll protein at 9 ~g/ml 
was treated as for the other constructs and diluted a further 20 times in DPBS. Protein was 
captured onto carbon-coated copper grids (200 mesh, obtained from Electron Microscopy 
Sciences, Pennsylvania) using the HPV16-conformation-specific antibody V5 (a gift from Dr 
Neil Christensen), which should capture Ll pentamers and VLPs onto the grids (Christensen 
et at., 1996; Varsani et at., 2003). Grids were incubated on 20 ~l ofa 1:1000 dilution ofV5 in 
lXPBS, washed twice with water, then incubated on 20 ~l of protein sample for 20 min and 
washed with water three times. Grids were stained with 2% uranyl acetate and visualised 













3.3.1 Humoral immune responses against the major capsid protein, Ll 
Antibodies, specifically neutralising antibodies against the immunodominant major capsid 
protein, Ll, have been shown to confer excellent protection against infection with HPV 
(Schiller et al., 2008). Therefore the ability ofthe LI/L2 chimaeric vaccines to elicit antibody 
production against Ll was assessed by ELISA. The LlIE7 chimaeras were also tested, but, 
since mice were only vaccinated twice, instead of four times, the results were not comparable 
to the other chimaeras. The results of the ELISA is shown in Figure 3.1. 
L2.56 elicited production of significantly higher levels of antibodies than the negative control 
(P=0.0002), L2.17 (P=0.0114) and SAF (0.0184) at a 1 :50 dilution. As expected, E7M and 
E+E7M did not elicit as high levels of antibodies. At a 1 :50 dilution, the absorbance ofE7M 
was significantly different from that of the negative control, but this was not the case for 
E+E7M. The mean absorbance for E+E7M, however, was higher than that for the negative 
control. BPV did not elicit a response higher than the negative control. (P=0.3553) SAF and 
L2.17 were not significantly different from one another. (P=0.3938) The prebleeds did not 
elicit a response (data not shown) The titres of the chimaeric vaccines are shown in Table 3.4. 
According to the titres, the three L 1 IL2 chimaeras, excluding BPV, elicited similar immune 
responses, E7M and E+E7M elicited positive but low responses and BPV no response. 
In summary, all chimaeric vaccines except BPV elicited some anti-Ll immune response, as 
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Figure 3.1. Anti-SAF responses elicited by immunisation with different chimaeric L1 
vaccines and detected in the final bleed serum. Three groups of mice were vaccinated on 
day 0, day 14, day 42 and day 70 and bled 7-10 days after the last vaccination for the 
L11L2 chimaeras. Mice were vaccinated twice at 2 week intervals and sacrificed 7 days 
after the last vaccination for all the LlIE7 chimaeras. The negative control is wild-type 
baculovirus-infected insect cell lysate. Sera from the immunised mice were bound to semi-
purified plant-produced SAF in a direct ELISA. Sera from each group of mice vaccinated 
were pooled and assayed in triplicate. The error bar indicated here is standard error of 
the mean of the three groups per vaccine. 








Negative Control 50 
'7itres were calculated as the dilution at which the mean absorbance was twice that of the 
mean absorbance of the prebleed at a 1 :50 dilution. 
3.3.2 Humoral immune responses against the inserted L2 peptides 
We tested for the presence of antibodies in the sera of mice vaccinated with SAF, L2.56, 
L2.17, BPV and E+E7M or all those chimaeras including L2 peptides. This was done by 











linearised form of full-length L2. Antibodies against L2 would indicate whether the peptides 
inserted into L1 are displayed on the surface of the particle, so that they are detected by the 
immune system. It is also antibodies against L2 that would be responsible for cross-
neutralisation ofHPV types other than type 16, since antibodies against L1 are type-specific. 
Various attempts were made at detecting the response on a western blot, without cross-
absorption and with cross-absorption as described in Sections 3.2.4.2 and 3.2.4.3, because the 
prebleeds and the negative control showed non-specific reactions. Cross-absorption was 
attempted with both E7M-infected insect cell lysate, which might get rid of cross-reacting 
antibodies against L1, insect cells and baculovirus, as well as an irrelevant His-tagged protein 
prepared from E. coli in a similar manner to the His-tagged L2 protein, which might get rid of 
all the cross-reacting anti-E. coli and anti-His tag antibodies. However, despite this extensive 
cross-absorption, non-specific reactions remained for the prebleeds and the negative control. 
Despite the non-specific reactions, the consistent result was that anti-L2 antibodies could 
only be detected for sera from L2.56- and L2.17-vaccinated mice with an intensity above that 
of the background. A representative result is shown in Figure 3.2, showing darker and more 
pronounced bands for sera from L2.56- and L2.17-vaccinated mice than for sera from any of 
the prebleeds or negative contro 1-vaccinated Ill1ce. 
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Figure 3.2. Detection of antibodies against L2 elicited by vaccination with chimaeric 
vaccines. Three groups of mice were vaccinated on Day 0, Day 14, Day 42 and Day 70 
and bled 7-10 days after the last vaccination for the LIIL2 chimaeras. Mice were 
vaccinated twice at 2 week intervals and sacrificed 7 days after the last vaccination 
for E+E7M. The negative control is wild-type baculovirus-infected insect cell lysate. 
His-tagged L2 expressed in E. coli was subjected to electrophoresis and transferred 
unto a nitrocellulose membrane. Sera from different groups of vaccinated mice were 
bound to L2 and visualised. M=marker, indicating the size in kDa; prebleed=serafrom 
blood taken before mice were vaccinated; Final bleed=sera from blood taken after 
vaccination; Neg=negative control; Anti-HIS=antibody against histidine tag attached 











3.3.3 Homologous protection against HPV-16 
HPV -16 is the most common cancer-causing type overall and in Africa (Bosch et at., 2008). 
For this reason, and because the chimaeric vaccines were based on HPV-16 L1, sera from 
mice vaccinated with the chimaeric vaccines were tested for protection against HPV -16 in 
vitro, by pseudo virion neutralisation assays. Since no antibodies were detected for BPV by 
ELISA, its sera were not tested. Pseudovirion neutralisation assays were also carried out for 
sera from E7M and E+E7M, as for the ELISA, but no response was detected (data not 
shown). The lack of response could be attributed to fewer vaccinations than for the other 
chimaeras. The prebleeds also showed no response (data not shown). Figure 3.3 shows the 
results of the neutralisation assay and Table 3.5 shows the titres. For SAF, as seen in Figure 
3.3(A), only two of the three vaccinated groups, groups 1 and 2, could neutralise HPV -16 
pseudovirions at titres of 2560 and more than 10240 respectively. Group 3 showed no 
neutralisation. Sera from mice vaccinated with L2.17, shown in Figure 3.3(B), from all three 
groups showed neutralisation with titres of 2560 for one group and > 1 0240 for the other two 
groups. The same was seen for sera from mice vaccinated with L2.56 (Figure 3.3(B). 
SAF, L2.56 and L2.17 therefore show potential as vaccines capable of eliciting neutralising 
antibodies against HPV -16, as can be seen from the significantly high titres, and there was no 
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Figure 3.3. Neutralisation of HPV-16 pseudovirions by sera from 
mice vaccinated with (A) SAF (B) L2.17 and (C) L2.56. Three 
groups of mice were vaccinated on Day 0, Day 14, Day 42 and Day 
70 and bled 7-10 days after the last vaccination. The negative 
control is wild-type baculovirus-infected insect cell lysate. Sera from 
each group of mice vaccinated were pooled and assayed in triplicate. 
The "no antibody " control wells contained only pseudovirions, but 












Table 3.5. Titres of neutralising antibodies against HPV -16 pseudovirions 
Chimaera Titrea 
SAF o to> 10240 
L2.17 2560 to > 1 0240 
L2.56 2560 to 10240 
E7M 40 
E+E7M Oto 40 
Negative control o to 40 
aThe titre was calculated as the highest dilution of serum where the SEAP activity is reduced 
by at least 50% as compared to the maximum SEAP activity. 
3.3.4 Heterologous protection by chimaeric Ll vaccines 
As many as 12 other types are implicated in cervical cancer (Castellsague, 2008). An aim of 
our study was to create a monovalent vaccine with cross-neutralising ability that would also 
protect against types other than type 16. The HPV-16 L2 peptides included in the LlIL2 
chimaeras, SAF, L2.56, L2.17 and E+E7M, have previously been shown to mediate 
neutralisation against various other types of HPV (Schellenbacher et al., 2009; Rubio et al., 
2009; Kondo et al., 2007; Kondo et al., 2008; Alphs et al., 2008; Gambhira et al., 2007b; 
Embers et al., 2004; Kawana et aI., 2003; Kawana et al., 1998; Kawana et al., 1999). All 
three peptides have shown to mediate neutralisation against HPV -18. This type of HPV is 
ranked as the second-highest cause for cervical cancer (Bosch et aI., 2008) and therefore is an 
important type to consider when testing vaccines for their ability to mediate cross-
neutralisation. Due to the unavailability of monoclonal antisera to HPV-18, we tested sera 
from mice vaccinated with SAF, L2.56 and L2.17 for cross-neutralisation of the closely 
related type (de Villiers et aI., 2004), HPV-45, instead, as an indication of HPV-18 
neutralisation ability. We also chose to test neutralisation of HPV -52 by these sera, because 
this type has emerged in a recent study as major cause of cervical cancer in South Africa 
(Personal communication, Anna Salimo). Sera from mice vaccinated with E+E7M was not 
tested against HPV -45 or -52 pseudovirions, since these sera did not contain high levels of 
neutralising antibodies against HPV-16 Ll. Since Ll is the immunodominant protein, it was 
therefore highly unlikely that an immune response to L2 could be detected in sera from mice 











Figure 3.4 shows the results we obtained for type 45 pseudovirions. None ofthe sera seemed 
to neutralise type 45 pseudovirions, however, the results are not conclusive. A monoclonal 
antibody neutralising HPV -45 pseudovirions, H45.N5, did not behave as expected with 
respect to neutralisation of pseudo virions, which would be neutralising almost 100% of 
pseudovirions at high concentrations of the antibody, with this percentage decreasing with 
decreasing antibody concentration. Instead, as seen in Figure 3.4A, H45.N5 only neutralised 
up to 50%-60% strength, even at high concentrations of antibody and the level of 
neutralisation stayed constant, even when the antibody was diluted 1 :25600. Even though the 
antibody neutralised pseudovirion infectious activity by 50%, none of the sera tested could do 
so, as seen in Figure 3.4B. Therefore it seems like sera from mice vaccinated with SAF, 
L2.56 and L2.17 were not capable of neutralising HPV -45. 
Figure 3.5 shows results for type 52 pseudovirions. Similar to the results for type 45, none of 
the test sera could neutralise HPV-52, but once again this is not conclusive. H52.Dll, the 
positive control monoclonal antibody known to neutralise HPV -52 pseudovirions, did not 
neutralise HPV-52 pseudovirions in our experiments at all, as can be seen in Figure 5A. 
Another monoclonal antibody, H52.C1, delivered the same result (Figure 3.5A). This result 
was not due to the pseudo virion concentration being too high and not in the linear part of the 
curve, since, even at half the concentration of pseudovirions, the same effect was observed. 
Once again, none of the test sera neutralised HPV-52 pseudovirions, as seen in Figure 3.5B, 
but whether this is due to the conditions of the experiment or the inability of the sera to 
neutralise, is not clear. 
In summary, none of the sera from mice vaccinated with SAF, L2.56 or L2.17 could 
neutralise the HPV types other than type 16 that we tested for in vitro, but the result is not 
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Figure 3.4. (A) Neutralisation of HPV-45 pseudo virions by the monoclonal antibody H45.N5 
at different dilutions. The error bars indicate standard deviation between 4 replicates. (B) 
Neutralisation of HPV-45 pseudovirions by sera from mice vaccinated with SAF, L2.17 and 
L2.56. Three groups of mice were vaccinated on Day 0, Day 14, Day 42 and Day 70 and bled 
7-10 days after the last vaccination. The negative control is wild-type baculovirus-infected 
insect cell lysate. Sera from each group of mice vaccinated were pooled and assayed in 
triplicate. The "no antibody" control wells contained only pseudovirions, but no antibodies. 
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Figure 3.S.(AJ Neutralisation of HPV-52 pseudovirions by the monoclonal antibodies 
H52.D11 and H52.C1 over various dilutions of the antibody. Shown for H52.D11 , whereas 
for H52. C1, the relative light units (RLU) are shown for two different dilutions of 
pseudovirions. (Ps V) Std=standard curve. (BJ Neutralisation of HPV-52 pseudovirions by 
sera from mice vaccinated with SAF, L2.17 and L2.56. Three groups of mice were 
vaccinated on Day 0, Day 14, Day 42 and Day 70 and bled 7-10 days after the last 
vaccination. The negative control is wild-type baculovirus-infected insect cell lysate. Sera 
from each group of mice vaccinated were pooled and assayed in triplicate. The "no 
antibody " control wells contained only pseudovirions, but no antibodies. The error bars 











3.3.5 Cellular immune responses against the inserted E7 pep tides 
3.3.5.1 IFN-y ELlspot assay 
Splenocytes isolated from spleens harvested from mice vaccinated with SAF (as a negative 
control), E7M, E+E7M and HPV-16E7SH, a DNA vaccine serving as a positive control and 
known to elicit cellular immune responses (Ohlschliiger et al., 2006) were used in an IFN-y 
ELI SPOT assay to determine the frequency of E7 specific CD8 T cells induced by the 
vaccines. The splenocytes from all vaccinated groups were capable of responding to the 
polyclonal positive control, Con A, indicating that the splenocytes were intact and that they 
were capable of secreting IFN-y. No responses were seen for the other vaccine groups except 
HPV-16E7SH, not even when IL-2, a cytokine important for the maintenance of CD8+ T-
cells was included in the assay. HPV-16E7SH-vaccinated mice had only low levels ofCTL 
responding to the E7 peptide and the response was not enhanced by the addition ofIL-2. The 
results are shown in Figure 3.6. 
3.3.5.2 Flow cytometric bead array assay 
The lack of detection ofIFN-y secreting cells in the spleens of vaccinated mice could indicate 
that E7-specific effector cells were not present above levels of detection or that they simply 
did not preferentially secrete IFN-y, but some other cytokine, which in turn may indicate that 
CD4+ T -cells were present and not CD8+ T -cells. Therefore a flow cytometric bead array 
(CBA) assay, which detects multiple cytokines was performed. For this, splenocytes were 
stimulated with the E7 peptide and then the content of various cytokines detected in the 
extracellular supernatant. The nature of cytokines in the supernatant also indicates whether 
the response to the vaccine is of a Thl or Th2 type (Garcia-Pineres et al., 2007; Janeway et 
al., 1997c). Release of IL-6 and IL-lO during stimulation indicate a Th2 response, which 
favours a humoral immune response (antibody development), whereas IFN-y, tumour 
necrosis factor (TNF) and IL-12 indicate a Thl response, or cell-mediated immune response. 
The CBA assay used also detected the chemokine, macrophage chemoattractant and 
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Figure 3. 6. IFN-y ELlspot responses, indicating the presence of E7 peptide 
(RAHYNIVTF) specific CD8+T cells generated by the indicated vaccines. HPV-
16E7SH was the positive control, SAF the negative control, E7M and E+E7M 
the test vaccines. Mice were vaccinated twice at 2 week intervals and sacrificed 
7 days after the last vaccination. Spleens were harvested and the spleens in each 
group pooled. An aliquot of the splenocytes from each group was then used in the 
IFN-y ELlspot assay. The cells were stimulated with medium only, medium+IL-2, 
RAHYNIVTF only, RAHYNIVTF+IL-2 or the polyclonal stimulus, Concanavalin 
A. (Con A)in triplicate for 24 hours. The number of cells secreting IFN-y was then 
counted in each well. Shown in the figure are the mean number of spot forming 
units per million cells for each vaccine. The error bars indicate standard error of 
the mean. (N=3) 
3.3.5.2.1 Cytokine release as measured by the CBA assay after stimulation with E7 
peptide for 48 hours 
When splenocytes were stimulated for 48 hours with the E7 peptide, only splenocytes from 
mice vaccinated with HPV -16E7SH responded and only IFN-y could be detected above 
background levels (Background levels are cytokines released when stimulated with medium 
only). These results correspond to the results ofthe ELIspot. The splenocytes were capable of 
secreting all cytokines in response to the positive control, the polyclonal stimulus Con A. The 
response to Con A once again indicates that splenocytes were intact and healthy and capable 
of secreting cytokines. However, no IL-12 secretion in response to stimulation with Con A 
was detected suggesting the level secreted by antigen presenting cells in the splenocyte 











Table 3.6. Cytokine release in response to vaccination with LlIE7 chimaeras and stimulation 
with various media. 
Vaccine Stimulant IL-6 IL-I0 MCP-l IFN-y TNF IL-12 
(pg/ml) (pg/ml) (pglml) (pg/ml) (pg/ml) (pg/ml) 
SAF Medium 42.0 12.8 182.3 0.0 19.7 0.0 
(negative 
control) 
Medium + 40.0 16.3 183.5 0.6 12.9 0.0 
IL-2 
E7 peptide 64.5 12.1 198.4 0.3 12.6 0.0 
E7 peptide 46.0 17.1 164.8 1.5 22.2 6.8 
+lL-2 
Con A 357.1 69.6 777.0 393.9 82.9 0.0 
E7M Medium 34.6 22.1 140.1 0.3 22.2 5.4 
Medium + 37.1 14.3 145.3 0.3 19.0 0.0 
IL-2 
E7 peptide 34.1 22.6 112.1 4.0 18.7 0.0 
E7 peptide 39.7 16.7 156.0 0.3 19.8 0.0 
+IL-2 
Con A 284.2 79.9 460.3 509.7 116.6 0.0 
E+E7M Medium 97.2 26.2 357.2 0.6 49.7 5.1 
Medium + 43.1 27.6 205.5 0.9 36.6 0.0 
IL-2 
E7 peptide 53.0 20.8 203.6 1.4 43.6 0.0 
E7 peptide 36.3 18.3 199.1 1.3 33.6 0.0 
+IL-2 
Con A 331.0 88.6 600.1 1088.0 154.6 0.0 
HPV-16 Medium 298.1 36.1 481.0 313.8 165.8 0.0 
E7SH 
Medium + 411.3 38.3 612.8 192.0 135.8 1.8 
IL-2 
E7 peptide 340.6 45.0 350.0 722.7 144.9 0.0 
E7 peptide 303.9 52.2 267.3 1099.2 154.6 0.0 
+lL-2 
Con A 694.8 139.9 378.7 2615.6 405.1 3.8 
.. 
Bold=p0sltIve levels of cytokme. ConcentratIons of cytokme were accepted as positive when 











3.3.5.2.2 Cytokine release after stimulation with E7 peptide for 6 days 
The lack of cytokine detection after 48 hours could indicate that the cytokines were below 
levels of detection and that a longer time period of stimulation with E7 peptide is necessary 
for clonal expansion of memory CD8 T -cells before E7 peptide specific CD8 T cells can be 
detected. Therefore splenocytes were stimulated with RAHYNIVTF, but not IL-2, for 6 days. 
After 6 days, the lymphocytes were harvested and the generated effectors were stimulated 
with E7 peptide in the presence of EL-4 antigen-presenting cells. Cultures were stopped at 4 
hours, 8 hours and 24 hours respectively, and the cytokine content determined using the CBA 
assay. Because cells in this experiment were not stimulated with medium only, the baseline 
values were provided by splenocytes from mice vaccinated with the negative control, SAF. 
SAF does not contain an E7 peptide and therefore the effectors from mice vaccinated with 
SAF should not respond to antigen-presenting cells presenting the E7 peptide. 
As seen in Figure 3.7, the nature of cytokines released indicated the vaccine E7M induced a 
Th2 response with IL-6 and IL-lO levels 1.4 fold higher than that for SAF at the 24h time 
point. For E+E7M: only at the 4 hour time point were IL-lO levels 3.9 fold higher than 
baseline. There was no increase in IL-lO production above baseline with time. On the other 
hand, IFN-y, which would indicate a Thl response, was not secreted above baseline for any 
ofthe test vaccines. E+E7M vaccination, however, resulted in about 2-fold secretion ofTNF-
a above baseline at all time points. MCP-l levels above background were secreted in 
response to E7M vaccination only at the 24h time point. No MCP-l levels above background 
were seen for vaccination with E+E7M or the DNA vaccine. Very low levels ofIL-12 were 
secreted but this was not a positive response. Vaccination with the DNA vaccine, even 
though it served as a positive control, did not lead to cytokine release above the non-specific 
levels ofSAF, except at 4 hour time points for IL-lO and IFN-y. IL-lO and IFN-y secretion 
would favour antibody as well as CTL responses. 
To summarise all the results for cellular immune responses elicited by E7M and E+E7M: 
Splenocytes required a six-day stimulation period with E7 peptide to effect clonal expansion 
of E7-specific memory CD8 T cells above levels of detection. E7M vaccination led to Th2 
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Figure 3. 7. Differential cytoldne release in response to vaccination with 
LlIE7 chimaeras. Mice were vaccinated twice at 2 week intervals with 
SAF as the negative control, HPV-J6-E7SH as the positive control, E7M 
and E+E7M and sacrificed 7 days after the last vaccination. Splenocytes 
from J 0 mice per vaccine were pooled and cultured for 6 days in the 
presence of RAHYNIVTF to generate effector cells. On day 6, lymphocytes 
were isolated and further cultured in the presence of EL-4 cells and 
RAHYNIVTF. Aliquots of the supernatant were taken at 4 hour, 8 hour 
and 24 hour time points and used in a CBA assay to determine cytoldne 
content. A * above the bar indicates a positive response above baseline 
levels, which are provided by the negative control. 
3.3.6 Tumour regression 
We also tested the effect that vaccination with the L1 fE7 chimaeras would have on existing 
tumours in mice. The DNA vaccine, HPV-16E7SH, previously shown to effect tumour 
regression (OhlschHiger et al., 2006) was used as a positive control. The negative control was 
wild-type infected insect cell lysate as for the other experiments. We also included SAF, for 











regression in mice when C3 cells, the same cells we used in our study, were used to induce 
tumours (OhlschIager et al., 2003; De Bruijn et al., 1998). 
3.3.6.1 Growth rate of tumours 
In order to deal with differences between average initial tumour sizes for the different vaccine 
groups, the average growth rate was analysed for each group. This analysis was done over the 
fIrst 36 days since vaccination for E7M, E+E7M and the negative control, and the fIrst 39 
days since vaccination for SAF and the positive control. These time periods were chosen, 
since, after this time, mice had to be culled due to tumour size exceeding the upper limit. SAF 
and the positive control were monitored after 39 days, since these two vaccine groups were 
not done concurrently with the others, and so the tumours were not measured on exactly the 
same days as for the other three groups. The 39-day time period was the closest one to 36 
days. The results ofthis analysis is shown in Figure 3.8. 
Table 3.7 lists the P-values associated with whether the means are significantly different. 
Only the negative and positive control differed signifIcantly with respect to growth rate, and 
so did E+E7M and the positive control. The test vaccines (SAF, E7M and E+E7M) therefore 
did not show a clear trend in slowing the growth rate of tumours, since their growth rates 
were not significantly different to the negative control. The test vaccines also did not differ 
signifIcantly from each other in their ability to slow the growth rate oftumours. 
In terms of regression, 6 out of the 9 mice in the positive control group showed complete 
eradication of tumours, whereas only lout of nine mice in the E7M and SAF groups, and 
none in the E+E7M and negative control group, showed complete eradication of tumours 
(data not shown) confIrming that none of the test vaccines had an effect on the growth of 
tumours in mice. 
3.3.6.2 Effect on tumour volume after administration of second boost 
The remaining mice in the negative control and test vaccine groups that had not been culled, 
were given another boost on Day 39. The boost was given to see if the lack of tumour growth 
inhibition was perhaps due to the number of doses given. In an attempt to include this data 











group to reach a size of250 mm3• This arbitrary cut-offwas chosen, because a tumour of that 
size was unlikely to regress. The curve is shown in Figure 3.9. The positive control is 
significantly different from the test vaccines, but not the negative control, although the P-
value for this analysis was 0.07, yielding a 93% chance that they are different. E7M and 
E+E7M therefore did not have an effect on tumour size under these experimental conditions 
and there was no difference in their effect on the tumours. Despite the second boost given on 
day 39, the remaining tumours still increased in size, therefore the negative results do not 
seem to be a dose-dependent effect. 
In summary, SAF-, E7M- and E+E7M-vaccination did not have any effect on the size of 
existing tumours in mice. 
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Figure 3.8. Average growth rate of tumours after 
vaccination with L11E7 chimaeras and SAF. Mice were 
injected once subcutaneously with O.5x106C3 cells. When 
tumours reached a diameter of 2-3mm, mice were 
vaccinated on Day 0 and 14 with the three test vaccines, 
wild-type baculovirus-infected insect cell lysate as negative 
control and a DNA vaccine expressing the shuffled E7 
oncogene as a positive control. Tumour size was monitored 
until the first mouse had to be culled 36 days after the first 
vaccination, due to tumour size, for the LlIE7 chimaeras 
and the negative control; and 39 days for SAF and the 
positive control. Growth rate was calculated as ((endpoint 
tumour volume-initial tumour volume)lnumber of days). The 
horizontal bars indicate the mean growth for the group of 












Table 3.7. P-values for two-tailed, unpaired t-tests to determine significance of difference 
between mean growth rates of different vaccine groups in the tumour regression experiment 
HPV- Negative E7M E+E7M SAF 
16E7SH control 
HPV- 0.0186 0.1123 0.0108 0.1526 
16E7SH 
Negative 0.0186 0.3358 0.1433 0.3877 
control 
E7M 0.1123 0.3358 0.9278 0.9931 
E+E7M 0.0108 0.1433 0.9278 0.9413 
SAF 0.1526 0.3877 0.9931 0.9413 
Bold=Significant P-values<0.05 
100 
In -e- E7M 
110.. 
~ --- E+E7M 0 80 E 
'"*'" Negative ~M ... E 60 HPV-16E7SH '0 E ...... 
CI) Q 
tnlt) 40 ftI ('II 
~ 1\ 
CI) 




0 20 40 60 80 
Days 
Figure 3.9. Percentage of tumours that have reached a tumour volume larger 
than 250 mm3. Mice were injected once subcutaneously with 0.5x106C3 cells. 
When tumours reached a diameter of 2-3mm, mice were vaccinated on Day 0, 
14 and 39 with the two test vaccine and wild-type baculovirus-infected insect 
cell lysate as negative control. A DNA vaccine expressing the shuffled E7 
oncogene was given on Day 0 and 14 as a positive control. Tumour volume 
was calculated as 0.5xwidth2xlength and monitored over 60 days. 
3.3.7 Electron microscopy analysis 
The ability of L1 protein to assemble into higher order structures, especially cap somers, has 
been positively correlated with its ability to elicit high levels of antibodies (Schadlich et al., 











surface of the virus particle has been implied in the acute activation of dendritic cells, the 
most important antigen-presenting cells (APCs) of the immune system. The interaction of 
dendritic cells with VLPs, not capsomers, has been shown to be essential for their activation 
(Rudolf et at., 200la; Lenz et aI., 2001). For this reason, it was important to analyse the 
structure of the chimaeric vaccines, because their ability to assemble into higher-order 
structures may explain differences in immunogenicity observed. The preparations captured 
onto electron microscopy grids were treated the same way as the vaccines were treated, since 
freeze-thaw cycles, as well as incubation at 37°C may have an effect on assembly. All 
vaccine preparations were stored at -80°C, defrosted prior to vaccination and incubated at 
37°C to enhance emulsification with Freund's adjuvant. 
Important controls were included in the electron microscopy analysis. Wild-type baculovirus-
infected insect cell lysate as used in vaccination was used as a negative control to avoid false 
positives. Humanised L1 was also expressed in insect cells and prepared the same way as for 
the vaccine proteins in order to determine whether the preparation conditions had any effect 
on the assembly of Ll. In an effort to select for the proteins in pentamer or VLP 
conformation, protein preparations were captured onto the grids using V5 antibody, which 
binds only to conformation-dependent sites on L1 pentamers or VLPs. 
The negative control showed high levels of protein as expected, as well as structures of 
similar size to capsomers and "small" VLPs, which could be confused with those, as can be 
seen in Figure 3.10(C). However, no spherical structures with a diameter of 50 to 70 nm were 
observed in the negative control. VLPs are about 55 nm in diameter. 
Because the structures observed in the negative control images could be confused with 
capsomers and "small" VLPs, the presence of structures with a diameter in the range of 50 to 
60 nm was used to determine assembly-competence of chimaeric L1 proteins. This could be 
done, since occasional VLPs are often seen in preparations only expected to form capsomers. 
Figure 3.1O(A) shows VLPs purified by caesmm chloride gradient ultracentrifugation, 
showing staining of the cylindrical cavity. This staining of the cylindrical cavity was not seen 
in the spherical structures seen in the negative control, and this cylindrical staining provided 











Figure 3.1O(B) shows the presence of these structures in insect cell lysate containing wild-
type L 1. These structures indicate that, under the given experimental conditions, L 1 protein 
was capable of assembly into higher-order structures. 
The other chimaeric vaccines were analysed for the presence of VLPs with staining of the 
cavity, structures with a diameter in the range of 50 to 60 nm, as well as for any structures 
that are significantly different from that seen in the negative control. As can be seen in Figure 
3.11(A), SAF formed putative VLPs about 50 nm in size. Similar structures could be seen for 
L2.17 (Figure 3.11(B)), but it looks as if it may be in a state of partial assembly. In both 
cases, these particles were only seen rarely. 
Significantly different spherical particles with an appearance differing from protein 
aggregates seen in the negative control, were observed for L2.56, as seen in Figure 3.11(C). 
These ranged in size from 30-50 nm and occurred frequently. The particles may be "small" 
and full-size VLPs. 
In the case of BPV, the background is covered with ring-like structures, with an appearance 
unlike the background seen in the negative control. The size of each particle is between 10 
and 20 nm and therefore it is proposed that these are aggregates of pen tamers. There may also 
be some VLPs in a partial state of assembly of about 50 nm. This can be seen in Figure 
3.11(D). 
As Figure 3.12 shows, E7M and E+E7M also formed putative VLPs, which were more 
abundant in the E7M preparations than in the E+E7M preparations. 
In summary, all the chimaeric proteins showed the potential to assemble into tertiary 
structures. However, these structures are most likely to be pentamers, since VLP-like 
structures were not abundant in the images. The exception is L2.56, which showed the 











Figure 3.10. Transmission electron micrographs of 
(A) wild-type Ll purified by caesium chloride 
gradient ultracentrifugation, (B) insect cell lysate 
infected with wild-type Ll recombinant baculovirus, 
(C) wild-type baculovirus infected insect cell lysate. 
Protein preparations were captured onto carbon-
coated copper grids with V5 antibody, negatively 
stained with 2% uranyl acetate and viewed under 















Figure 3.11. Transmission electron micrographs of 
insect cell lysate containing (A) SAF, (B) L2.17, (C) 
L2.56, (D) BPV Protein preparations were captured 
onto carbon-coated copper grids with V5 antibody, 
negatively stained with 2% uranyl acetate and 
viewed under 50,OOOxmagnijication. The diameter of 













Figure 3.12. Transmission electron micrographs of 
insect cell lysate containing (A) E7M and (B) 
E+E7M. Protein preparations were captured onto 
carbon-coated copper grids with V5 antibody, 
negatively stained with 2% uranyl acetate and viewed 
under 50,000xmagnijication. The diameter of 
particles are indicated. 
3.4 Discussion 
The first aim of this project was to select vaccine candidates for purposes of creating a 
monovalent vaccine capable of simultaneous protection against infection with multiple types 
of HPV. The second aim was to test the idea of a vaccine capable of protecting against 
infection with HPV, while at the same time treating existing infections. 
3.4.1 BPV is not a vaccine candidate 
The BPV construct did not show potential as a vaccine candidate. Antibodies against Ll 
could not be detected in sera of mice vaccinated with this construct, as can be seen in Figure 
3.1 and Table 3.4. In the same way, antibodies against HPV -16 L2 could not be detected 
(Figure 3.2). It is unlikely that the lack of anti-L2 antibodies is due to the fact that the inserted 
epitope is from a divergent papillomavirus, BPV -1, since Pastrana et al. (Pastrana et al. , 
2005) showed that polyclonal antisera against BPV -1 L2 bound to purified HPV -16 L2 
protein at a similar titre than to purified BPV -1 L2. This cross-reaction is most probably due 
to amino acids 1-88 of BPV -1 L2, since antisera to this peptide could also cross-neutralise 











antibodies seen, the BPV construct was not tested further in pseudo virion neutralisation 
assays. 
There are various explanations for the lower immunogenicity of BPV. It was injected at a 
lower total dose than for the others. However, at a total dose of 1.8 ~g, some immune 
response may be expected, since, according to Oh1schHiger et ai. (Ohlschliiger et ai., 2003) a 
humoral response was elicited by at least 1 ~g of capsomers. E+E7M was administered at 
twice the dose, but only twice, yet an immune response could be detected in the ELISA 
(Figure 3.1). 
Another explanation for the lack of immune response induced by BPV could be the 
destruction of important anti-L1 neutralising antibody sites by the replacement and thus 
deletion of88 amino acids from the C-terminal ofHPV-16 Ll. A deletion and point mutation 
study ofHPV-16 L1 (Varsani et ai., 2006) showed that the deletion of amino acids 428-483 
of HPV-16 L1 abolishes critical sites for the binding of known conformation-specific 
monoclonal antibodies. This region is deleted in the BPV construct and it is therefore 
conceivable that the deletion lowers this construct's ability to elicit conformation-specific 
antibodies that would bind to HPV-16 L1 in an ELISA. However, the deletion of amino 
acids 428-483 may not be the reason, since amino acids 414-439 and 414-433, which overlap 
with this region are deleted in the L2.56 and L2.17 constructs and these were capable of 
eliciting an anti-L1 response in our study. 
Other studies have shown that capsomer formation is not tolerated when more than 32 (Kuck 
et ai., 2006) or 34 (Schiidlich et aI., 2009) amino acids are deleted from the C-terminal of 
Ll. Assembly of monomers into capsomers is very important for the induction of high titres 
of conformation-specific antibodies (Kuck et aI., 2006). In the BPV construct, 88 amino acids 
are deleted. However, in our study, after electron microscopy analysis, we detected possible 
pentamer aggregates, as seen in Figure 3.11(D). It may be that these were baculovirus or 
insect cell proteins, since the lack of antibodies elicited by BPV seems to indicate that 
capsomers did not assemble. 
The inferior expression levels of the BPV construct in insect cells (see Table 2.4) as well as 
in plants, as seen in other work done in our research group, also does not make BPV a 












3.4.2 L2.56 is the best vaccine candidate 
SAF, L2.17 and L2.56 all show potential as prophylactic vaccines against HPV-16, the 
homologous type. All three constructs elicited anti-L1 antibodies, that were also capable of 
neutralising HPV-16 in vitro, as seen in Figures 3.1 and 3.3, and Table 3.5. Sera from one of 
the groups immunised with SAF did not show an average inhibition of alkaline phosphatase 
activity, although the standard deviation for the particular group was quite large. The 
standard error of the mean is also high for SAF in the ELISA, suggesting that one of the 
immunised groups did not react to the vaccine. For this reason the antibody titres for SAF 
could be artificially lowered. The most likely explanation for the lack of reaction to SAF by 
one of the mouse groups is technical. It may be that this group of mice was vaccinated last 
and that the vaccine emulsion in Freund's adjuvant had started to become destabilised, so that 
the concentration of antigen left in the syringe was not as high as for the other two groups. 
Because a high volume of vaccine was injected per mouse, it may be that for this particular 
group, not all of the vaccine was injected. A repeat of these mouse experiments will confmn 
whether the lack of response to SAF was due to technical error. 
No comparison could be made between the antibody titres elicited by these three constructs in 
the pseudovirion neutralisation assays, since the sera were not assayed to their endpoints in 
all cases, due to the expense of the assays. However, the ELISA indicates that L2.56 elicited 
significantly higher levels of antibodies than L2.17 and SAF. 
The antigen used in ELISA was plant-produced SAF. SAF has been shown by other members 
in our laboratory to assemble into capsomers in plants. Therefore this antigen could be 
utilised to test for conformation-specific antibodies, since antibodies against cap somers can 
still neutralise live virus, (Rizk et at., 2008; Thanes et al., 2008) and important binding sites 
for known monoclonal conformation-specific antibodies are not destroyed in SAF (Varsani et 
at., 2003). It is conceivable that if sera elicited by SAF is bound to SAF protein in an ELISA, 
antibodies that were elicited against amino acids 108 -120 in the chimaeric protein would also 
bind to these amino acids in the protein bound to the ELISA well. Not only anti-L1 
antibodies will therefore bind to the SAF protein in the ELISA. In the case ofSAF, an ELISA 
utilising SAF as an antigen does not assay only for anti-L1 antibodies. In our study, using 
SAF as antigen was not considered to be a problem, because SAF did not induce detectable 











SAF is therefore unlikely to show an artificially higher anti-Ll immune response than the 
other constructs in the ELISA. 
The highest titre observed in the ELISA was 800 (Table 3.4). This is a low titre obtained in 
an ELISA when compared to titres obtained after vaccination with Ll VLPs. Maclean et al. 
(Maclean et al., 2007) obtained titres of the order of 40000 after two vaccinations with 10 ~g 
of insect cell-derived VLPs without adjuvant. It should be considered that pentamers do not 
elicit as high titres of antibodies as VLPs (Thanes et al., 2008). Even so, when Schadlich et 
al. administered two doses of 5 ~g of E. coli-derived pentamers to mice, they still obtained 
titres of the order of 20 000 to 50 000, even when adrninstering constructs where the helix 4 
was deleted, which in their study showed even lower immunogenicity than pentamers where 
only the first 10 amino acids were deleted from the N -terminal. In our study the helix 4 was 
effectively deleted for all ofthe constructs. Constructs where both the helix 4 was deleted as 
well as 29 amino acids from the C-terminal, which is comparable with the extensively 
modified L1 chimaera, BPV, in our study, elicited titres of about 1600. However, in other 
studies where capsomers were administered at a similar dose, the titres were of the same 
order as in our study (OhlschIager et al., 2003; Thanes et al., 2008) The low titres we 
obtained in our study may be due to many factors: firstly, it could not be confirmed what 
proportion of each vaccine preparation assembled into pentamers, due to the high quantity of 
other insect cell and baculovirus proteins (see Figure 3.10 (C)) and assembly into at least 
pentamers has been found to be crucial for eliciting antibodies (Schellenbacher et al., 2009). 
Secondly, the high quantities of protein other than L1 in the vaccine preparations could have 
masked the immune response to L1, thus lowering it (Cleveland et al., 2000a). Thirdly, as 
observed from Thanes et al. (Thanes et al., 2008) and Ohlschlager et al. (Ohlschliiger et al., 
2003) a higher dose may be necessary in order to achieve titres of an order of 10 000. Varsani 
et al. (Varsani et al., 2003) immunised mice with 100 ~g of Chi-F (similar in amino acid 
sequence to SAF in our study) and obtained titres of 20 000. Therefore, in order to increase 
the titres obtained by the chimaeric Ll proteins in our study, purification ofpentamers and/or 
VLPs may be necessary, as well as immunisation with a higher dose. 
The presence of anti-L2 antibodies above background, as seen in Figure 3.2, for L2.56 and 
L2.17 may indicate their ability to elicit cross-neutralising antibodies, because neutralising 
antibodies against L1 is highly type-specific (Breitburd et al., 1995), and anti-L2 antibodies 











L2 antibodies for the two constructs suggests that L2 is sufficiently displayed on the surface 
of chimaeric Ll protein. However, the sera from mice immunised with these constructs could 
not neutralise the heterologous HPV-45 and HPV-52 pseudovirions, as seen in Figures 3.4(B) 
and 3.5(B). This lack of neutralisation could be because the levels ofanti-L2 antibodies were 
not high enough to mediate neutralisation, which could be improved by increased dosage, as 
well as selectively purifying capsomers and VLPs by a purification method that selects for 
these, such as sucrose gradient ultracentrifugation. By selecting for capsomers and VLPs, the 
display of L2 in repetitive arrays on the surface of the particle is ensured, which would 
increase humoral immunity against the displayed epitope. 
The lack of cross-neutralisation could also be due to an inherent fault with the pseudovirion 
neutralisation assay. The positive control monoclonal antibody, developed against HPV -45 
virus particles, H45.N5, could only neutralise HPV -45 pseudovirions to a level of 50%, even 
at high concentrations of the antibody, as seen in Figure 3.4(A). This low level of 
neutralisation may indicate contamination with another type of pseudovirion, most likely type 
52, which was transfected at the same time as type 45. Pseudovirions are highly infectious. 
Cross-contamination with HPV-45 pseudovirions could also explain why neither H52.Dll 
nor H52.Cl, monoclonal antibodies that neutralise HPV-52 tested, could neutralise HPV-52 
pseudovirions, as shown in Figure 3.5(A). Future experiments need to be performed, 
involving direct binding of H45.N5, H52.Cl and H52.Dll to the pseudovirion preparations 
in an ELISA, to elucidate whether the antibodies were functional and whether contamination 
could explain the lack of neutralisation seen in our study. 
It is also possible that the concentration of pseudovirions used in the assay was too high and 
therefore at a level of saturation with respect of infection. It was observed (data not shown), 
that the RLU increased each week after storage at -80DC, for both HPV -45 and -52, which 
suggests, however unlikely, a maturation process taking place over time. This apparent 
maturation process could be why, despite titration of pseudovirions and choosing the 
concentration such that it would not be at saturation level, saturation level could have been 
reached. But the RLU observed in subsequent experiments, was still within the linear range 
for HPV-45, however, for type 52, the RLUs could have been in the region of saturation. 
Figure 3.5(A) shows that H52.Cl had the same linear titration curve at halfthe concentration 
of pseudovirions, at an RLU which would fall into the linear range of the titration curve, 











problem could be that crude cell lysate and not purified pseudovirions were employed in the 
assays. The neutralising antibodies in the antisera to L2.56, L2.17 and SAF may have 
preferentially cross-reacted with mammalian cell lysate components instead of pseudovirions. 
This effect was not seen in assays for HPV -16, therefore it is not clear whether crude cell 
lysates influenced the lack of cross-neutralisation. 
The data suggests that L2.56 may be the preferred vaccine candidate. This construct elicited 
significantly higher levels of antibodies than the other constructs, as seen in Figure 3.1. L2.56 
also elicited the highest levels of anti-L2 antibodies, as seen in Figure 3.2, lane 7. Electron 
microscopy analysis revealed the presence of possible VLPs in a range of sizes. (Figure 
3.11(C)) This regular array of particles with their particular appearance was not observed in 
the negative control (Figure 3.l0(C)). The presence of a regular array of particles suggests 
that of all the chimaeras, L2.56 showed the highest probability of assembling into higher-
order structures, which correlates with levels of antibodies elicited. Even though SAF and 
L2.17 may have assembled into higher order structures as seen in Figure 3.11(A) and (B), 
these were not observed in such a regular array and as frequently as for L2.56. 
3.4.3 Therapeutic vaccine candidates 
E7M and E+E7M were constructs created to have a dual function: protection against 
infection with HPV, while at the same time treating an existing infection. The aim of our 
work was only to provide the proof of concept for this idea, since the E7M epitope is a CTL 
epitope for mice and will need to be replaced with an epitope specific to human alleles. Also, 
in the case ofE7M, even ifthe epitope is replaced with a human CTL epitope, such a vaccine 
construct will only prevent infection with HPV -16, and is only likely to treat existing HPV-
16 infections, due to the insertion of an HPV-16 E7 epitope (Youde et ai., 2005; Piersma et 
ai., 2008; Hohn et ai., 1999; McCarthy et ai., 2006). E+E7M, which contains a cross-
neutralising L2 epitope, is therefore a more feasible idea, since it has the potential to protect 
against infections with types other than type 16, while treating existing HPV -16 infections, 
which in the majority of cases is the most likely type a person would be infected with. 
The L1 in LlIE7 chimaeras could also function as a carrier molecule for the E7 epitope, 
better presenting the CTL epitope to the immune system on its first encounter with it (Street 











the immune system. (Lenz et al., 2003; Da Silva et al., 2001) However, combining Ll with 
E7 may not always be a good idea, since L 1 may dominate the immune response. (Bian et al., 
2008) LlIE7 chimaeras have been tested in human clinical trials, but their efficacy in 
treatment of cervical cancer was not clear (Kaufmann et aI., 2007), yet this approach is 
showing promise, due to the detection of cellular immune responses in vitro (Kaufmann et 
al., 2001). 
Our main aim in this study was to test for cellular immune responses and tumour regression 
induced by vaccination with E7M and E+E7M. In addition the sera were tested for the 
presence of anti-Ll antibodies. The results were not comparable to those of the LI/L2 
chimaeras, since only two vaccinations were administered for the LlIE7 chimaeras, and not 
four, as for the others. Figure 3.1 shows that E7M and E+E7M elicited a higher average 
humoral response to Ll than the negative control, although this was only significant for E7M. 
Table 3.1 also indicates that E+E7M and E7M elicited similar titres ofanti-Ll antibodies that 
were higher than that ofthe negative control. Electron microscopy analysis also indicated the 
possible presence of higher-order structures, as seen in Figure 3.12(A) and (B). Taken 
together, E7M and E+E7M are capable of eliciting antibodies against Ll at similar levels. 
Sera from mice immunised with E+E7M were also tested for anti-L2 antibodies, but these 
could not be detected. Neutralisation ofHPV-16 in vitro could also not be detected, as seen in 
Table 3.5. Once again, optimisation of dosage and selective purification of higher-order 
structures may effect the induction of anti-L2 antibodies and anti-Ll antibodies capable of 
neutralising HPV -16 in vitro. 
Ex vivo E7 peptide IFN-y ELI SPOT responses using splenocytes from E7M- and E+E7M-
vaccinated mice were negative -no E7 specific IFN-y secreting cells were detected and when 
the splenocytes were stimulated for 48h with the E7 peptide no cytokines could be detected in 
the culture supernatant. However a 6-day in vitro stimulation of the splenocytes from mice 
immunised with E7M and E+E7M with the E7 peptide revealed an interesting cytokine 
release profile when the generated effectors were stimulated for a further 24h period with the 
E7 peptide. Restimulated lymphocytes from E7M-vaccinated mice released Th2 type 
cytokines (IL-6 and IL-I0 and Mep-l) while these cells from E+E7M vaccinated mice 
released Thl type cytokines (TNF-a). No IFN-y was detected for either vaccine. These data 
suggest that E7M induces E7-specific cells that favour antibody responses while E+E7M 











T-cells (Janeway et al., 1997c). Cell-mediated immune responses are implicated in the 
combating of tumours by the immune system (Human PapillomavirusesfIARC Working 
Group on the Evaluation of Carcinogenic Risks to Humans, 2005). For this reason, E+E7M 
may be the preferred vaccine candidate over E7M for treatment ofHPV -induced tumours. 
It could be speculated that the L2 epitope included in the E+E7M construct enhanced the 
interaction of this construct with cells of the immune system, leading to infection of the cells 
with VLPs or capsomers. It is known that chimaeric VLPs (cVLPs) are capable of entering 
dendritic cells in the same way as live virus, thus initiating an MHC class I response, for 
which intracellular penetration of virus is important. The cVLPs are degraded in the 
cytoplasm and peptides presented by MHC class I molecules on the surface of the molecules, 
thus initiating a cellular immune response (Kaufinann et al., 2001). L2 amino acids 108-126, 
similar to the L2 peptide included in E+E7M, have been shown to interact with different cell 
lines and to enter the cytoplasm (Kawana et al., 2001). It is therefore plausible that including 
this peptide in E+E7M enhances the infectivity of the construct, thus enhancing the cellular 
immune response. However, the cells tested for infectivity with the L2 peptide were all of 
epithelial origin, so it is not clear whether antigen-presenting cells have appropriate receptors 
for this peptide to bind to. Also, it is not clear whether capsomers, which we expected to 
obtain for E+E7M, can infect and penetrate cells to the same extent as VLPs (Lenz et al., 
2001). 
The weak cellular immune responses induced by the LlfE7 chimaeras did not translate into 
tumour regression (Figures 3.8 and 3.9 and Table 3.7). The negative control group in fact 
showed a slower tumour growth rate than any of the test vaccines. Because the negative 
control started out with significantly smaller tumours than for the positive control and SAF 
(data not shown), it could also mean that a group with slower-growing tumours were selected 
for in the negative control group. This could have been circumvented by redistributing the 
mice when their tumours have grown to the required size before vaccination so that the 
spread of initial tumour size is similar for the different groups. 
However, the results indicate that the test vaccines had no clear effect on tumour growth. It 
could be that Ll dominated the immune response, weakening the immune response to the E7 
epitope. The lack of response to E7 may be rescued by using appropriate adjuvants, which 











and have been shown to enhance the cellular immune response to peptides included in c VLPs 
(Qian et aI., 2006). Another problem could be that a primary immune response to cVLPs 
cannot be boosted with the same cVLP, due to the induction ofneutralising antibodies to the 
construct (Da Silva et al., 2003). Heterologous boosting may be the solution to this problem 
(Da Silva et aI., 2003; Qian et al., 2006). 
3.4.4 Summary 
In summary: BPV did not show potential as a prophylactic vaccine candidate. L2.17 and 
L2.56 showed potential as monovalent prophylactic vaccines protecting against multiple 
HPV types, because they elicited detectable levels of anti-L2 antibodies. L2.56 showed the 
greatest potential as a prophylactic vaccine, because it elicited the highest level of anti-Ll 
antibodies as measured by ELISA, elicited the highest level of anti-L2 antibodies as 
measured by Western blotting and showed the greatest potential for assembling into more 
immunogenic higher-order structures. As for therapeutic vaccines, E+E7M may be preferred 
over E7M, because vaccination with E+E7M led to the activation of the cellular arm of the 
immune system, which is important for the eradication oftumours, whereas E7M vaccination 
led to activation of the humoral arm of the immune system. By optimisation of experimental 
conditions, which would include increasing the dose of test vaccine administered to the 
animals as well as selectively purifying capsomers and/or VLPs from insect cell extracts, in 
vitro cross-neutralisation as well as tumour regression may be observed, which would verify 












4.1 Expression of chimaeric Ll protein vaccines 
All eight chimaeric L1 proteins constructs used in this study could be expressed in insect 
cells; however, expression levels varied markedly between them. The highest concentration 
of protein obtained was for L2.17, followed by L2.56, E7M, SAF, BPV and E+E7M in that 
order. Protein concentrations ranged from 3.7 to 562 ~g/ml per 106 cells. 
We consistently obtained a lower amount of protein for the L1/BPV-L2 chimaera and the 
LlIL2/E7 chimaera. This difference in expression for some constructs when compared to 
others highlights an important aspect of recombinant protein production; namely, that it is not 
always possible to predict whether a particular construct can be expressed to high levels in a 
given expression system. Currently, the ability to expressa construct in a given expression 
system is something that needs to be empirically determined for each construct. Expression 
levels ofHPV-derived and other proteins may vary between the same genes with as little as 
one nucleotide difference between them (Touze et al., 1998); and when constructing 
chimaeric genes where part of one gene is replaced, the exact position of the replacement or 
insertion may also have an effect on expression levels of the construct (Murata et al., 2009). 
Expression levels can be optimised to some extent by employing the optimum way to modify 
the L1 sequence, as indicated by previous authors' work. There have been other studies 
which have shown that deletion of more than 20 amino acids from the C-terminal of L1 
affected expression levels negatively (Senger et al., 2009; Maclean et al., 2007) and 
abolished capsomer assembly of these proteins (Kuck et al., 2006; Schiidlich et al., 2009), 
which may leave the protein more prone to degradation. The data from these studies suggest 
that deleting more than 20 amino acids from the C-terminal of L1 is not a good approach. 
These results agree with results from this study, where BPV, the construct where 88 amino 
acids were replaced on the C-terminal of HPV-16 L1, expressed poorly. Because the 
LlIL2/E7 and LlIBPV-1 L2 expressed at lower levels than the other chimaeras, and were the 
only chimaeras with modifications to the C-terminal of amino acid 439 ofHPV-16 L1, these 
data may indicate that replacing amino acids to the C-terminal end of amino acid 439 of 
HPV-16 L1 may be detrimental to the expression of the protein. These data should be 











peptide needs to be inserted into a protein, one should consider inserting the peptide without 
replacing amino acids ofL1 or replacing as few as possible amino acids. 
The expression levels obtained in this study will need to be optimised before large-scale 
production of any of these chimaeric constructs will become commercially viable. 
Optimisation would include adjusting the multiplicity of infection (Mal), cell density or time 
of infection. Expression in a different cell line, such as Trichopiasia ni cells, may also be 
necessary. Lastly, the MultiBac baculovirus expression system, which has been shown to 
enhance the yields of insect cell produced proteins (Senger et ai., 2009), can be employed. 
Large-scale production of these chimaeric vaccines may, however, be more cost-effective and 
efficient in other production systems, like moulds, yeasts or plants, and attempts should 
therefore be made to also produce them in these systems. Correctly folded VLPs have 
previously been expressed in plants (Kohl et ai., 2007; Warzecha et ai., 2003; Regnard et ai., 
2010), yeasts (Sasagawa et ai., 1995; Carter et ai., 1991) and the mold Pichia Pistoris (Bazan 
et ai., 2009). The advantages of these systems include high expression levels, easy 
cultivation, robustness and ability to be scaled up (Rybicki, 2009; Demain & Vaishnav, 
2009). 
Vaccines that could potentially be administered to humans need to be purified extensively. 
Purification will therefore need to be optimised for the chimaeric vaccines in this study. In 
our study, an already published method (Cook et ai., 1999), which was also employed in the 
purification of VLPs in the formulation of Gardasil® (Shi et ai., 2007), was attempted for 
SAF. This method involves cation exchange purification using the HS50 paRaS column, 
which has a polystyrene divinylbenzene matrix. It was found that this method could be 
applied to the purification ofSAF. However, Sepharose columns, which consist of6% highly 
cross-linked agarose matrices, did not bind SAF. The difference in matrices was suggested to 
affect the binding of SAF to the column. Results from our work suggest that cation exchange 
chromatography, employing the method published by Cook et ai., should be considered as a 
method to purify chimaeric L1 capsomers and/or VLPs, whereas Sepharose columns should 
not be considered as a method to do so. 
Ultracentrifugation is a method often employed in the purification ofL1 to a level suitable for 











Schellenbacher et ai., 2009). In this study, we attempted purification by employing a self-
generated 24% OptiprepTM gradient. This method was not shown to effectively purify the 
insect cell extract. However, the advantages of OptiprepTM over other gradient media (Axis-
Shield, 2007), such as caesium chloride or sucrose - which include its lack of osmolarity, and 
the fact that it can be injected without harm - provides incentive for investigating purifying 
L 1 chimaeric vaccines by this method for animal studies. 
4.2 L2 and the design of prophylactic chimaeric vaccines 
Research towards second-generation prophylactic HPV vaccines is, amongst other things, 
currently focusing on approaches including potentially cross-neutralising peptides from L2 
(Bosch, 2009). This is because peptides may potentially be produced more cost-effectively in 
E. coli, which is a simpler expression system than the eukaryotic systems currently used for 
HPV vaccine production. Researchers in the developing world may have more access to such 
an expression system, which could mean that HPV vaccines could be produced locally in 
countries where they are most needed. Current HPV vaccines are unaffordable to many in 
developing countries (Techakehakij & Feldman, 2008). 
However, L2 is immunogenic ally subdominant to Ll (Roden et ai., 2000) and thus a higher 
dose of L2 will need to be administered in order to achieve levels of protection similar to 
current HPV vaccines based on Ll. Peptides in general also display low immunogenicity 
unless cross-linked to another protein or adjuvanted (Rubio et ai., 2009). For these reasons 
and because Ll-based vaccines have already been thoroughly researched, tested and proven 
to be highly immunogenic and effective (Schiller et ai., 2008), cross-linking L2 peptides to 
Ll may be the best and fastest approach towards putting broadly neutralising second-
generation HPV vaccines on the market. Creating a monovalent chimaeric vaccine, as 
opposed to a polyvalent vaccine including VLPs of many carcinogenic and potentially 
cutaneous HPV types, will also be more cost-effective (Bosch, 2009). 
HPV-16 Ll should be utilised in the creation of chimaeric Ll vaccmes, because the 
overwhelming burden of cervical cancer is due to this type worldwide (Bosch et ai., 2008). 











while also protecting against other types of HPV due to the L2 peptides included in the 
vaccme. 
The L2 peptide showing the most promise in cross-neutralisation of other types according to 
the literature, consists of amino acids 17-36 (Rubio et al., 2009; Gambhira et al., 2007b). 
However, in our study, amino acids 56-81, when cross-linked to HPV-16 L1, elicited the 
highest levels of anti-L2 antibodies and showed great promise as a cross-neutralising 
sequence. This result reinforces the idea that the region comprising amino acids 56-81 
contains multiple epitopes and that shorter peptides from this region may not be as effective 
in achieving broad cross-neutralisation as the entire region (Rubio et al., 2009). Amino acids 
1-88 from BPV -1 have not been extensively tested by other groups and may also show 
promise. However, such a long peptide may need to be inserted into HPV -16 L 1 without 
replacing too long a stretch of amino acids from Ll. 
The helix 4 and the DE loop have shown the most promise as region ofHPV-16 L1 to be 
modified with the insertion of L2 peptides. Our study supports the modification of the helix 
4, because antibodies against both Ll and L2 could be elicited by two of the chimaeric L1 
vaccines: L2.56 and L2.17. 
A more meaningful comparison could be made between the immunogenicities of the different 
constructs if a higher dose were administered, since the titres obtained by ELISA and L2 
western were very low. Pentamers, which are formed when the helix 4 has been deleted 
(Schadlich et al., 2009), have shown a requirement to be administered at higher doses than 
VLPs to elicit comparable titres (Thanes et al., 2008). This requirement should be 
considered when further studies are undertaken using chimaeric L 1 cap somer vaccines. 
Another way of obtaining higher titres of protective antibodies would be to immunise with 
extracts where capsomers and/or VLPs are selectively purified for, since the assembly of L1 
into at least pentamers is a requirement for eliciting high levels of neutralising antibodies 
against Ll (Schadlich et al., 2009) and the inserted L2 peptides (Schellenbacher et al., 2009). 
Purification of chimaeric L1 protein would also clarify whether the proteins assemble into 
capsomers and/or VLPs, since the high level of background proteins in cell lysate samples 











pseudovirion neutralisation assays in order to detect cross-neutralisation in vitro by sera 
elicited by L2.56, L2.17 and SAF. 
In our study, L2.56 showed the highest potential for a monovalent, prophylactic, broad-
spectrum vaccine against HPV, followed by L2.17 and SAF in that order. SAF did not elicit 
detectable levels of anti-L2 antibodies, but further experimental work in animals, immunising 
them with a higher dose, may effect this, thus SAF may still be considered a candidate. 
BPV did not show potential as a monovalent, prophylactic, broad-spectrum vaccine against 
HPV, because it did not express to high levels in insect cells in our study or in plants 
(Personal communication, Cathy Pineo) or elicit detectable levels of antibodies. This 
construct should therefore not be considered in future work. 
4.3 The design of therapeutic chimaeric vaccines 
Creating chimaeric LlIE7 vaccines has as its main goal the creation of a dual vaccme 
possessing both prophylactic and therapeutic properties. A person already infected with HPV, 
could be treated for the infection in order to clear it, whilst at the same time preventing 
infection with the same or similar type. It would be more useful if such a dual vaccine 
protected against infection with types of HPV other than the types the person was infected 
with. It would therefore be imperative to include an HPV -16 L2 cross-neutralising epitope in 
such a vaccine. For this reason, the creation ofthe LlIL2/E7 chimaeras in this study, E+E7M 
and E+E7H, was a novel and interesting idea that could be further pursued. 
In our study, E7M and E+E7M were capable of eliciting similar, but very low levels of anti-
Ll antibodies as measured by ELISA. No anti-L2 antibodies above detectable levels were 
elicited by E+E7M. In both cases, for both ani-Ll antibodies and anti-L2 antibodies, the low 
levels may be due to the low dose administered and the titres should be enhanced in further 
work as discussed for the other chima eric constructs in Section 4.2. E7M and E+E7M 
therefore show potential to prevent infection by HPV -16, but this should be confIrmed in 
further experiments, since in vitro neutralisation of HPV -16 pseudovirions was not seen. 
Whether E+E7M would be capable of eliciting cross-neutralising antibodies in animals 











The inclusion of the L2 epitope in the E+E7M chimaera seemed to have enhanced the 
vaccine's ability to elicit cellular immunity, which would be more beneficial to treating 
cervical cancer, rather than humoral immunity. This effect is something that would have to be 
investigated further. However, the enhancement of cellular immunity may indicate that 
E+E7M would be preferred as a therapeutic vaccine candidate over E7M. 
No tumour regression was effected in the mouse model by vaccination with E7M or E+E7M. 
Tumour regression could possibly be effected in further experiments by optimising the dose 
and purification as discussed above in section 4.2. Because this effect could also be due to 
immunodominance ofL1, the use of adjuvants such as anti-CD40 and GM-CSF (Qian et al., 
2006), that would enhance the immune response to the peptide included in the c VLPs, should 
be considered in future experiments involving LlIE7 chimaeras. Heterologous boosting with 
a DNA vaccine expressing the E7 peptide or the E7 peptides with adjuvant may also enhance 
immunity to the E7 peptide by circumventing humoral immunity against chimaeric L1 
protein induced by the primary vaccination (Da Silva et al., 2003; Qian et al., 2006). 
The concept of an LlIL2/E7 chimaera may, for various reasons listed above, be highly 
feasible for the creation of a prophylactic and therapeutic HPV vaccine. The concept could 
also be developed further by creating other chimaeras based on it. For example, the L2 
epitope, amino acids 108-120, used in the E+E7M chimaera in our study, could be replaced 
with an L2 epitope that has shown more promise for cross-neutralisation, such as HPV -16 L2 
amino acids 17-36 or 56-81. 
CTL epitopes from other early HPV proteins, especially E6 but also others, could also be 
included in this chimaeric vaccine, since these have also shown to have the potential to 
mediate tumour regression (Brandsma et al., 2007; Govan & Williamson, 2007; Liu et al., 
2007). 
The E7 epitope in this chimaera could also be replaced with another E7 epitope that would be 
specific to alleles other than the HLA-A2 alleles. Peptides specific to other alleles need to be 
considered, since the HLA-A2 alleles are not necessarily as common in all populations, and 
women possessing alleles other than HLA-A2 alleles may be at greater risk for cervical 











The E7 epitope could also be replaced with an E7 CTL epitope from another carcinogenic 
type, like HPV -18, which causes a large proportion of cervical cancers worldwide (Bosch et 
al., 2008). This replacement will be necessary, as E7 epitopes have not been shown to cross-
react broadly between types (Youde et ai., 2005; Piersma et al., 2008; Hohn et al., 1999; 
McCarthy et al., 2006). Priorities, as informed by epidemiological studies, will need to be set 
for which E7 CTL epitopes to be included in such a chimaeric LlIE7 vaccine, since there are 
indications that HPV types other than -16 and -18 may be responsible for a higher proportion 
of cervical cancer than previously expected in sub-Saharan Africa (Louie et al., 2009) where 
there is also a high number of HIV -infected women, a factor which shifts the distribution of 
HPV types to types other than HPV-16 and -18 (Clifford et al., 2006; Adler et al., 2008). 
Types that may have to be considered include HPV-35, 45, 33 (Louie et al., 2009), 52 
(Banura et al., 2008; Blossom et al., 2007), 58 (Xi et ai., 2003), 51 (Moodley et ai., 2009), 53 
(Sahasrabuddhe et al., 2007) and 31 (Allan et al., 2008). 
The inclusion of a CD4+ T-helper epitope is another important aspect to consider in the 
creation ofa chimaeric Ll therapeutic vaccine, since the T-helper epitope has been shown to 
be important in stimulating the immune system to eradicate tumours (van Driel et al., 1999; 
Muderspach et al., 2000; Steller et al., 1998; Daftarian et al., 2006; Doan et al., 2005; 
Vambutas et al., 2005; Tindle et al., 1991; Qin et ai., 2005; Xu et al., 2009) 
4.4 Conclusions of this study and future work 
In conclusion, L2.56 and L2.17 showed potential as broad-spectrum vaccines, because they 
elicited detectable levels of anti-L2 antibodies. Anti-L2 antibodies could not be detected for 
SAF or E+E7M, but it is possible that these were below levels of detection and that by 
improving experimental conditions, anti-L2 antibodies may be detected. Even though in vitro 
cross-neutralisation was not detected for antisera to any of these three constructs, the 
presence of anti-L2 antibodies suggests that pseudovirion neutralisation assays should be 
repeated under different conditions. Other types of HPV pseudovirions should be tested, 
pseudo virions should be purified from cell lysate, pseudo virions should be used at a 
concentration within the linear range of RLU versus concentration, and positive control 











BPV was eliminated as a potential vaccine candidate, due to low expression, and lack of anti-
L I antibodies elicited by this construct. 
Weak cellular responses were elicited by E7M and E+E7M, which did not translate into 
tumour regression, but the responses elicited by vaccination with E+E7M were predominated 
by responses beneficial to tumour regression, whereas those elicited by E7M were not. 
Therefore E+E7M may be a better therapeutic vaccine candidate than E7M. Both of these 
constructs showed potential to protect against HPV -16, because ant i-L 1 antibodies could be 
detected by ELISA. 
The lack of anti-L2 antibodies observed for SAF, the lack of cross-neutralisation, the lack of 
neutralisation of HPV-16 pseudovirions by E+E7M and E7M and the lack of tumour 
regression effected by the latter two constructs could all be improved by administering a 
higher dose of protein, and by selectively purifying capsomers andlor VLPs. Tumour 
regression could also be effected by boosting with a DNA vaccine or with peptides or 
including appropriate adjuvants as discussed above. Purification of chimaeric L1 protein from 
insect cell lysate will also improve electron microscopy analysis and result in more 
conclusive results with respect to the ability of our constructs to assemble into higher-order 
structures. 
Chimaeric L1 vaccines which incorporate cross-neutralising L2 epitopes and T-cell epitopes 
from early HPV proteins for the treatment of cervical cancer, and are produced in more cost-
effective production systems, are promising second-generation HPV vaccine candidates. 
Such vaccines could induce high levels of protective antibodies against HPV, mediate 
protection against multiple HPV types, treat existing HPV infections and become affordable 
to the developing world. L2.56, L2.17, SAP and E+E7M should be tested further as vaccine 
candidates, but other novel chimaeric L1 vaccines could be created, especially ones based on 
the concept ofE+E7M. According to this study, up to 27 amino acids ofthe region to the C-
terminal of the helix 4 ofHPV-16 L1 can be replaced in the construction of such chimaeras, 












Adenocarcinoma in situ (AIS): A precursor to adenocarcinoma, which is a cancer 
originating in glandular tissue. 
Adjuvant: An adjuvant is mixed with an antigen and used to enhance the immune response 
to the antigen. 
Afferent immune system: The arm of the immune system which receives the foreign 
material or intruder and sends danger signals to the rest of the immune system, for example 
by presenting the antigen on antigen-presenting cells. 
Antigen-presenting cells (APCs): Cells of the immune system which process antigen and 
display peptide fragments on their surfaces for recognition by lymphocytes, such as B cells 
and T cells. 
Antisera: The fluid component of clotted blood containing antibodies against the antigen the 
person or animal was immunised against. 
B cells: One of two major classes oflymphocyte. Upon activation by their specific antigen, B 
cells differentiate into cells producing antibody of the same specificity as their initial 
receptor. 
CD8 T -cells: T cells that differentiate into cytotoxic T lymphocytes. They recognise antigen 
presented in complex with MHC class Ion antigen-presenting cells. 
CD4 T -cells: T cells specialised to activate other cells. They are divided into two subsets: 
Thl and Th2 cells. They recognise antigen presented in complex with MHC class II 
molecules. 
Cellular immunity (Cell-mediated immune responses): An adaptive immune response 
involving antigen-specific T -cells. It includes all adaptive immune responses that cannot be 
transferred to a naive recipient with serum antibody. Adaptive immune responses are divided 
into humoral and cell-mediated immunity. 
Cervical intraepithelial neoplasia grade 1 (CINl): Abnormal cell growth corresponding to 
one third of the basal epithelium of the cervix. Equivalent to LSIL. 
Cervical intraepithelial neoplasia grade 2: (CIN2): Abnormal cell growth spanning two 
thirds of the basal epithelium of the cervix. 
Cervical intraepithelial neoplasia grade 3 (CIN3): Abnormal cell growth spanning more 
than two thirds of the basal epithelium of the cervix. Also referred to as cervical carcinoma in 
situ. 










Conformational epitopes : Also called discontinuous epitopes. They are made up of several 
separate regions in the primary sequence of a protein by folding ofthe protein. They are not 
displayed when the protein is denatured. 
Cross-neutralisation (cross-protection): When antibodies elicited by a particular antigen 
bind and neutralise an antigen by which they were not elicited. 
Cross-presentation: The ability of certain antigen-presenting cells to take up, process and 
present antigens to CD8 T cells. 
Cytokines: Proteins made by cells that affect the behaviour of other cells, specifically cells 
of the immune system. 
Cytotoxic T-Iymphocyte (CTL): T cells that kill other cells, important for killing 
intracellular cytosolic antigens. They are mostly CD8 T cells. 
High-grade squamous intraepitheliallesions (HSILs): Equivalent to CIN2+. 
Human leukocyte antigen (HLA): The genetic designation for the human major 
histocompatibility complex. An example is HLA-A*0201 where the A designates the locus 
and the numbers designate the alleles. 
Humoral immunity: Immunity mediated by antibodies. Adaptive immune responses are 
divided into humoral and cell-mediated immunity. 
Invasive cervical cancer (ICC) : Cancer ofthe cervix that has spread deeper into the cervix 
and/or to other parts of the body. 
Linear epitopes: Also called continuous epitopes. They are made up of contiguous regions 
ofthe primary protein sequence and are displayed even when the protein is denatured. 
Low-grade squamous intra epithelial lesions (LSILs): Equivalent to CINI. 
Major histocompatibility (MHC) class I molecules: Proteins that present peptides on 
antigen presenting cells to CD8 T cells. 
MHC class II molecules: Proteins that present peptides on antigen presenting cells to CD4 T 
cells. 
Monoclonal antibodies: Antibodies produced by a single clone ofB-lymphocytes, therefore 
they only bind to one specific epitope on a protein 
Pan DR: Relating to T helper epitopes capable ofbinding to more than one allele ofHLA 
MHC class II molecules. 
Pentamers (Capsomers): The HPV capsid consists of72 pentamers ofLl. One pentamer is 
also called a capsomer. 
Polyclonal sera : Antisera containing antibodies against multiple epitopes on the same 











Pseudovirions : An infectious HPV particle, consisting of the capsid, but containing a 
reporter plasmid instead of the HPV genome. 
Restriction elements: Another term for human leukocyte antigens. 
Squamous cell carcinoma (SCC): A malignant tumour of squamous epithelium. 
T cells: One oftwo major classes oflymphocyte. They are defined by their development in 
the thymus. 
T helper epitope: An epitope presented in complex with an MHC class II molecule and 
recognised by a T helper cell. T helper cells provide signals for B cell activation, but also 
playa role in the activation of cytotoxic T lymphocytes. 
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